State of Ohio,) 1 SS:) 2 County of Cuyahoga.) 3 IN THE COURT OF COMMON PLEAS 4 5 Iwona Valdivieso, etc., 6 Plaintiff, 7) Case No. 443978 8 vs. Judge Mannen University Hospitals of 9 Cleveland, et al., 10 Defendants. 11 12 13 DEPOSITION OF TIMOTHY J. KINSELLA, M.D. 14 WEDNESDAY, MAY 1, 2002 15 The deposition of Timothy J. Kinsella, M.D., called by 16 the Plaintiff for examination under the Ohio Rules of 17 Civil Procedure, taken before me, Ivy J. Gantverg, 18 Registered Professional Reporter and Notary Public in and 19 for the State of Ohio, by agreement of counsel and 20 without further notice or other legal formalities, at the 21 offices of Reminger & Reminger, 113 St. Clair Building, 22 23 Cleveland, Ohio, commencing at 9:12 a.m., on the day and date above set forth. 24 25 MORSE, GANTVERG & HODGE

п

APPEARANCES: 1 On Behalf of the Plaintiff: 2 Ronald A. Margolis, Esq. 3 Daniel M. Finelli, Esq. Finelli & Margolis 4 730 Leader Building Cleveland, Ohio 44114 5 On Behalf of Defendant University Hospitals of Cleveland: 6 7 Kevin M. Norchi, Esg. Moscarino & Treu 8 630 Hanna Building Cleveland, Ohio 44115 9 On Behalf of Defendant Dr. Shina: 10 Timothy G. Sweeney, Esq. 11 Bonezzi, Switzer, Murphy & Polito 1400 Leader Building 12 Cleveland, Ohio 44114 On Behalf of Defendants Case Western Reserve University, 13 Dr. Barry Wessels and Dr. Sam Beddar: 14 Stephen D. Walters, Esq. 15 Weston, Hurd, Fallon, Paisley & Howley 2500 Terminal Tower Cleveland, Ohio 44113 16 On Behalf of Defendants Dr. Wiersma and Dr. Kinsella: 17 18 Marc W. Groedel, Esq. David H. Krause, Esq. 19 Reminger & Reminger 113 St. Clair Building 20 Cleveland, Ohio 44114 On Behalf of Dr. Wiersma and Dr. Kinsella Personally: 21 22 Matthew P. Moriarty, Esq. Brzytwa, Quick & McCrystal 1660 West 2nd Street - Suite 900 23 Cleveland, Ohio 44113 24 Also Present: 25 Susan Wiersma, M.D. Barry Hersch, Videographer MORSE, GANTVERG & HODGE

| 1 | |
|----|--|
| 2 | (Thereupon, Kinsella Exhibits A (1-19) |
| 3 | and B (1-87) were previously marked for |
| 4 | identification.) |
| 5 | (Thereupon, Plaintiff's Exhibit 100 was |
| 6 | marked for identification.) |
| 7 | TIMOTHY J. KINSELLA, M.D. |
| 8 | a defendant herein, called by the plaintiff for |
| 9 | examination under the Rules, having been first duly |
| 10 | sworn, as hereinafter certified, was deposed and said as |
| 11 | follows: |
| 12 | MR. MARGOLIS: Would counsel just please |
| 13 | identify themselves for the record, and who they |
| 14 | represent? |
| 15 | MR. GROEDEL: My name is Marc Groedel, I |
| 16 | represent Dr. Kinsella and Dr. Wiersma. |
| 17 | MR. NORCHI: My name is Kevin Norchi, I |
| 18 | represent University Hospitals of Cleveland. |
| 19 | MR. WALTERS: My name is Stephen Walters, I |
| 20 | represent Case Western Reserve University, |
| 21 | Dr. Barry Wessels and Dr. Sam Beddar. |
| 22 | MR. SWEENEY: My name is Tim Sweeney, I |
| 23 | represent Dr. Shina. |
| 24 | MR. KRAUSE: David Krause, I represent |
| 25 | Dr. Kinsella and Dr. Wiersma. |
| | |
| | |
| | |

7

[1

MR. MORIARTY: Matt Moriarty, personal 1 counsel to Drs. Kinsella and Wiersma. 2 MR. MARGOLIS: And I am Ron Margolis, the 3 gentleman to my left is Dan Finelli. Jointly, we 4 represent the plaintiffs. 5 CROSS EXAMINATION 6 BY MR. MARGOLIS: 7 Doctor, have you ever had your deposition taken 8 Ο. before today? 9 No. 10 Α. This is the first time you have ever testified 11 Ο. under oath? 12 I have been an expert witness, which I would have 13 Α. testified under oath, yes. 14 15 Ο. Okay. When you were an expert witness, did you ever give 16 a deposition where your opinions were inquired by the 17 counsel representing the adverse party? 18 I can't recall. It was back in the 1980s. Α. 19 20 Ο. Okay. I think I was representing the physicians. 21 Α. All right. 22 Ο. 23 How many times have you served in the capacity as an expert witness in a medical malpractice case? 24 I think there are three or four. 25 Α.

And on those three or four occasions, when did Ο. 1 they start? When was the first time you served as an 2 expert witness? 3 It may have been 1982 or 1983. And I left the Α. 4 National Cancer Institute in 1987, I don't think I did 5 anything after that. 6 All right, so from 1987 to present, to the best of 7 Ο. your knowledge, you have not served in the capacity of an 8 expert witness? 9 That is right, that is correct. 10 Α. Have there been any other circumstances where you 11 Ο. have given testimony under oath? 12 13 Α. Not -- no, not that I can recall. Q. All right. 14 Doctor, I have handed you what has been marked for 15 identification purposes as Plaintiff's Deposition Exhibit 16 100, which is your curriculum vitae. Is that a current 17 18 copy? Yes, as of April of 2002. Α. 19 20 Q. Thank you. You were also asked to bring with you today some 21 other documents, specifically the original office file 22 23 including any and all correspondence which represent plaintiffs in this case. Have you brought that with you 24 today? 25

No one made that request of me, I think. Α. 1 MR. GROEDEL: Well, we have given you the 2 office chart. You have the original there. 3 Dan is looking at it right now. 4 5 MR. MARGOLIS: Okay. Dan, can I have that for one second? Let 6 7 me just mark it. Ivy, can I have an exhibit sticker. 8 Just mark it 101. 9 10 (Thereupon, Plaintiff's Exhibit 101 was marked for identification.) 11 BY MR. MARGOLIS: 12 Doctor, handing you what has been marked as 13 Ο. Plaintiff's Exhibit 101 --14 15 Α. Yes. -- would you please identify that for me? 16 Ο. It is the department of radiation oncology 17 Α. treatment record for Joshua Valdivieso. 18 And is that the original chart, sir? 19 Ο. 20 Α. Yes, it appears to be. All right. 21 Ο. Where would that chart be kept in the normal 22 routine course? 23 While Joshua was a patient, it would be kept in 24 Α. 25 the department of radiation oncology. MORSE, GANTVERG & HODGE

Ο. All right. 1 Do you have any other records relative to Joshua 2 Valdivieso, other than what is set forth in Exhibit 101? 3 No, I do not. Α. 4 MR. MARGOLIS: All right, can I have that, 5 Marc? 6 7 (Thereupon, the file was handed to Mr. Margolis.) 8 BY MR. MARGOLIS: 9 And Exhibit 101 would contain a complete and 10 Ο. accurate copy of all the records which would have been 11 generated by your department and yourself relative to 12 care of Joshua Valdivieso? 13 Α. Yes. 14 Have any records been removed from that chart? 15 Q. No, they have not. 16 Α. I also asked you to bring with you today, sir, any 17 Ο. and all billings relative to the care and treatment 18 rendered to Joshua Valdivieso. Do you have that? 19 20 Α. No, I do not. MR. GROEDEL: We will provide you with 21 I did not ask Dr. Kinsella to provide that 22 that. 23 information. MR. MARGOLIS: Okay. 24 25 MORSE, GANTVERG & HODGE

1 BY MR. MARGOLIS:

| 2 | Q. I also asked you to bring with you today any and | | |
|----|---|--|--|
| 3 | all documents that you have prepared subsequent to your | | |
| 4 | receipt of the lawsuit in this matter, certainly not | | |
| 5 | documents to your lawyers. | | |
| 6 | Have there been any documents that you have | | |
| 7 | prepared after you received the initial lawsuit in this | | |
| 8 | matter? | | |
| 9 | A. No, there have not. | | |
| 10 | Q. So you would not have altered or changed any | | |
| 11 | documents in the medical record after you received the | | |
| 12 | lawsuit in this matter? | | |
| 13 | A. No, I did not. | | |
| 14 | Q. Did you review any hospital protocols, rules, | | |
| 15 | regulations, bylaws or guidelines after the lawsuit was | | |
| 16 | received by you in this matter? | | |
| 17 | A. No, I did not. | | |
| 18 | Q. In your position at University Hospital at the | | |
| 19 | time that you treated Joshua Valdivieso, were you aware | | |
| 20 | of the hospital protocols, rules, regulations and | | |
| 21 | guidelines that would govern a physician's treatment of a | | |
| 22 | patient? | | |
| 23 | A. I was aware of them. | | |
| 24 | Q. Are they in a written format somewhere, sir? | | |
| 25 | A. I am sure they are. I don't have them in my | | |
| | | | |
| | | | |

8

1 office or I don't keep them.

| 2 | Q. As the chairman of the department, though, would |
|----|--|
| 3 | you have some administrative responsibilities? |
| 4 | A. Yes, I do. And those records would probably be in |
| 5 | the administrator's office. |
| 6 | Q. I also asked you to bring certain documents which |
| 7 | were generated relative to an investigation that was |
| 8 | performed at the University of Wisconsin Medical School |
| 9 | Department of Human Oncology involving yourself during |
| 10 | the years 1996 and 1997. Do you have any documents in |
| 11 | your possession that were generated as a result of that |
| 12 | investigation? |
| 13 | A. No, I do not. |
| 14 | Q. Were you ever forwarded any letters or documents |
| 15 | by Phillip Farrell relative to that investigation or any |
| 16 | decisions made as a result of that investigation? |
| 17 | A. I may have received some, but I certainly didn't |
| 18 | save those. I can't recall specifically. I have no |
| 19 | records from there. |
| 20 | Q. What do you believe you would have received from |
| 21 | Phillip Farrell? |
| 22 | MR. GROEDEL: Objection. |
| 23 | You may answer, if you can. |
| 24 | A. He is or was the Dean of the medical school. I am |
| 25 | not sure what records he would have sent me. I don't |
| | |
| | |
| | MORSE, GANTVERG & HODGE |

| 1 | have those. I certainly didn't save anything from I | |
|----|---|--|
| 2 | left there five years ago. | |
| 3 | Q. What about Gordon Derzon? | |
| 4 | A. He was the CEO of the hospital. Again, I have no | |
| 5 | records. | |
| 6 | Q. Were you provided any records by Gordon Derzon | |
| 7 | that you have recollection of, whether you retained them | |
| 8 | or not? | |
| 9 | MR. GROEDEL: Objection. | |
| 10 | You may answer. | |
| 11 | A. I can't recall receiving any. | |
| 12 | Q. What about David Ward? | |
| 13 | A. He is he was the Chancellor of the university, | |
| 14 | and again, I have no records, and I can't recall anything | |
| 15 | specifically. | |
| 16 | Q. Do you believe that you were forwarded any records | |
| 17 | by David Ward relative to that investigation | |
| 18 | MR. GROEDEL: Object. | |
| 19 | Q and its conclusions? | |
| 20 | MR. GROEDEL: Objection. | |
| 21 | You may answer. | |
| 22 | A. I can't recall. | |
| 23 | Q. What about Dr. Scott Springman? | |
| 24 | A. He is an anesthesiologist. I am not sure if he is | |
| 25 | still there. Again, nothing that I have. | |
| | | |
| | | |

| 1 | Q. | What about documents from Lisa Brunette? | |
|----|---|---|--|
| 2 | Α. | I don't know who Lisa Brunette is. Sorry. | |
| 3 | Q. | All right. | |
| 4 | | What about documents from UW Provost John Whiley? | |
| 5 | Α. | Again, I don't have any recollection and I don't | |
| 6 | have a | ny records. | |
| 7 | Q. | What about documents from Casey Nagy? | |
| 8 | A. | I don't have any records or a recollection of | |
| 9 | receiving anything. | | |
| 10 | Q. | You will agree with me that an investigation was | |
| 11 | commen | ced relative to your time at University of | |
| 12 | Wisconsin Medical School involving yourself and medical | | |
| 13 | records and billing practices, correct? | | |
| 14 | | MR. GROEDEL: Objection. | |
| 15 | | You may answer. | |
| 16 | A. | Correct. | |
| 17 | Q. | And you will agree with me that as a result of | |
| 18 | that i | nvestigation, allegations were made that you saw | |
| 19 | patien | ts, charted clinical findings and diagnoses, | |
| 20 | billed | , but in fact did not examine the patients on the | |
| 21 | indica | ted dates; are you aware that substantively those | |
| 22 | were t | he allegations of that investigation? | |
| 23 | | MR. GROEDEL: Objection. | |
| 24 | | You may answer. | |
| 25 | A. | There were allegations of procedures occurring | |
| | | | |
| | | | |

1 called simulations where I wasn't present, and a bill was sent, but it didn't require my presence, based on that 2 time frame. 3 Q. Why did --4 Α. There was a change in our physician or attending 5 to resident responsibilities. 6 Is it your testimony here today that you did 7 Ο. nothing improper relative to the substantive matters 8 which were being investigated by the University of 9 Wisconsin? 10 Α. Yes. 11 Why did you voluntarily choose, then, to reimburse 12 Q. them \$15,000 to help defray the costs of the 13 investigation? 14 15 MR. GROEDEL: Objection. Α. I actually can't recall the specifics of that. 16 You have no recollection as to whether or not you 17 Ο. voluntarily paid money to the University of Wisconsin 18 Medical School to defray the costs of the investigation 19 that was conducted involving yourself? 20 21 MR. GROEDEL: Objection. I can't recall the specifics. Α. 22 Did you issue them a check for \$15,000 at the 23 Ο. conclusion of the investigation? 24 MR. GROEDEL: Objection. 25

MORSE, GANTVERG & HODGE

| 1 | You may answer. | | |
|----|--|--|--|
| 2 | A. I can't recall. | | |
| 3 | Q. Did you reimburse \$5,815 for billings that were | | |
| 4 | made to patients that were determined to be inappropriate? | | |
| 5 | MR. GROEDEL: Objection. | | |
| 6 | A. I can't recall. They we had a practice plan | | |
| 7 | that may have done that. I don't think I personally did | | |
| 8 | that. | | |
| 9 | Q. What about the 15,000, was that from the practice | | |
| 10 | plan, as well? | | |
| 11 | A. I can't recall. | | |
| 12 | Q. You had counsel that represented your interests in | | |
| 13 | that matter, did you not? | | |
| 14 | A. Yes. | | |
| 15 | Q. And what was the name of counsel? | | |
| 16 | A. It was I am blocking on his name right now. | | |
| 17 | Q. Okay. | | |
| 18 | While you were at | | |
| 19 | A. Michael Weiden. | | |
| 20 | Q. Tell me the position that you held, sir, at | | |
| 21 | University of Wisconsin Medical School? | | |
| 22 | A. I was chairman of the department of human oncology | | |
| 23 | and a professor, I had a named chair, and I can't it | | |
| 24 | is, I think, the Anderson chair. | | |
| 25 | Q. Were you involuntarily removed from the | | |
| | | | |
| | | | |

chairmanship of that department? 1 MR. GROEDEL: Objection. 2 You may answer. 3 Each year we had a vote for the chairs at Α. 4 Wisconsin, it is the faculty members. One year I did not 5 receive a majority of the votes. 6 Were there allegations by your colleagues against 7 Ο. you that you were administering treatment that was 8 medically excessive and not warranted for billing 9 10 purposes? MR. GROEDEL: Objection. 11 You know, I think, Ron, I have let you go, 12 13 you know, as far as I think you should go in this matter, and I am going to instruct the witness not 14 to answer any further questions about what 15 happened back at the University of Wisconsin. 16 You know, I think you have gone far enough in that 17 regard. I don't think it is relevant, you have 18 withdrawn your discovery requests for that 19 information. 20 MR. MARGOLIS: Well, the discovery 21 requests, Marc, that were withdrawn, were 22 23 withdrawn at this point in time for our specific strategy reasons in the case. That does not act 24 as a waiver, or preclude me. There are still 25

MORSE, GANTVERG & HODGE

pending claims that are directly relevant to that. 1 I would ask your indulgence, I have one or 2 two questions on this area, and then I am done. 3 MR. GROEDEL: Restate that -- repeat the 4 question. 5 MR. MARGOLIS: Fair enough. 6 Could you please read back the last 7 question. 8 (Record read.) 9 Objection. MR. GROEDEL: 10 If you know. 11 Allegations were made. Nothing was substantiated. 12 Α. All right. 13 Q. And my last question on this issue -- and Marc, I 14 15 appreciate your allowing me to finish this area --16 subsequent to this investigation that we discussed, did you receive any disciplinary notification or action? 17 MR. GROEDEL: Objection. 18 No, I did not. 19 Α. You were also asked to bring with you today the 20 Ο. 21 Record and Verify System and any and all documents that would be produced relative to the total body irradiation 22 administered to Joshua on January 26th, 27th and 28th of 23 24 2000. Those should be in the chart. 25 Α.

1 0

| 1 | Q. Okay, could you point those out to me, please? We |
|----|--|
| 2 | will provide you with the chart. |
| 3 | And before you do that, please tell me what the |
| 4 | Record and Verify System is? |
| 5 | A. It is a backup system that allows the therapist to |
| 6 | enter a dose, and if it is a wrong dose, it would not |
| 7 | allow the machine to deliver the dose. |
| 8 | Q. Okay. |
| 9 | And would that have been a system that would have |
| 10 | been in effect in January of 2000 when Joshua was |
| 11 | receiving his TBI? |
| 12 | A. I can't recall when exactly we started the Record |
| 13 | and Verify. |
| 14 | Q. How would I determine that, sir? |
| 15 | A. You would have to you have to go back and ask |
| 16 | the physicist when that was installed. |
| 17 | Q. All right. |
| 18 | Was that a system that was utilized during your |
| 19 | time at Wisconsin? |
| 20 | A. I think it was. I think Record and Verify is a |
| 21 | Varian product. |
| 22 | Q. And Doctor |
| 23 | A. We had some Varian equipment. |
| 24 | Q. I had asked you about this Record and Verify |
| 25 | System in the documents generated, and you had indicated |
| | |
| | |
| | |

| 1 | that it would be in the chart, and I forwarded you the |
|----|--|
| 2 | chart. Is it in there, sir? |
| 3 | A. I don't see it. I see the recording of the dose, |
| 4 | but they don't |
| 5 | Q. And we will get to that. |
| 6 | Would is there a specific document which is |
| 7 | generated by the Record and Verify System? |
| 8 | A. I think there is. |
| 9 | Q. All right. |
| 10 | Would it normally be in your office chart? |
| 11 | A. That is a department chart, not my office chart. |
| 12 | But I assume it is. |
| 13 | Q. And when you have looked in it, you have not been |
| 14 | able to locate it in the departmental chart? |
| 15 | A. Just looking now, I can't see it. It should be |
| 16 | right in that treatment area, that summary. |
| 17 | Q. All right. |
| 18 | I know that there is a hospital chart on Joshua, I |
| 19 | know that there is a departmental chart. |
| 20 | A. Uh-huh. |
| 21 | Q. Is there any other chart? I used the word, office |
| 22 | chart. Is that part of your departmental chart? |
| 23 | A. That is the departmental chart. |
| 24 | Q. Okay. |
| 25 | Let me just quickly scan your CV. |
| | |
| | |

| l | Doctor, have you authored any articles on | | |
|----|--|--|--|
| 2 | neuroblastoma? | | |
| 3 | A. No, I have not. | | |
| 4 | Q. When did you meet Dr. Wiersma? | | |
| 5 | A. In 1990. | | |
| 6 | Q. And you were married? | | |
| 7 | A. In 1993. | | |
| 8 | Q. Have you and Dr. Wiersma always worked at the same | | |
| 9 | medical institutions? | | |
| 10 | A. Yes. | | |
| 11 | Q. And Dr. Wiersma is a Board certified pediatric | | |
| 12 | oncologist? | | |
| 13 | A. Correct. | | |
| 14 | Q. And you, sir, are a Board certified pediatric | | |
| 15 | oncologist, as well as a pediatric radiation oncologist; | | |
| 16 | is that correct? | | |
| 17 | A. No, I am not a Board certified pediatric | | |
| 18 | oncologist nor | | |
| 19 | Q. Okay. | | |
| 20 | A. And there is no Board certification for pediatric | | |
| 21 | radiation oncologist. I am a Board certified internist, | | |
| 22 | Board certified adult medical oncologist and a Board | | |
| 23 | certified radiation oncologist. | | |
| 24 | Q. All right. | | |
| 25 | Does Dr. Wiersma regularly refer patients to you | | |
| | | | |
| | | | |

| 1 | for radiation oncology evaluation and treatment? | |
|----|--|--|
| 2 | A. Yes. | |
| 3 | Q. Has Dr. Wiersma regularly referred patients to | |
| 4 | you, from '93 to present? | |
| 5 | A. Yes. | |
| 6 | Q. Approximately, can you tell me since the time that | |
| 7 | Dr. Wiersma did she start at UH at the same time you | |
| 8 | did, sir? | |
| 9 | A. Started three years later. I started in '87 and | |
| 10 | Susan started in '90. | |
| 11 | Q. All right. | |
| 12 | MR. NORCHI: University of Wisconsin? | |
| 13 | THE WITNESS: Yes, University of Wisconsin. | |
| 14 | Q. (Continuing) My question is, at University | |
| 15 | Hospitals of Cleveland, when did you start? | |
| 16 | A. I started in November of 1997 in an administrative | |
| 17 | role. My Ohio license was not issued until February or | |
| 18 | March of 1998, so that is when I would have started | |
| 19 | practice. | |
| 20 | Q. When did Dr. Wiersma start? | |
| 21 | A. I think in July of 1998. | |
| 22 | Q. Can you give me any kind of idea of how many | |
| 23 | patients Dr. Wiersma would refer to you for evaluation | |
| 24 | and treatment on a yearly basis? | |
| 25 | A. Ten or 15. | |
| | | |

| 1 | Q. | Would you ever discuss your evaluation of the |
|----|---|--|
| 2 | patier | nts jointly with her? |
| З | Α. | Yes. |
| 4 | Q. | All right. |
| 5 | | I know there are consult notes that go back and |
| 6 | forth. | |
| 7 | Α. | Right. |
| 8 | Q. | But given the fact that you are married, would you |
| 9 | ever d | liscuss what is going on with the patients outside |
| 10 | ofar | professional setting? |
| 11 | Α. | We try not to. |
| 12 | Q. | Does it happen? |
| 13 | A. | It happens. |
| 14 | Q. | If there are cases that are out of the ordinary |
| 15 | for or | ne reason or another, the two of you may discuss |
| 16 | that out of the hospital on your personal time? | |
| 17 | A. | Yes. |
| 18 | Q. | All right. |
| 19 | | Has your medical license ever been revoked, |
| 20 | susper | nded? |
| 21 | Α. | No. |
| 22 | Q. | Has there ever been any disciplinary action taken |
| 23 | agains | st your medical license? |
| 24 | A. | No. |
| 25 | Q. | In any state? |
| | | |
| | | |

| 1 | A. No. | |
|----|--|-----|
| 2 | Q. The expert work that you did, did it involve | |
| 3 | issues of neuroblastoma? | |
| 4 | A. Did not. No, it did not. | |
| 5 | Q. Would you feel that Dr. Wiersma, based upon her | |
| 6 | education, skill and experience, has more experience ir | 1 |
| 7 | treating patients with neuroblastoma than you? | |
| 8 | A. Yes. | |
| 9 | Q. Would you defer to Dr. Wiersma on issues of | |
| 10 | prognosis for this disease? | |
| 11 | A. Possibly. | |
| 12 | Q. What is the caveat? Usually when I say, defer t | :0 |
| 13 | my wife, I do it blankly. So what is the caveat here? | |
| 14 | A. Well, again, I certainly know the disease proces | s, |
| 15 | so I could render an opinion that could be different th | ıan |
| 16 | hers. | |
| 17 | Q. Okay. | |
| 18 | A. And certainly in other pediatric cancers that ar | re. |
| 19 | common cancers, I clearly have much more experience that | ın |
| 20 | probably the majority of pediatric oncologists in the | |
| 21 | world, such as Ewing's sarcoma. | |
| 22 | Q. Doctor, what medical records have you reviewed i | .n |
| 23 | preparation for this deposition? | |
| 24 | A. I have reviewed the department of radiation | |
| 25 | oncology records. | |
| | | |

Which would be Exhibit 101? Q. 1 Right. 2 Α. I reviewed the pediatric -- pediatric oncology 3 records. And this morning, for the first time, I saw the 4 5 hospital records. 6 MR. GROEDEL: Portions of them. 7 (Continuing) Yes, I saw the -- right, the note I Α. wrote on 1-26 I didn't know existed before. 8 Doctor, what I have done to try to make it easier Ο. 9 for us is I have bound exhibits that I will be making 10 reference to during the course of this deposition, and at 11 12 this point, counsel, this will be given to the court reporter. 13 I am asking you to look at the file marked 14 Dr. Kinsella A, and I would ask you to please turn to 15 Exhibit 19. 16 MR. WALTERS: What is this? 17 18 MR. MARGOLIS: This is the 5-31-2000 letter. 19 20 Do you have yours that you could like give back to them, so that they can --21 MR. FINELLI: Yes. 22 23 MR. MARGOLIS: 19, Steve. MR. WALTERS: Thank you. 24 MR. MORIARTY: With all of its attachments? 25

MORSE, GANTVERG & HODGE

| 1 | MR. MARGOLIS: No, it is just the front |
|----|---|
| 2 | page of the letter. |
| 3 | BY MR. MARGOLIS: |
| 4 | Q. That is okay, if you could just look at it, |
| 5 | because it is marked, and I am going to give that to her. |
| 6 | Doctor, handing you Exhibit 19, please take your |
| 7 | time to review it. |
| 8 | A. (Witness complies). I have read it. |
| 9 | Q. Is that is this the first time that you have |
| 10 | seen that document? |
| 11 | A. No, Marc Groedel provided me with a copy of this |
| 12 | approximately a month ago. |
| 13 | Q. Prior to receiving the document sometime in March |
| 14 | of 2002, have you ever seen Exhibit 19 before that date? |
| 15 | A. No, I have not. |
| 16 | Q. Did you have any knowledge that Exhibit 19 existed |
| 17 | prior to March of 2002? |
| 18 | A. No, I did not. |
| 19 | Q. Were there any rumors or rumblings within the |
| 20 | department that you had knowledge of prior to March of |
| 21 | 2002 on the issues set forth in Exhibit 19? |
| 22 | MR. GROEDEL: Objection. |
| 23 | You may answer. |
| 24 | A. I know of no rumors or rumbles, however you |
| 25 | phrased it. |
| | |
| | |

Ī

23

| l | Q. | Do you know who authored Exhibit 19? | | |
|----|------------|---|--|--|
| 2 | Α. | No, I do not. | | |
| 3 | Q. | Doctor, do you remember when you were served with | | |
| 4 | the la | the lawsuit in this case? | | |
| 5 | Α. | I can't actually recall the date. | | |
| 6 | Q. | Do you remember the month? | | |
| 7 | Α. | It was July of last year. | | |
| 8 | Q. | That is probably right. It was filed July 11th, | | |
| 9 | 2001. | | | |
| 10 | | Who did you speak with after you received a copy | | |
| 11 | of the | e lawsuit, starting, if we can, first? | | |
| 12 | Α. | I actually didn't read it, I think, for up to a | | |
| 13 | month, | I didn't. And I think I talked to my wife, Susan, | | |
| 14 | about | it, since she was named. | | |
| 15 | Q. | And you were you expecting to be sued in this | | |
| 16 | case? | | | |
| 17 | Α. | No. | | |
| 18 | Q. | And you saw that you were named as a party | | |
| 19 | defendant? | | | |
| 20 | Α. | Right. | | |
| 21 | Q. | And you did not read any portions of the lawsuit | | |
| 22 | for ap | proximately a month after you received it? | | |
| 23 | A. | I think so. | | |
| 24 | Q. | All right. | | |
| 25 | | Did you turn it over to someone to handle on your | | |
| | | | | |
| | | | | |

24

| 1 | behalf? | | |
|----|---|--|--|
| 2 | A. No, I did not. | | |
| 3 | Q. Okay, so it sat on your desk for about a month, | | |
| 4 | and then you decided it would be a good idea to review | | |
| 5 | it? | | |
| 6 | A. I think Susan actually also received a copy, and I | | |
| 7 | think she read it first. | | |
| 8 | Q. All right. | | |
| 9 | Did you speak with Dr. Shina about the lawsuit at | | |
| 10 | any point in time from when you received it until | | |
| 11 | present? | | |
| 12 | A. Once, about a month ago, after he was named. | | |
| 13 | Q. Tell me where that discussion occurred and what | | |
| 14 | was said? | | |
| 15 | A. It occurred, I think, in the clinic. He said he | | |
| 16 | was named along with Dr. Wessels and Dr. Beddar. And I | | |
| 17 | was surprised, I didn't know why he would be named. And | | |
| 18 | that was the conversation. | | |
| 19 | Q. Was anyone present when he had this discussion | | |
| 20 | with you? | | |
| 21 | A. I don't think so. | | |
| 22 | Q. Did he initiate it, or did you? | | |
| 23 | A. He did, because he had been named. | | |
| 24 | Q. And he simply said to you, I have been named in | | |
| 25 | this lawsuit along with these physicists? | | |
| | | | |
| | | | |

1 A. Correct.

2 Q. And you said nothing?

A. Correct. I said -- well, I expressed surprise.
Q. Did Dr. Shina bring to your attention that Joshua
was administered 1 Gray during his TBI as opposed to 10
Grays?

7 A. No.

Q. Did anyone bring to your attention at any point in
time that Joshua was administered 1 Gray during his TBI
instead of 10?

11 A. Not that I recall, no.

If that information had been brought to your 12 Ο. attention, i.e. that Joshua was administered 1 Gray 13 instead of 10, what action would you have taken? 14 Oh, I would have notified the physicians involved, 15 Α. 16 I think we would have notified the hospital, and they would notify the -- obviously the patient and/or the 17 parents. 18

19 Q. So it is your testimony, Dr. Kinsella, that at no 20 point in time before this lawsuit being filed were you 21 ever advised by anybody that this patient had received 1 22 Gray of TBI instead of 10?

23 A. Yes, correct.

Q. Dr. Kodish, did you have any discussions with himrelative to the lawsuit?

Α. No, I did not. 1 Dr. Shurin? Ο. 2 I had a discussion with Dr. Shurin, I think in --3 Α. I would guess in September of 2001, or it could have been 4 5 October, that she brought it up that she was aware, and I said I made a mistake in the prescription, and it was a 6 7 brief conversation. She related a time when she had made a mistake in a prescription, and basically said, you 8 know, things like that can happen. It was a very brief 9 discussion. 10 What about Barb Scott? 11 Ο. 12 Α. No. Sam Beddar? 13 Q. Ά. No. 14 Barbara Gleason? 15 Q. 16 Α. No. Dr. Kitchen? 17 Q. 18 Α. No. Dr. Wiersma? 19 Q. Not -- I mean, obviously after the suit, we were 20 Α. aware of it, I certainly talked to her about it. 21 David Abrams [sic]? 22 Ο. 23 Α. No. 24 Barry Wessels? Ο. 25 Α. No.

Diane Otto? Ο. 1 Α. No. 2 You told me that you started at UH in November of 3 Ο. '97 and you started your clinical work February of '98. 4 Give me --5 Or March, I can't recall. Ά. 6 7 Go ahead. All right. Ο. 8 Give me an idea of what your duties and 9 responsibilities are at Case -- or at UH? You are the 10 chairman of the department? 11 12 Α. Correct. 13 And chairman of what, the department of radiation Ο. oncology? 14 Radiation oncology, yes. 15 Α. All right. 16 Q. And does that attendant responsibility have 17 certain administrative duties? 18 Yes. Α. 19 And how much of your time is involved in 20 Ο. administrative duties? 21 I probably spend 20 percent of my time in 22 Ά. 23 administration. And what do the administrative duties involve? 24 Ο. I am the director of radiation oncology in the 25 Α. MORSE, GANTVERG & HODGE

28

University Hospitals of Cleveland there in the Cancer 1 Center and the Health System. 2 So when I came, we were treating in two 3 facilities, University Hospitals of Cleveland and the 4 5 Willoughby facility, which subsequently closed and opened -we established an affiliation with the Lake University 6 7 Ireland Cancer Center, it is the Lake Hospital System. That was in '98. 8 In '99 -- I am not clear of all the dates -- we 9 10 established a treatment facility called an Ireland Cancer Center Southwest General Hospital. 11 In 2000, we established a treatment facility at 12 University's Westlake facility. 13 In 2001, we established a treatment facility at --14 I am sorry, in 2000, also at Mercy Hospital in Canton, 15 16 again. So part of your administrative responsibilities 17 Ο. would be developing new centers where --18 19 Α. Right. 20 Ο. Okay. In 2001, we opened a facility, Chagrin Highlands, 21 Α. part of University Hospitals, and we assumed directorship 22 23 of radiation oncology at the VA Hospital, that that is a 0.5 FTE position through the government. 24 And last week, we set up a new facility at Lorain 25

29

Community, the Community Health Partners. 1 So is part of your administrative duties Ο. 2 supervising all these various locations? З Α. That is correct. 4 All right, anything else in your administrative 5 Ο. duties, teaching? 6 A small amount. I have graduate students that I 7 Α. teach and post-doctoral students that aren't under the 8 quise of University Hospitals of Cleveland. That would 9 be under Case Western Reserve University. 10 My other responsibilities are at the Ireland 11 12 Cancer Center, I am the program director, and I am on their board of internal advisors and support various 13 programs, clinical research. 14 I am the representative for radiation oncology on 15 several multi-disciplinary tumor boards, the 16 gastrointestinal tumor boards, sarcomas and pediatric 17 oncology, in particular. That is a weekly commitment. 18 Do you have any involvement in the supervision of Ο. 19 the physics personnel? 20 21 Α. I am technically over the -- yes, yes. So physics and therapy, the research group that is over at Case 22 would be all under my direction. And there are several 23 researchers over there, there are actually -- we have 24 dramatically increased the research funding, also. 25

MORSE, GANTVERG & HODGE

| 1 | Q. You admit that the radiation dose of 1 Gray to | | |
|----|---|---|--|
| 2 | Joshua Valdivieso instead of 10 was a mistake? | | |
| 3 | A. Yes, I do. | | |
| 4 | Q. And you admit that giving him 1 Gray of radiatic | n | |
| 5 | for the circumstances that you were providing that | | |
| 6 | treatment was a breach of the standard of care? | | |
| 7 | MR. GROEDEL: Objection. | | |
| 8 | You may answer. | | |
| 9 | A. Well, the intended dose was 10 Gray. So yes. | | |
| 10 | Q. All right. | | |
| 11 | Doctor, I want you to educate me now on the | | |
| 12 | protocols, the documents that would be generated, the | | |
| 13 | paper trail and the people involved in treating Joshua | | |
| 14 | for total body irradiation under the circumstances that | | |
| 15 | he was. | | |
| 16 | First, would a physicist be involved? | | |
| 17 | A. Yes. | | |
| 18 | Q. Would a dosimetrist be involved? | | |
| 19 | A. Yes. | | |
| 20 | Q. Would a radiation technologist be involved? | | |
| 21 | A. Right, yes. | | |
| 22 | Q. Usually would a referring oncologist be involved | ? | |
| 23 | A. Not in the delivery. | | |
| 24 | Q. No. I am saying, from the inception | | |
| 25 | A. Yes, yes. | | |
| | | | |

1 Ο. -- through the conclusion. 2 Α. Yes. 3 Ο. All right. And then there would be a consultation by the 4 radiation oncologist? 5 Α. Correct. 6 Would there be anesthesia involved? 7 Ο. Yes. In someone Joshua's age, yes. Not for 8 Α. adults. 9 Would there be nurses involved? 10 Ο. Α. Yes. 11 All right. 12 Q. What I would like you to do is to tell me what the 13 role is of the physicist in these circumstances? 14 The physicist supervises the machine calibration, 15 Α. 16 the setup and the delivery of the radiation. Q. 17 Okay. And what duties does the physicist execute to 18 accomplish those goals, the calibration and the delivery 19 of the radiation? In other words, you are the radiation 20 21 oncologist. 22 Α. Right. You make a determination of what is the dose that 23 Ο. 24 you want the patient to receive, correct? Uh-huh, uh-huh. Yes. 25 Α.

| 1 | Q. And walk me through, when does the physicist get | | |
|----|---|--|--|
| 2 | involved in the process? | | |
| 3 | A. Shall we use the specifics of Joshua? | | |
| 4 | Q. Yes, sir. | | |
| 5 | A. Well, if I can have the chart, I can I don't | | |
| 6 | have all the dates. | | |
| 7 | Q. You may want to look at Exhibit they are all in | | |
| 8 | there, I believe, and certainly refresh your recollection | | |
| 9 | with 101, but I would like you to go through Exhibit A, | | |
| 10 | Doc, and if you could find the corresponding record, it | | |
| 11 | would be easier for me to follow. | | |
| 12 | A. So I first met Joshua, the patient, and his mother | | |
| 13 | on the 6th of January of 2000. | | |
| 14 | Q. Can you tell me what document you are looking at, | | |
| 15 | sir? | | |
| 16 | A. I am looking at Document 6. | | |
| 17 | Q. Thank you. | | |
| 18 | And that would be the first time that you had any | | |
| 19 | involvement with Joshua Valdivieso? | | |
| 20 | A. Correct. | | |
| 21 | Q. And that was at the referral of Dr. Wiersma? | | |
| 22 | A. Correct. | | |
| 23 | Q. Okay. | | |
| 24 | A. And that is what it says, this is the initial | | |
| 25 | consultation, it is a four page document where I review | | |
| | | | |
| | | | |

the history of the patient's presentation of disease. 1 Uh-huh. Ο. 2 The review of systems that I obtained through the 3 Α. mother. 4 Uh-huh. 5 Ο. The past medical history that principally came 6 Α. 7 from the patient's mother. Uh-huh. 8 Ο. The social history, again obtained principally 9 Α. from the mother, the family history, and then the 10 physical examination. 11 12 0. Okay. And the reason that you were seeing Joshua in 13 14 January of 2000 was to determine whether or not he was an appropriate candidate for consolidative irradiation as 15 part of his CCG protocol for treatment of Stage IV 16 17 neuroblastoma; is that correct? Correct, yes. 18 Α. 19 Q. And if you determined at that point in time that you did not believe total body irradiation would be 20 beneficial for him, it was certainly your judgment to 21 22 say, I don't think this treatment has the potential to help this child, correct? 23 I was -- the question I was asked at that time and 24 Α. the reason for the consultation was to look at local 25

irradiation to sites of residual disease, and as well as 1 the primary site. 2 Q. Let me take the dive this way: 3 Doctor, if a pediatric oncologist refers you a 4 patient for any type of radiation oncology treatment, and 5 you determine, in your medical judgment, that it is not 6 7 in the best interests of the patient to undergo that treatment, you can certainly say, I choose to not provide 8 this treatment to this patient? 9 10 Α. Correct. All right. 11 Q. So before you would institute any radiation 12 oncology treatment to a patient, you have satisfied 13 yourself that it is medically warranted and indicated for 14 treatment of the patient's condition, true? 15 16 Α. Correct. 17 Q. All right. So you saw Joshua on January 6th. 18 Α. Right. 19 20 And at that time, the question that was being asked was whether he would be appropriate for local 21 irradiation to sites of residual disease as well as to 22 23 the primary sites, which there were multiple ones. He was scheduled for rescanning, actually, 24 25 subsequent to when I saw him. But at that time I talked
to the mother about the use of twice daily radiation over 1 seven treatment days, delivering 1.5 Gray fractions twice 2 daily to the total dose of 21 Gray, which was part of the 3 protocol that we were following at that time. 4 Ο. All right. 5 And then did there come a time where some 6 decisions were altered and it was decided that he was 7 going to receive TBI? 8 The patient subsequently had a restaging in early 9 Α. to mid January of 2000 -- this is -- yes, this is 2000 --10 that involved an MIBG scan, which is a nuclear medicine 11 scan of a tracer element that is specific for 12 neuroblastoma, for the most part, as well as an MRI scan 13 of the skull and basically a total body MRI scan. And 14 15 those were subsequently performed. And based upon the tests, did a determination --16 0. was a determination made that this child was going to be 17provided TBI? 18 That is right, we had an intervening pediatric 19 Α. 20 oncology tumor board where that was discussed, and the extent of disease was found to be too extensive to 21 consider him for the local irradiation, what I had talked 22 to the mother about on the 6th. 23 Okay, so sometime after the 6th and before the 24 Ο, 25 26th of January, some additional diagnostic testing was

| 1 | done and then Joshua's case was presented to the tumor | | |
|----|---|--|--|
| 2 | board? | | |
| 3 | A. That is my recollection. I know that the | | |
| 4 | additional diagnostic studies were done. | | |
| 5 | Q. And physicians who would be present at the tumor | | |
| 6 | board would be specialists from pediatric oncology? | | |
| 7 | A. Correct. | | |
| 8 | Q. And your colleagues from the pediatric radiation | | |
| 9 | oncology, or just you? | | |
| 10 | A. Well, I am the only one that attends. | | |
| 11 | Q. The tumor board? | | |
| 12 | A. Correct. | | |
| 13 | Q. Okay. | | |
| 14 | What is the purpose of the tumor board, sir? | | |
| 15 | A. It is a management and educational discussion, | | |
| 16 | which in this case focuses on new patients with pediatric | | |
| 17 | malignancies, or we could talk about existing patients | | |
| 18 | where there is a potential change in the course of the | | |
| 19 | disease. And it is to bring together people to review | | |
| 20 | the new diagnostic studies or the new pathology reports. | | |
| 21 | So it involves pediatric pathologists, sometimes | | |
| 22 | hematopathologists, pediatric diagnostic radiology, | | |
| 23 | pediatric oncology, the pediatric oncology Fellows often | | |
| 24 | attend, and the pediatric residents on the inpatient | | |
| 25 | pediatric service often attend, and the nurses from | | |
| | | | |
| | | | |

| l | pediatric oncology, and probably half the time my nurse | | |
|----|--|--|--|
| 2 | will attend. | | |
| 3 | Q. Does Dr. Wiersma take notes at these tumor board | | |
| 4 | meetings? | | |
| 5 | A. I think | | |
| 6 | MR. GROEDEL: Objection. | | |
| 7 | You may answer. | | |
| 8 | A. (Continuing) I don't see the notes. I think she | | |
| 9 | is the coordinator of the pediatric tumor board. | | |
| 10 | Q. Are minutes or notes taken at these meetings, | | |
| 11 | based upon your recollection of them? | | |
| 12 | A. I don't see the minutes. | | |
| 13 | Q. I didn't ask if you saw them. | | |
| 14 | A. I don't know. | | |
| 15 | Q. Okay. | | |
| 16 | A. The only thing I see is the semi a sheet a | | |
| 17 | couple days beforehand, I received it last night for the | | |
| 18 | cases on Thursday, that just list on Thursday there will | | |
| 19 | be four patients discussed. | | |
| 20 | Q. Does anybody from the radiation oncology | | |
| 21 | department, other than you, attend these tumor board | | |
| 22 | meetings? | | |
| 23 | A. No. They certainly could, but they don't. | | |
| 24 | Q. Would you agree with the statement that the reason | | |
| 25 | that you present patients' cases at tumor boards is to | | |
| | | | |
| | | | |
| | MODGE GANGUEDO 5 HODGE | | |

tap into the collective expertise, wisdom, education and 1 experience of specialists knowledgeable in treating the 2 patient's disease, to discuss it amongst yourselves and 3 to come up with a collective decision of what would be 4 5 the best way to treat the patient's condition? Correct. 6 Α. 7 Q. All right. The other group that would be there at times would 8 Α. be the pediatric surgeons, again depending on the 9 specific case. 10 All right. 11 Ο. Pediatric neurosurgery, pediatric otolaryngology Α. 12 13 in the case of head and neck cancers, pediatric general surgery. 14 15 Ο. Okay. They generally don't attend the other conferences 16 Α. if they are not -- if a specific patient of theirs isn't 17 18 being discussed. And after the presentation of Joshua's case at the 19 Ο. 20 tumor board in January, the decision was made that Joshua should receive TBI? 21 Α. Correct. 22 23 Ο. All right. And you concurred in that? 24 Yes, I did. 25 Α.

And to your knowledge, did Dr. Wiersma concur in 1 Ο. that? 2 Yes. 3 Α. All right, getting back to at what point the Ο. 4 physicist gets involved. 5 Now the collective decision is made how we are 6 going to approach treating this patient. You make a 7 determination TBI is the way to go. What next occurs, 8 sir? 9 I next meet with the mother and the patient, again 10 Α. on the 17th of January. 11 12 Ο. Can you show me where that note is? 13 Α. That is Number 4. Okay, uh-huh. 14 Q. The note reads, met with mother in --15 Α. MR. GROEDEL: Wait. He hasn't asked --16 THE WITNESS: Okay. It is hard. 17 18 MR. GROEDEL: Do you want him to read his note? 19 MR. MARGOLIS: Yes, please. 20 (Continuing) Met with mother in patient's Α. 21 presence; in light of the number involved sites at 22 23 restaging by MIBG and MRI, will plan no local XRT -meaning radiation therapy -- but will give TBI at 333 24 centiGray fractions q.d. times three to 1000 centiGray. 25

MORSE, GANTVERG & HODGE

If I can interrupt you, if I am at all up on the Q. 1 2 learning curve here, that means you want the kid to get 10 Gray? 3 Exactly. 4 Α. 5 Q. Okay. Discussed technique, risks, acute and late side 6 Α. effects with mother. TBI measurements taken. 7 TBI scheduled for 1-26, 1-27, 1-28. And then I signed it. 8 Doctor, what -- how many patients have you been 9 Ο. involved in that receive TBI? 10 Probably 350, 400. 11 Α. And how many TBI treatments are done yearly at UH 12 Ο. since you have been there? 13 It is a diminishing number, but I would say maybe 14 Α. 15 or 20. 15 When a patient -- and you are certainly 16 0. knowledgeable, and as the chairman of the department, you 17 are aware of the overall process of what happens when a 18 patient receives TBI? 19 20 Α. Yes. We have identified that the radiation technologist 21 Ο. is involved, a dosimetrist, physicist, nurses, 22 anesthesia. Anybody I have left out? 23 Α. No. 24 Is that a team approach in the treatment of a 25 Q.

| 1 | patient? | |
|----|--|---|
| 2 | Α. | During the treatment, it is a well, it is a |
| 3 | seque | ntial interaction. |
| 4 | Q. | Okay, but it is done as a team, to treat the |
| 5 | patie | nt? |
| 6 | Α. | Not the same team. |
| 7 | Q. | Not the same team, but in generality, I am talking |
| 8 | the p | hysicist |
| 9 | Α. | Right. |
| 10 | Q. | the radiation techs, the dosimetrists, they are |
| 11 | all part of the team that is rendering care to the | |
| 12 | patie | nt? |
| 13 | Α. | Yes. |
| 14 | Q. | Okay. |
| 15 | | And I understand that they may not all be |
| 16 | provid | ding care simultaneously, as what happens during an |
| 17 | opera | tive procedure. |
| 18 | Α. | But there is not a TBI team, per se. |
| 19 | Q. | I understand that. I am using team |
| 20 | А. | Right, right. |
| 21 | Q. | to indicate it is a collective |
| 22 | Α. | A group of people. |
| 23 | Q. | And you would agree with me that the physicists |
| 24 | have : | independent responsibilities and duties to the |
| 25 | patie | nt in the rendering of TBI care? |
| | | |
| | | |

Α. Yes. 1 You would agree with me that the radiation 2 Ο. technologists have independent responsibilities and duty 3 to a patient receiving TBI care? 4 Ά. Yes. 5 You would agree with me that the nurses have 6 Ο. various responsibilities and duties to a patient 7 receiving TBI? 8 Α. Yes. 9 10 Ο. Is there a system of checks and balances that is designed into the system where TBI is given to a patient? 11 MR. GROEDEL: Objection. It seems sort of 12 vaque, the question. 13 (Continuing) Do you understand what I meant? Q. 14 15 MR. GROEDEL: Are you talking about the dosing checks and balances? 16 Is there a written procedure? I don't know of 17 Α. any. 18 Let me ask you in generality, in a patient that is 19 Ο. being administered TBI, are there any checks and balances 20 inherent in the system relative to that care --21 MR. GROEDEL: Objection. 22 23 Ο. -- at UH, in January of 2000? 24 MR. GROEDEL: You may answer. 25 Objection.

I am not sure if there is a written set of Α. 1 quidelines. 2 3 MR. MARGOLIS: All right. Is -- excuse me one minute. 4 (Pause) 5 THE VIDEOGRAPHER: Straighten out your 6 7 mike. THE WITNESS: Okay, sorry. Bring it up 8 closer? 9 THE VIDEOGRAPHER: That is good. Thank 10 11 you. BY MR. MARGOLIS: 12 What about the general standard operating 13 0. procedure, whether there is written protocol delineating 14 it or not? 15 MR. GROEDEL: Objection. 16 17 You may answer. I am not sure if that existed at that time. Α. 18 19 Ο. Okay. 20 Did it exist when you were at the University of Wisconsin? 21 I am not sure if I was aware of one. 22 Α. Q. All right. 23 Let's talk about the specific of dosing a patient. 24 Are there checks and balances inherent in that system? 25 MORSE, GANTVERG & HODGE

Α. There wasn't. 1 At University Hospitals? 2 Ο. 3 Α. Right. In January of 2000? 4 Q. 5 Right. Α. Didn't you have to sign off on various physics 6 Ο. 7 computation sheets? Ά. NO. 8 Was there any type of checks and balances inherent 9 Q. in the system of TBI at facilities other than RB&C in 10 January of 2000 --11 12 MR. GROEDEL: Object. -- based upon your knowledge? 13 Ο. MR. GROEDEL: Objection. 14 You may answer. 15 I don't know. A. 16 17 Ο. Doctor, you are a nationally renowned expert in your area of specialization, are you not? 18 19 Α. Yes. Q. All right. 20 You regularly lecture colleagues in your area of 21 22 specialization, correct? Α. Yes, I do. 23 You have designed radiation oncology programs in 24 Ο. the course of your career, correct? 25 MORSE, GANTVERG & HODGE

Α. Yes, I have. 1 You are knowledgeable generally about what it is 2 Ο. 3 that is done in the, quote unquote, medical specialty of radiation oncology relative to the systems used for 4 administering TBI treatment to a patient, correct? 5 Correct. 6 Α. 7 Ο. In any institution that you are aware of, were there checks and balances that were designed into the 8 system relative to the dosing of a patient for TBI? 9 10 MR. GROEDEL: Objection. 11 You may answer. In reviewing what existed in January of 2000, I am 12 Α. aware of, that the system was not fail-safe, obviously. 13 I am not asking you, sir, the specific system at 14 Ο. I am asking you in generality, given the fact that 15 UH. you have testified of your level of expertise in this 16 17 area, both at UH and what was done in the, quote unquote, community of radiation oncology, would a checks and 18 balance system be something that would exist in other 19 20 facilities, albeit not UH? MR. GROEDEL: Objection. 21 22 If you know. (Continuing) That you know of? 23 Q. Well, a system existed at UH, but it wasn't 24 А 25 fail-safe.

Okay, I don't want to get in a semantic exchange Q. 1 here. 2 3 I asked you if there was a check and balance system that existed at UH relative to the dosing rates of 4 a patient undergoing TBI in January. You have told me 5 now that there was not. 6 7 Α. Because --I didn't ask you if it was a fail-safe system. Ο. 8 Α. Okay. 9 Okay? I think everybody at this table has no 10 Ο. problem knowing that it wasn't fail-safe. 11 12 Α. Correct. My question to you again is, in January of 2001 --13 Ο. 2000? 14 15 Α. 2000. -- 2000, was there any check and balance system 16 Ο. that would have been in effect relative to the dosing 17 rates of a patient undergoing TBI at UH? 18 MR. GROEDEL: Objection. 19 20 I am not sure you two are connecting with respect to your use of the word, checks and 21 balances. 22 (Continuing) Quality control. 23 Q. MR. GROEDEL: I mean, answer the question 24 25 to the best of your ability, Doctor.

A. Yes, I mean, there is the machine calibration, the
setups, the dose delivery and notes in terms of any other
specific technical issues. So those were checks and
balances. But what didn't happen is it doesn't come back
to the physician to see beforehand.
Q. So once you write the prescription for the dosing

rates, you are not involved with the process from that 7 point until after the treatment has been rendered? 8 Well, I see the patient on treatment. But I did 9 Α. not see anything come back to me, which is different than 10 the 99 percent external beam treatment we do, where there 11 12 is a lot of interactions between when you see a patient, 13 and the patient then gets CT treatment plan, and then simulated, and then has their ports taken, and then 14 starts treatment. There are usually four separate 15 interactions where you review things, which is not done 16 with the TBI, or was not done with the TBI. 17

18 Q. Would you please turn to Exhibit 15.

19 A. (Witness complies).

20 MR. MORIARTY: When you get to a convenient 21 spot, I would like to take a couple minute break. 22 MR. MARGOLIS: We can do it right now. 23 MR. MORIARTY: If this is convenient. 24 MR. MARGOLIS: This is as convenient as any 25 other spot.

| 1 | (Short recess had.) |
|----|--|
| 2 | BY MR. MARGOLIS: |
| 3 | Q. Doctor, what I would like you to do, if you could |
| 4 | look at Exhibit 101, which is the original, and then if |
| 5 | you would be kind enough to cross reference it in what |
| 6 | you have there, I would like you to tell me by name and |
| 7 | title and what their responsibilities would have been, |
| 8 | each medical care provider that was involved in the TBI |
| 9 | administered to Joshua? |
| 10 | You have identified Dr. Wiersma, you have |
| 11 | identified the decision of the tumor board, you have |
| 12 | identified your involvement. I want to take it from |
| 13 | there, fair enough? |
| 14 | A. Okay. |
| 15 | Q. Okay. |
| 16 | A. So we are not referencing 16 any more? |
| 17 | Q. You can certainly reference it. I am just saying |
| 18 | that if you need to reference 101, because it may have |
| 19 | individuals who are not referenced in Exhibit 1, that is |
| 20 | fine. But if it is in fact represented in Exhibit 1, I |
| 21 | would appreciate you identifying it by the number set |
| 22 | forth in the Exhibit A binder, okay? |
| 23 | A. According to the note on the 17th, which is |
| 24 | Q. 4? |
| 25 | A Number 4, I asked a dosimetrist that day |
| | |
| | |
| | MORSE, GANTVERG & HODGE |

Ī

| l | well, I was seeing the patient and the mother right |
|----|--|
| 2 | after I saw the patient and the mother, to take the TBI |
| 3 | measurements, so that would be that person. |
| 4 | Q. Do you know who that person was? |
| 5 | A. Actually, I do not know who that person was, or I |
| 6 | cannot recall. |
| 7 | And those measurements taken on that day would be |
| 8 | recorded on this Page Number 17, okay? |
| 9 | Q. Okay. |
| 10 | And what would have been the purpose of those |
| 11 | measurements that are on 17? |
| 12 | A. They take measurements of the diameter of various |
| 13 | body parts, starting under three anatomical measurements |
| 14 | Q. Okay. |
| 15 | A of head and neck, mediastinum, umbilicus, hip, |
| 16 | knee, ankle. |
| 17 | Q. All right. |
| 18 | A. And I don't in here, there is no signature, I |
| 19 | am not sure whose handwriting this is, so I can't tell. |
| 20 | Q. Would this basically be |
| 21 | A. There is no date on this, either. But I assume |
| 22 | I had asked them to do it, according to my note, on the |
| 23 | 17th, so |
| 24 | Q. Okay. |
| 25 | A I assumed it was done that day. |
| | |
| | |

| 1 | Q. | All right. |
|----|--------|--|
| 2 | | And this would not at all involve a usage or |
| 3 | calcul | ation of the dosage? |
| 4 | A. | No, no. |
| 5 | Q. | Okay. |
| 6 | | Who were the dosimetrists that were employed by |
| 7 | the de | partment at that point? |
| 8 | A. | David Abraham is it Abramson Abraham, I |
| 9 | think | it is. |
| 10 | Q. | Okay. |
| 11 | A. | And Joann, I think she was still there at that |
| 12 | time. | I don't recall her last name. |
| 13 | Q. | Okay. |
| 14 | | Was Deb Harrp at all involved in the care provided |
| 15 | to Jos | hua? |
| 16 | A. | She is a nurse, she is my nurse. |
| 17 | Q. | Was she at all involved? |
| 18 | Α. | During his TBI |
| 19 | Q. | At any point, sir, from when you first saw the |
| 20 | child | through the treatment. |
| 21 | A. | She would have seen Joshua and his mother on the |
| 22 | 6th. | |
| 23 | Q. | Okay. |
| 24 | А. | Possibly on the 17th, although I know that was on |
| 25 | a Mond | lay, and that is usually a very busy day, she is |
| | | |
| | | |
| | ,, | MORSE, GANTVERG & HODGE |

doing a lot of things that day, so I am not sure. 1 Ο. Would she accompany the patient when the TBI was 2 being administered? Certainly not in the room at the 3 time it was being administered, but --4 May or may not. It depends on the schedule, if 5 Α. they are early or late. Our clinics run from around 7:00 6 7 in the morning to, at that time, probably 6:30 or 7:00 o'clock at night, so the nursing hours were often 8 staggered, so I don't know. 9 Would she document any progress notes relative to 10 Ο. any care she had of the patient? 11 12 Α. No. Would the radiation techs document any records 13 Ο. relative to the job they have in the TBI? 14 15 Α. Yes, and that is documented in the chart, which is listed Number 13 and 14. 16 17 Q. Okay, let me look at that, sir. So 13 would be a document generated by the 18 radiation technologist? 19 20 Α. Correct, 13 and 14, it is the same document, it is just the other side of the page. 21 Would they provide any other documentation in 22 Ο. addition to what is set forth in 13 and 14? 23 24 А. No. 25 Ο. And would 13 and 14 be made contemporaneous with

MORSE, GANTVERG & HODGE

the administering of the TBI --1 Α. Yes. 2 -- by the radiation technologist? 3 Q. Α. Correct. 4 5 Do we know who the radiation techs were by looking Ο. at 13 and 14? 6 Yes, they initial. 7 Α. Where is it on 13, sir? 8 Q. Therapists Initials, it is on 14. 9 Α. Okay, 14. All right. Q. 10 And who would the therapists have been? 11 BS would be Barb Scott and DO would be Diane Otto. 12 Α. All right, now what about the box that says M.D. 13 Ο. Initials? 14 Again, that is something that I, personally, never 15 Α. signed on any patient. 16 17 Ο. What is it for? Α. I am not sure. 18 19 Ο. So would it be that the M.D. would come down and oversee the administration of TBI and then sign off? 20 MR. GROEDEL: Objection. 21 22 You may answer. This is a standard form for all of our patients. 23 Α. 24 But again, in the four years I have been treating, I 25 can't recall ever signing that in that column. I put

notes in the chart. 1 Do you know what its purpose is? 2 Q. No, I do not. Α. 3 Why is every other box to the left of the title Q. 4 box filled in, but the M.D. Initials are not? 5 MR. GROEDEL: Objection, asked and 6 7 answered. Go ahead. 8 Well, again, it is not a policy. 9 Α. Okay, we have identified the dosimetrist. You 10 Ο. have been kind enough to point out to me which document 11 the dosimetrist authored. We also have identified the 12 radiation technologists by their initials. Do you know 13 their names? 14 15 MR. WALTERS: He just told you. MR. GROEDEL: He told you. 16 17 MR. MARGOLIS: I am sorry. MR. GROEDEL: Yes, he did. 18 (Continuing) What about the physicists? 19 Q. 20 You don't need this, do you, Doctor (indicating)? Well, I may. It is easier for --21 Α. 22 Q. We will get it back, if you do. The physicists -- there are two documentations 23 Α. from the physicists. The first is Number 15, and the 24 second is Number 16. 25

54

What is Number 15, Doctor? Q. 1 The 15 is actually the calculation, it is listed 2 Α. 18 MV X-rays Total Body Irradiation Calculation Sheet, 3 and it says, Use Spoiler Factor, this is the standard, 4 this is the checks and balances you were asking about, 5 these are some of the checks and balances. 6 7 Ο. Would 15 be generated by the prescription? Α. Yes. 8 9 Ο. All right. Now, where it says, calculated by, would that be 10 David Abrams [sic]? 11 DA, I assume that is his initials. 12 Α. And where it says, checked --13 Ο. Α. 14 Right. 15 -- who is that? Ο. SAB would be Dr. Beddar. 1.6 Α. 17 Ο. Who is -- and he is a physicist? Physicist, yes. 18 Α. Sam Beddar? 19 0. 20 Α. Yes, Sam Beddar. Is he employed by Case? 21 Ο. 22 MR. GROEDEL: Objection. You may answer, if you know. 23 Yes, he is, but he is paid by University Hospitals 24 Α. of Cleveland. 25

```
Q.
            All right.
 l
            Do you, as the chairman of the department, do
 2
     you -- can you, if you choose, exercise control over
 3
     Mr. Beddar's conduct?
 4
                    MR. GROEDEL: Objection.
 5
                    You may answer.
 6
 7
     Α.
            In my role as chair, I -- he is under my
     direction.
 8
     Q.
            Okay.
 9
            Why would a physicist check the calculation as
10
     opposed to the radiation oncologist?
11
            Because that is what physicists do.
12
     Α.
13
     Ο.
            Okay.
            And would Mr. Beddar --
14
            He is a Ph.D., he is Dr. Beddar. Ph.D. phys --
15
     Α.
     not a physician, he is a Ph.D.
16
17
     Q.
            Okay.
            And he has worked hard for his Ph.D. status?
18
19
     Α.
            Right.
            Would Dr. Beddar refer, if you know, to your
20
     Ο.
     prescription?
21
2.2
     Ά.
            Yes.
            How many patients have you worked with Dr. Beddar
23
     Ο.
     on, where TBI was administered? Is this the first case?
24
25
     Α.
            I don't know. He was one of, at that time, five
                       MORSE, GANTVERG & HODGE
```

| 1 | or six physicists that could have been involved in these |
|----|--|
| 2 | calculation checks. |
| 3 | Q. Do you know if you had ever worked with |
| 4 | Dr. Beddar prior to Joshua Valdivieso in a patient |
| 5 | receiving TBI? |
| 6 | A. I do not know. |
| 7 | Q. Do you know if this was the first case that |
| 8 | Dr. Beddar was ever involved with, in a patient getting |
| 9 | TBI? |
| 10 | A. I do not know. |
| 11 | Q. And what is Exhibit 16, Dr. Kinsella? |
| 12 | A. 16 is a further check with in vivo measurements, |
| 13 | it was dated the 18th, but these are in vivo, they have |
| 14 | to be done during the treatment themselves, and this is |
| 15 | just to make sure well, these are just the phantoms. |
| 16 | They may just be running a check. |
| 17 | Q. Was this a simulation? |
| 18 | A. Well, but the patient isn't there. This is dated |
| 19 | the 18th. So they either do it, just a setup, and these |
| 20 | are calculations based on the measurements. |
| 21 | Q. Would these calculations also be dependent upon |
| 22 | the prescription that you wrote? |
| 23 | A. Yes. Although the prescription is not outlined as |
| 24 | it was on the previous page in terms of the tumor dose |
| 25 | and dose per fraction. |
| | |

| 1 | Q. | Okay. |
|----|----------|--|
| 2 | A | But they are both dated the same day, so |
| 3 | Q. | Doctor, did Dr. Beddar ever discuss with you the |
| 4 | dose of | 1 Gray? |
| 5 | A | No, he did not. |
| 6 | Q. | Would you expect a physicist discharging the |
| 7 | duties | that Dr. Beddar was discharging in the care of |
| 8 | Joshua ' | Valdivieso to bring to the attention of the |
| 9 | prescri | bing radiation oncologist a subtherapeutic dose? |
| 10 | | MR. GROEDEL: Objection. |
| 11 | | You may answer. |
| 12 | | MR. WALTERS: Objection. |
| 13 | А. | I would have wished he questioned that. Doses in |
| 14 | the ran | ge of 1 Gray have been given before. |
| 15 | Q | For patients with the medical profile and goals |
| 16 | that Jo | shua was being administered TBI? |
| 17 | A | No. |
| 18 | Q. (| Okay. |
| 19 | A | But pediatric and adult patients, in some |
| 20 | pediatr | ic malignancies. |
| 21 | Q. 1 | My question is this: |
| 22 | | Has there ever been a dosage of 1 Gray for TBI |
| 23 | under t | he circumstances of the patient profile of |
| 24 | Joshua' | s? |
| 25 | A | Not that I can recall. |
| | | |
| | | |

| 1 | Q. All right. |
|----|---|
| 2 | Would you, based upon your knowledge as the |
| 3 | chairman of the department, would you expect that to be |
| 4 | something that would be picked up by Dr. Beddar? |
| 5 | MR. GROEDEL: Objection, asked and |
| 6 | answered. |
| 7 | MR. WALTERS: Objection. |
| 8 | MR. NORCHI: Objection. |
| 9 | MR. GROEDEL: Asked and answered. Go |
| 10 | ahead. |
| 11 | MR. MARGOLIS: Respectfully, he didn't |
| 12 | answer. He said he wished he did, and that wasn't |
| 13 | what I asked you. |
| 14 | A. But I wrote the prescription. |
| 15 | Q. I am not asking that. |
| 16 | I am asking you corrected me when I referred to |
| 17 | Dr. Beddar as Mr. Beddar, and I acknowledged that he |
| 18 | certainly has a lot of training and education and |
| 19 | experience. And you told me earlier that he has |
| 20 | independent responsibilities and duties to the patient |
| 21 | under these circumstances. |
| 22 | Would you have expected him to have brought to |
| 23 | your attention the dose of 1 Gray? |
| 24 | MR. GROEDEL: Objection. |
| 25 | MR. WALTERS: Objection. |
| | |
| | |
| | MORSE, GANTVERG & HODGE |

MR. GROEDEL: You may answer. 1 MR. NORCHI: Objection. 2 Possibly. 3 Α. You have no opinion -- what does possibly mean? Q. 4 My point is, I wrote the prescription wrong. 5 Α. You --6 Ο. 7 And he carried out the prescription. Α. Ο. Okay. 8 On its face, would you expect, under these 9 circumstances, the physicist to bring to your attention 10 the prescription of 1 Gray? 11 MR. GROEDEL: Objection, asked and 12 13 answered. MR. WALTERS: Same objection. 14 MR. NORCHI: Objection. 15 Maybe. I am not sure. Yes. Α. 16 You said maybe, you said you are not sure, and 17 Ο. then you said yes. And I am trying to get you to commit 18 yourself to one of the three. 19 MR. GROEDEL: Objection. If you --20 Α. I am not sure. 21 Would you -- are you responsible for QA in the 22 Q. 23 department that you run? Technically, yes. 24 Α. All right. 25 Ο.

60

| 1 | Would you communicate to physicists that they have |
|----|---|
| 2 | some duty under a case such as this to bring to the |
| 3 | attention of the radiation oncologist that it is clearly |
| 4 | a subtherapeutic dose? |
| 5 | MR. GROEDEL: Objection. |
| 6 | You may answer. |
| 7 | MR. MORIARTY: Could you read that back for |
| 8 | me, please. I am sorry. |
| 9 | (Record read.) |
| 10 | MR. MORIARTY: Thank you. Sorry. |
| 11 | A. At that time, there was no QA policy that would |
| 12 | have brought that to the attention that the physicist |
| 13 | should have brought that to the attention of the |
| 14 | prescribing radiation oncologist. |
| 15 | Q. So is it your testimony that the only |
| 16 | responsibility of the physicist under these circumstances |
| 17 | is to do the computations based upon the prescription, |
| 18 | and that is it? |
| 19 | A. And to safely deliver the treatment, right. They |
| 20 | are responsible for all the technical aspects. |
| 21 | Q. In this case, did you review any of Dr. Beddar's |
| 22 | records |
| 23 | A. No. |
| 24 | Q prior to TBI being administered? |
| 25 | A. No, I did not. |
| | |
| | |

Do you have any type of routine with him, where he Q. 1 does the initial calculations and then he sends them to 2 you with a yellow sticky on them for your approval or 3 review? 4 No. 5 Α. Ο. All right. 6 And in this case, it is your testimony that 7 Dr. Beddar never brought to your attention the dosage of 8 1 Gray? 9 Α. Yes. 10 Had he brought it to your attention prior to the 11 Q. TBI being delivered, what would you have done? 12 I would have corrected the mistake on the 13 Α. prescription and delivered the correct dose, or rewrote 14 the prescription and instructed him to recalculate it and 15 deliver the right dose. 16 When Dr. Beddar is doing his calculations on this 17 Ο. case, would he have had the benefit of Exhibit 4, which 18 is your 1-17 note which says 10 Grays? 19 20 Α. Well, he did the calculation on the 20th, according to this signature, so he would have had the 21 22 17th. Ο, All right. 23 So had he chosen to review your note of 1-17, he 24 25 would have seen that there was a discrepancy between what

MORSE, GANTVERG & HODGE

| 1 | you said you wanted the patient to get and the | |
|----|---|---|
| 2 | prescription that you wrote? | |
| 3 | A. Correct. | |
| 4 | Q. Okay, would you please show me the therapy | |
| 5 | prescription for Joshua's TBI in Exhibit 101? | |
| 6 | Doc, I am sorry, I should follow my outline a | |
| 7 | little bit. Let me withdraw that and ask you another | |
| 8 | question. | |
| 9 | In this case, would you expect a radiation | |
| 10 | therapist to know that the dose is subtherapeutic? | |
| 11 | A. No. | |
| 12 | Q. Isn't there a period of time that it takes to | |
| 13 | deliver 1 Gray versus 10? | |
| 14 | A. Yes. | |
| 15 | Q. And isn't there a meter that clicks every time | |
| 16 | some dosage is delivered? | |
| 17 | A. Yes. | |
| 18 | Q. And wouldn't the dosage of 1 Gray be significantly | T |
| 19 | less than the dosage of 10? | |
| 20 | A. Correct. | |
| 21 | Q. Are you aware in this case as to whether or not | |
| 22 | any of the radiation technologists had any discussions | |
| 23 | with the child's mother about how quickly the treatment | |
| 24 | went? | |
| 25 | A. No. | |
| | | |
| | | |

| 1 | Q. | What is the name of the piece of equipment that |
|----|--------|---|
| 2 | clicks | every time a dosage of administration is a |
| 3 | dosage | of radiation is administered? |
| 4 | A. | Well, there is a control panel for the linear |
| 5 | accele | rator that is programmed with the dose as part of |
| 6 | that. | |
| 7 | Q. | Is there some audible sound that is made? |
| 8 | Α. | No. |
| 9 | Q. | Do you know what the time would be for a dosage of |
| 10 | l Gray | that is fractionated? |
| 11 | A. | The prescription was written to go to a dose rate |
| 12 | of 5 t | o 10 centiGray a minute. I think this machine, |
| 13 | with t | hese calculations, typically delivers it around 7.5 |
| 14 | centiG | ray a minute. So a hundred centiGray would be |
| 15 | about | 14 minutes. |
| 16 | Q. | And that would be at what total dose? |
| 17 | Α. | At a hundred, as I said. |
| 18 | Q. | My question is, if this child had received 10 |
| 19 | Grays, | how long would it have taken to administer the |
| 20 | treatm | ent on a daily basis? |
| 21 | Α. | About 45 minutes or longer each day. |
| 22 | Q. | And based upon the prescription of 1 Gray, how |
| 23 | long w | ould it take on a daily basis, 14 minutes? |
| 24 | Α. | Substantially, yes. |
| 25 | Q. | Would you expect that to be something to be picked |
| | | |
| | | |

up by a radiation technologist? 1 MR. GROEDEL: Objection. 2 You may answer. 3 MR. WALTERS: Objection. 4 They were carrying out the prescription. 5 Ά. Would you expect the radiation technologists under 6 Ο. these circumstances to recognize that this was a 7 subtherapeutic dose? 8 No. Α. 9 Is there ever a point in medicine where nurses 10 Ο. will question the dose of a certain medicine that is 11 12 written by a physician because they know it to be not a therapeutic dose, or do they just blindly go forward and 13 administer whatever the physician has written? 14 MR. GROEDEL: Objection. 15 16 You may answer. 17 MR. WALTERS: Objection. There is possibly a situation where they should 18 Α. 19 question. 20 All right, but that doesn't exist in radiation Ο. oncology, in your opinion, under these circumstances? 21 22 Α. No, no, it could exist, but it didn't. Is there any other individual that was involved in 23 Ο. the delivery of TBI to this child who we have not 24 identified? 25

65

| 1 | Α. | No. |
|----|-----------------------------|--|
| 2 | Q. | Were there any radiation records that you removed |
| 3 | from t | his chart at any point in time? |
| 4 | A. | No. |
| 5 | Q. | When a patient is being treated for TBI, do you |
| 6 | evaluate the patient at all | |
| 7 | A. | Yes. |
| 8 | Q. | on the dates of treatment? |
| 9 | Α. | Typically on the first and last day, if it is |
| 10 | twice | daily. In this case, it was just on the first day. |
| 11 | Q. | So you evaluated Joshua on 1-26 before or after |
| 12 | his TE | 31? |
| 13 | A. | I think it is probably afterwards, because I |
| 14 | commen | t he tolerated it. |
| 15 | Q. | Where is your note of seeing him on 1-26? |
| 16 | A. | It is in the hospital record. |
| 17 | Q. | Okay, can you show that to me? |
| 18 | | MR. GROEDEL: We didn't bring the hospital |
| 19 | | record with us. |
| 20 | | MR. MARGOLIS: Well, maybe we can break and |
| 21 | | you can get it, because I asked you to bring any |
| 22 | | and all records that he authored relative to his |
| 23 | | treatment of Joshua, and he certainly identified |
| 24 | | that as a record. |
| 25 | Q. | (Continuing) So you would have seen him on the |
| | | |
| | | |
| | | MORSE, GANTVERG & HODGE |

26th? 1 Correct, that is what I wrote, a note. 2 Α. Okay. Q. 3 And do you recall what the note indicated? 4 Α. It is a short note, basically, patient was seen, 5 plan to deliver TBI at 333 centiGray fractions q.d., б 7 received first TBI dose, tolerated treatment well, and I signed it. 8 MR. MARGOLIS: Marc, if you want to break 9 now, or I can come back to it later. 10 MR. GROEDEL: No. 11 MR. MARGOLIS: I need it. 12 MR. GROEDEL: I think we have it in this 13 folder here. Yes, this is the one, I think. 14 Is this it? 15 THE WITNESS: Uh-huh. 16 MR. GROEDEL: This is it. 17 18 MR. MARGOLIS: Yes, that is fine, if you could show it to him. 19 BY MR. MARGOLIS: 20 Doctor, your 1-26 note, that was done after the Ο. 21 TBI was administered? 22 I will read it. It identifies itself as radiation 23 Α. oncology, because this in an inpatient hospital note. 24 Starts TBI this a.m., will receive 3 fractions, 25

| 1 | then I put parentheses, one q.d. of 333 centiGray from |
|----|---|
| 2 | 1-26 to 1-28 prior to BMT bone marrow transplant. |
| 3 | Tolerate at first, XRT fraction, without acute toxicity, |
| 4 | and I signed it. |
| 5 | Q. Did you review any records before you dictated the |
| 6 | 1-26 note, or signed the 1-26 note? |
| 7 | A. I wrote it. Yes, I handwrote it. |
| 8 | Q. I understand that. Did you review any records? |
| 9 | A. I can't recall. |
| 10 | Q. Why would you have you indicate in your 1-26 |
| 11 | note that he received that would be a therapeutic dose |
| 12 | of 10 Grays, would it not? |
| 13 | A. That was the intended dose. That is what I |
| 14 | thought he received. |
| 15 | Q. Okay. |
| 16 | Well, why if you are checking on the patient |
| 17 | after TBI, why wouldn't you review the records of the TBI |
| 18 | to determine whether or not he received a proper dose? |
| 19 | A. Well, it was the chart was in the both |
| 20 | charts were available. I did not check it specifically. |
| 21 | Q. That is my question, if you wanted to, the chart |
| 22 | was available for you to check on 1-26, his TBI records? |
| 23 | A. Exactly. I have seen the patient in the clinic. |
| 24 | Q. Okay. |
| 25 | And had you done that, you would have been able to |
| | |
| | |

| 1 | deter | mine that there was an error in dosing, correct? |
|----|--------|---|
| 2 | A. | Correct. |
| 3 | Q. | Now, Doctor, would you please pull out for me |
| 4 | tellı | me this: |
| 5 | | Did you see him on any date other than 1-26 after |
| 6 | TBI, | either 1-27, 1-28? |
| 7 | А. | I can't recall. |
| 8 | Q. | If you would have, do you believe you would have |
| 9 | writt | en a note? |
| 10 | А. | Not necessarily, unless there was a change. |
| 11 | Q. | Okay. |
| 12 | | Now, please show me, from Exhibit 101, the |
| 13 | presc: | ription for Joshua's TBI? |
| 14 | A. | It is the top line (indicating). |
| 15 | | MR. MARGOLIS: Doctor, why is it, after |
| 16 | : | Joshua's you know what? Let me get back to |
| 17 | | that on clean-up, all right? |
| 18 | | Marc, I don't know how you want to do it. |
| 19 | | I want to mark this, to make reference to it, but |
| 20 | | I don't know if you want me to put it on the |
| 21 | | original, or how |
| 22 | | MR. GROEDEL: Why don't you put it on the |
| 23 | | back of it. |
| 24 | | MR. MARGOLIS: Fine. |
| 25 | | |
| | | |
| | | |

MORSE, GANTVERG & HODGE

| 1 | | (Thereupon, Plaintiff's Exhibit 102 was |
|----|---------|---|
| 2 | | marked for identification.) |
| 3 | BY MR. | MARGOLIS: |
| 4 | Q. | Doctor, handing you what has been marked on the |
| 5 | back lo | ower right-hand corner as Exhibit 102, what is |
| 6 | that? | |
| 7 | A. | This is the prescription. |
| 8 | Q. | For Joshua's TBI? |
| 9 | A. | Right, as well as his subsequent treatments. |
| 10 | Q. | And that is written in your hand? |
| 11 | A. | Yes. |
| 12 | Q. | Is there anyone's writing that appears on that, |
| 13 | other (| than your own? |
| 14 | A. | Yes. |
| 15 | Q. | Read it for me? |
| 16 | | MR. GROEDEL: Read what? |
| 17 | | MR. MARGOLIS: The writing that is not his. |
| 18 | Α. | I think the 18X. |
| 19 | Q. | Where is it? |
| 20 | А. | Under beam and energy, the second from the last |
| 21 | column | |
| 22 | Q. | Who wrote 18X? |
| 23 | Α. | From down below, it is Dr. Beddar. |
| 24 | Q. | All right. |
| 25 | | And is all of the other writing yours, other than |
| | | |
| | | |
| | | MORSE, GANTVERG & HODGE |

Ī

| 1 | 18X? | |
|----|---|--|
| 2 | A. Well, some things were crossed out. I don't know | |
| 3 | who wrote over some of this. | |
| 4 | Q. Okay. | |
| 5 | Is it your testimony that on the 1-17-2000 top | |
| 6 | line that says, total body irradiation, it says, Total | |
| 7 | Dose (Gy)? | |
| 8 | A. Yes, 1 Gy, yes. | |
| 9 | Q. And something is crossed out over that, in that | |
| 10 | box? | |
| 11 | A. Yes. | |
| 12 | Q. And that wasn't you that did that? | |
| 13 | A. I can't recall. When I met with after the | |
| 14 | lawsuit was filed, I was meeting with someone, and I made | |
| 15 | marks on it unintentionally, and he corrected me. | |
| 16 | Q. Okay, who were you meeting with when these marks | |
| 17 | were made? | |
| 18 | MR. GROEDEL: Objection. | |
| 19 | Q. (Continuing) Unless Mr. Groedel advises you not to | |
| 20 | answer, I am going to ask you who you were meeting with | |
| 21 | when the marks that are under the first line of 1-17 | |
| 22 | Total Dose were made? | |
| 23 | MR. GROEDEL: Well, I am going to instruct | |
| 24 | him not to answer, because we believe that that | |
| 25 | meeting took place in the context of quality | |
| | | |
| | | |
| | MORSE, GANTVERG & HODGE | |
assurance/peer review and therefore is privileged 1 from discovery. 2 3 So if that meeting is -- if that meeting is protected, then I think the identity of the person 4 5 involved in that meeting is protected, as well. MR. MARGOLIS: Marc, I guess my question 6 7 would be that the discussions of the meeting are, but I don't believe the attendees are. I am not 8 asking what was discussed, I just said, we have an 9 altered document --10 MR. GROEDEL: Right. 11 MR. MARGOLIS: -- he has testified that 12 there was a witness. 13 MR. GROEDEL: I understand. 14 MR. MARGOLIS: I just want to know who the 15 witness was. 16 17 MR. GROEDEL: Yes. And I think, for the time being, I have to take the position that I 18 cannot identify that person at this time. 19 20 MR. MARGOLIS: Okay, and just --MR. GROEDEL: I mean, we may change our 21 2.2 mind later, and if so, I will let you know. But I don't think you need that information 23 now, to continue on with your questioning about 24 25 this document.

MORSE, GANTVERG & HODGE

So for the time being, the answer is, we 1 are not going to identify that individual, and you 2 can go ahead and question him. 3 MR. MARGOLIS: And just in response, so 4 that the record is complete, a significant portion 5 of this case involves an alteration of a medical 6 record, when it was made, by whom it was made. I 7 think these are some of the most pivotal issues 8 that are in dispute in this case, and there was an 9 eyewitness, and that information is not being 10 provided to me at this point in time, based upon 11 counsel's instruction of the witness to not 12 answer. 13 BY MR. MARGOLIS: 14 Dr. Kinsella, was more than one person present 15 Ο. when -- well, let me ask the question this way, because I 16 think you contradicted yourself, and I want it to be 17 clear. 18 Did you author the change that is under Total Dose 19 20 1-17-2000? I am not sure. 21 Α. 22 Q. Okay. If you didn't, do you know who would have? 23 No, I do not. 24 Α. You may have made that change, but you don't 25 Q.

MORSE, GANTVERG & HODGE

. 73

| 1 | recall | whether you did or whether you did not? |
|----|--------|---|
| 2 | А. | That is correct. |
| 3 | Q. | Do you know how many changes were made in that |
| 4 | box? | |
| 5 | A. | No, I do not. |
| 6 | | MR. MARGOLIS: May I see that original, |
| 7 | | please. |
| 8 | | (Thereupon, the document was handed to |
| 9 | | Mr. Margolis.) |
| 10 | | MR. MARGOLIS: And in going forward, it |
| 11 | | should not be construed as a waiver for me to |
| 12 | | redepose the witness on these issues after the |
| 13 | | court rules. |
| 14 | BY MR. | MARGOLIS: |
| 15 | Q. | Do you always use a black pen? |
| 16 | Α. | No. |
| 17 | Q. | In looking at the alterations that are set forth |
| 18 | on Exh | ibit 102, in the top box of Total Dose (Gy), does |
| 19 | that a | ppear to you to be your handwriting? |
| 20 | Α. | I can't tell. |
| 21 | Q. | You indicated to me that that may have been you |
| 22 | that m | ade the change, but thereafter it would have been |
| 23 | brough | t to your attention that that was not something |
| 24 | that s | hould be done? |
| 25 | | MR. GROEDEL: Objection. |
| | | |
| | | |

MORSE, GANTVERG & HODGE

Can you restate that? I am not sure I 1 understand the question. 2 MR. MARGOLIS: Sure. 3 (Continuing) I thought I heard you testify that 4 Q. this may or may not have been you who made the change. 5 If it was you that made the change, it was brought to 6 7 your attention that that wasn't something that you should have done? 8 9 MR. GROEDEL: Objection. You can answer. 10 (Continuing) Is that --11 Q. 12 Α. Correct. 13 0. Okay. Why was it that you learned that that was 14 something that you shouldn't have done? 15 MR. GROEDEL: Objection. 16 17 You can answer. I was explaining to someone what the correct dose 18 Α. should have been, and unintentionally, I wrote in -- I 19 20 said, this is what I should. And then the person said, don't use it, don't use 21 22 a pen around a medical record. And you are indicating that this meeting that took 23 Q. place where you may have altered the medical record, but 24 25 you don't know if you did, was clearly done after the MORSE, GANTVERG & HODGE

75

в

| 1 | lawsuit in this case was filed? | |
|----|--|--|
| 2 | A. Right. | |
| 3 | Q. So there would be no way, if you made this | |
| 4 | alteration, that it would have been apparent in the | |
| 5 | medical record chart prior to July of 2001? | |
| 6 | A. This right, this meeting was after 2000 July | |
| 7 | of 2001. | |
| 8 | Q. And no one brought to your attention that there | |
| 9 | was a mistaken dose given to Joshua as part of his TBI | |
| 10 | before the lawsuit was filed? | |
| 11 | A. I do not recall. No one brought it to my | |
| 12 | attention. | |
| 13 | Q. And again, are you saying that it may have been | |
| 14 | brought to your attention but you do not recall, or it | |
| 15 | was not brought to your attention? | |
| 16 | A. I do not recall it brought to my attention. I | |
| 17 | don't remember. | |
| 18 | Q. Are you aware of anybody else who would have made | |
| 19 | the alterations on Exhibit 102? | |
| 20 | A. I mean, this is a department record. Anyone in | |
| 21 | the department could have, potentially. | |
| 22 | Q. Do you know why anyone would have? | |
| 23 | A. I do not. Possibly whoever wrote the anonymous | |
| 24 | letter. | |
| 25 | Q. So you are saying that someone may have had an | |
| | | |
| | | |

76

intention of framing you? 1 MR. GROEDEL: Objection. 2 3 Q. (Continuing) You make a corollary to the anonymous letter. What is your thought process on this? 4 Anyone could have. I mean, this is in an area 5 Α. where anyone in the department could find it. 6 7 Well, can you testify under oath today why anyone Ο. in the department would have any motivation to make this 8 alteration? 9 I don't know of any. 10 Α. 11 Q. Okay. 12 Well, what did you mean when you said it may have been the person who sent the anonymous letter? 13 Those are your words. 14 15 I am not sure. Α. So you said it, and you don't know what you meant? 16 Q. Uh-huh. 17 Α. If Dr. Shina were to testify that he brought the 18 Ο. subtherapeutic dose to your attention before the lawsuit, 19 20 are you saying that he would be untruthful in that issue? MR. GROEDEL: Objection. 21 2.2 You may answer. I do not recall any conversation with Dr. Shina. 23 Α. And there is no record of my meeting with Dr. Shina. 24 25 So the fact that there would not be a record of Q.

your meeting with Dr. Shina would mean that he wouldn't 1 have brought to your attention that this was a 2 subtherapeutic dose? 3 Not necessarily. But I schedule my meetings with Α. 4 people, or my secretary does. 5 Isn't it a fact, Doctor, that it was brought to 6 Q. your attention that there was a subtherapeutic dose prior 7 to the lawsuit being filed in this case? 8 No. 9 Α. MR. GROEDEL: Objection, asked and 10 answered. 11 (Continuing) No. 12 Α. And if other people were to testify that that did 13 Q. happen, they would be wrong? 14 15 Α. Right, correct. Would you please turn to Page 1? 16 Ο. In this (indicating)? 17 Α. Yes. 18 Q. Α. Okay. 19 Is all this your writing? 20 Ο. Again, except for the 18X and the note from 21 Α. Dr. Beddar. 22 23 Ο. Okay, the 1 Gray is yours? The 1 Gray is mine. 24 A MR. GROEDEL: The circle? 25

THE WITNESS: I have no idea. 1 MR. GROEDEL: On the copy that you gave 2 him, there is a circle, and he doesn't know how 3 that got there. 4 MR. MARGOLIS: Yes, I didn't see it on 5 6 there. 7 MR. GROEDEL: That may be inadvertent from your office. 8 BY MR. MARGOLIS: 9 Why is there a change on the 5-10 note between 10 Ο. Page 1 and Page 2? 11 12 I noted in my records, on 5-18, the patient gets a Α. 13 change in the prescription. So that the change from the 5-10 prescription reflects that on 5-18 on this chart 14 that we changed what we were doing, so we closed out that 15 prescription and wrote a new prescription. 16 But you gave him, on 5-10, 35 Gys; is that correct? 17 Ο. That was the intent. 18 Α. 19 Q. Okay. That was written in blue, it looks like. 20 Α. All right. 21 Q. And then when was the prescription changed? 22 23 Α. On the 18th. Then it would go to 17 and a half, correct? 24 Ο. Right. 25 Α.

79

| 1 | Q. Well, why is it, if you look on Page 2, there is a |
|----|---|
| 2 | change of the 5-10 prescription, why would you change |
| 3 | what was already administered, if you are administering a |
| 4 | new dosage on 5-18? |
| 5 | A. Because between 5-10 and 5-18, Joshua only |
| 6 | received 17.5 Gray. If we were going to continue this |
| 7 | without the change that is down here (indicating), he |
| 8 | would have received 35 Gray. But indeed, he only |
| 9 | received 17.5. |
| 10 | Q. How do you know that? |
| 11 | A. Because that is what he received. On 5-18, when I |
| 12 | am doing a second simulation, I write a note, and it is |
| 13 | on 5-18 it is here, but I am not sure where it is |
| 14 | here. Let me see. |
| 15 | Q. I guess my question, Dr. Kinsella |
| 16 | A. It is on Number 5, okay? |
| 17 | Q. Where are we at, 5-18? |
| 18 | A. 5-18. |
| 19 | Treatment fields modified based on MRI scan. Will |
| 20 | boost to 17.5 Gray and 7 fractions. Total dose 35 Gray. |
| 21 | Q. Okay, so that would be the dose that would be |
| 22 | changed from the 18th forward; is that correct? |
| 23 | A. Right. |
| 24 | And what that says is that prior to the 18th, if |
| 25 | you go back to the dosing, he received 17.5 Gray. |
| | |
| | |
| | MORSE GANTVERG & HODGE |

Okay. 1 Q. So the total dose I wanted to deliver is 35 Gray 2 Α. to this boost volume. 3 Q. 4 Okay. 5 Α. So I changed the prescription from the 10th, because he didn't indeed receive 35 Gray. It is updated 6 on the prescription from the 18th that he received only 7 7 of those intended 14 treatments, or he received only 17.5 8 of the intended 35 Gray. 9 10 Then our intent was to give the other 17.5 or seven treatments to this altered volume, based on the MRI 11 12 scan. 13 So you altered the document in the past to reflect Q. a modified prescription which would then appropriately 14 set forth what the intent was of this child to receive? 15 MR. GROEDEL: Do you understand the 16 question? 17 18 THE WITNESS: No. MR. MARGOLIS: Would you read it back. 19 (Record read.) 20 Yes, that would be a standard policy. 21 Α. Okay. 22 Q. 23 I guess what I don't understand is why you just wouldn't change the prescription on the 18th, and leave 24 the prescription that was administered to him on the 10th 25

MORSE, GANTVERG & HODGE

| 1 | the way it was? Because it had already been administered. | |
|----|---|--|
| 2 | A. No, it hadn't. | |
| 3 | Q. Okay, maybe that is where I am missing you. | |
| 4 | A. Right, right. | |
| 5 | So on the 10th | |
| 6 | Q. Well, on the 18th, Doctor, is when you changed the | |
| 7 | prescription, correct? | |
| 8 | A. Right. | |
| 9 | Q. And on the 10th, what did he receive? | |
| 10 | A. Between the 10th and the 18th, he received 17.5 | |
| 11 | Gray. | |
| 12 | Q. Okay. | |
| 13 | A. So on the 10th, he received 2.5 Gray, and I am not | |
| 14 | sure what day of the week it is, but | |
| 15 | Q. Okay. | |
| 16 | A you can go back, and then the next until he | |
| 17 | got he got seven treatments between the 10th and the | |
| 18 | 18th. | |
| 19 | Q. Okay. | |
| 20 | A. So then he has another MRI scan, we say, we don't | |
| 21 | have to treat the entire brain, he has got bone | |
| 22 | metastases, so we modify the field and modify the | |
| 23 | prescription because we didn't what we wrote on the | |
| 24 | 10th, indeed by the 18th we had modified, and then we | |
| 25 | wrote a new prescription. | |
| | | |

1 Q. Okay. Do you agree with me that there is no record in 2 the chart that you are able to show me that sets forth 3 that the TBI prescription that you gave him on the 17th 4 was 1 Gray? 5 I don't -- say that again. I didn't understand 6 Α. 7 that. MR. MARGOLIS: Sure. 8 Could you please reread that. 9 (Record read.) 10 BY MR. MARGOLIS: 11 Let me ask the question again, Doctor, try to 12 Ο. 13 clean it up. Can you show me anything in your handwriting which 14 sets forth that you prescribed 1 Gray of radiation on 15 January 17th to be administered in his TBI on the 26th, 16 27th and 28th? 17 Well, it looks like it is written over. I mean, 18 Α. that says 1 Gray and 0.333 Gray. 19 So Exhibit 102 -- is that what it says on the 20 Ο. back, sir? 21 22 Α. That is right. You are saying that if you look at that, that that 23 Ο. is what demonstrates the 1 Gray that he was administered? 24 25 Α. Right.

MORSE, GANTVERG & HODGE

| 1 | Q. | Okay. |
|----|------------|--|
| 2 | | And we agree that somebody wrote over it to show |
| 3 | what t | he therapeutic dose was, but you don't remember if |
| 4 | it was | you or not? |
| 5 | Α. | I do not. |
| 6 | Q. | Okay. |
| 7 | | Let's go the same thing, let's go the dose per |
| 8 | fracti | on. |
| 9 | Α. | Uh-huh, dose per fraction. |
| 10 | Q. | There also that also appears to be a |
| 11 | modifi | cation on 1-17? |
| 12 | A. | Right. |
| 13 | Q. | Would you agree with me that your same answers to |
| 14 | my que | stions would apply relative to that, as well, you |
| 15 | may or | may not have done it, you don't know? |
| 16 | A. | Right. |
| 17 | Q. | Okay. |
| 18 | | Do you know how many times that was altered? |
| 19 | Α. | No. |
| 20 | Q. | You would agree with yes, I will get to that |
| 21 | you wo | ould agree with me that any alteration would be |
| 22 | unethical? | |
| 23 | | MR. GROEDEL: Objection. |
| 24 | | You may answer. |
| 25 | Α. | Any intentional alteration, yes. |
| | | |
| | | |
| | | |

How do you find the word -- define intent? Ο. 1 That I purposefully changed it to hide something, 2 Α. how is that? 3 Q. Okay. 4 Is a negligent alteration violative of the 5 quidelines of UH? 6 MR. GROEDEL: Objection. 7 8 You may answer. I don't know. Α. 9 MR. MORIARTY: May I see that original for 10 11 one moment, please? (Thereupon, the document was handed to 12 Mr. Moriarty.) 13 MR. MORIARTY: Off the record for a second. 14 THE VIDEOGRAPHER: Off the record. 15 16 (Thereupon, a discussion was had off the record.) 17 BY MR. MARGOLIS: 18 What is the protocol, if you determined that there 19 Ο. has been an error made in the dosing of a patient such as 20 21 these circumstances? It generates a report called a dose discrepancy Α. 22 form, or something like that, that is outlined, and the 23 24 details are briefly summarized, and it is signed by the physician and reviewed by quality assurance. 25

MORSE, GANTVERG & HODGE

| l | Q. Did you ever represent to the tumor board that you | |
|----|--|--|
| 2 | gave Joshua 10 Grays when you knew you had not? | |
| 3 | A. No. I always thought I had given him 10 Gray in | |
| 4 | the tumor boards. | |
| 5 | Q. Was a dose description form or discrepancy form | |
| 6 | generated based upon the treatment you provided to | |
| 7 | Joshua? | |
| 8 | MR. GROEDEL: Objection. | |
| 9 | You may answer. | |
| 10 | A. I don't know of any. | |
| 11 | Q. Why wouldn't you have done so after you learned | |
| 12 | that there was an error? | |
| 13 | A. I learned of the error after July of 2001, and I | |
| 14 | am not sure what the purpose of that would be. | |
| 15 | Q. What duties do you owe the family of a patient | |
| 16 | under these circumstances? | |
| 17 | A. Well, I certainly will apologize when I see them, | |
| 18 | but I wasn't sure if it was appropriate at this point, | |
| 19 | when I learned of this, over a year after his death | |
| 20 | Q. Had you learned | |
| 21 | A that I would, you know you know, I am not | |
| 22 | sure if that is appropriate for a physician, at this | |
| 23 | point, when a suit has been made, to interface with a | |
| 24 | family. | |
| 25 | Q. Had this been brought to your attention earlier, | |
| | | |
| | | |

| 1 | what would you have done? |
|----|--|
| 2 | A. I would have met with the family, I would have |
| 3 | notified the pediatric oncologist and met with the |
| 4 | family. |
| 5 | Q. And the first time you would have informed |
| 6 | Dr. Wiersma of this mistaken dose on your behalf was |
| 7 | when? |
| 8 | A. It was when we reviewed the chart after the |
| 9 | lawsuit. |
| 10 | Q. At any point in time in your treatment of Joshua, |
| 11 | did you tell the family that you were a physician |
| 12 | operating independent of University Hospitals? |
| 13 | A. No. I have my name tag on all the time, it says |
| 14 | University Hospitals of Cleveland, and describes me. |
| 15 | Q. Who was your employer in 1999 and 2000? |
| 16 | A. Technically it is University Radiation Medicine |
| 17 | Associates. |
| 18 | Q. At all times you treated Joshua, it was on the |
| 19 | campus of University Hospitals? |
| 20 | A. Yes. That is the only place I treat patients. |
| 21 | Q. Do you have any independent recollection of |
| 22 | Joshua? |
| 23 | A. No, I do not. |
| 24 | Q. Would you agree with me that as a result of the 1 |
| 25 | Gray being administered, that Joshua was denied any |
| | |
| | |
| | MORSE, GANTVERG & HODGE |

87

opportunity of the benefit of TBI? 1 MR. GROEDEL: Objection. 2 You may answer. 3 Α. No. 4 So you believe that whatever benefit he could have 5 Ο. gotten from TBI would not have been altered had he 6 received 1 Gray versus 10? 7 I didn't -- my response was not to that question. 8 Α. And I know, and I followed up with another 9 Q. question, didn't I? 10 Would it have changed his outcome? 11 Α. No. MR. MARGOLIS: That wasn't the question I 12 asked you. 13 Would you read the question back to 14 Dr. Kinsella. 15 (Record read.) 16 17 Α. (Continuing) In Joshua's situation, I don't think the TBI played any -- either the 1 or the 10 Gray --18 19 played any dose in -- any role in his ultimate outcome. Why did you then tell him to get TBI, if it would 20 Ο. have played no role in his ultimate outcome? 21 22 Α. I think the intent and the discussions we had was this was an attempt to try to delay the time to failure 23 and death. 24 So let's talk about what the intent was of Joshua 25 Ο.

88

| 1 | being administered TBI. | |
|----|--|--|
| 2 | A. | Uh-huh. |
| 3 | Q. | It was to hopefully have him go into a period of |
| 4 | remiss | ion and increase his time of survival, but not an |
| 5 | ultima | te cure? |
| 6 | A. | That is correct. |
| 7 | Q. | Based upon him receiving 1 Gray as opposed to 10, |
| 8 | was th | e intent of him receiving TBI thwarted? |
| 9 | A. | No. |
| 10 | Q. | Then why do it at all? |
| 11 | Α. | Well, I think that it is not common it is not a |
| 12 | standard of care today, and it was an attempt to delay | |
| 13 | time to | o recurrence, but total body irradiation is a very |
| 14 | small | part of his overall treatment. |
| 15 | Q. | Okay, we are talking |
| 16 | Α. | His overall treatment wasn't working. |
| 17 | Q. | We are talking about what the standard of care was |
| 18 | in 200 | 0, are we not? |
| 19 | Α. | Correct. |
| 20 | Q. | All right. |
| 21 | | And it is your testimony today under oath that the |
| 22 | intent | of this child receiving TBI was not adversely |
| 23 | affect | ed as a result of him being administered 1 Gray |
| 24 | versus | 10; is that correct? |
| 25 | Α. | In Joshua's case, yes. |
| | | |

| 1 | Q. Okay. |
|----|---|
| 2 | A. Again, the intent was to give the 10 Gray, but I |
| 3 | don't think that it |
| 4 | Q. But it made no difference? |
| 5 | A. I don't in my heart of hearts, no, unfortunately |
| 6 | not. |
| 7 | Q. But in 2000 when it was administered, you were |
| 8 | hoping it would? |
| 9 | A. The repeat restaging by the MIBG and the MRI scan |
| 10 | that were done, I think, on the 6th and the 7th and the |
| 11 | 10th were pretty humbling in terms of assessing his |
| 12 | chances with anything we had. |
| 13 | Q. Doctor, did you expect this child to have the |
| 14 | potential of benefiting from TBI when it was administered |
| 15 | in January of 2000? |
| 16 | A. Yes. |
| 17 | Q. Okay. |
| 18 | And point in fact, it was represented to the |
| 19 | parents of this child that TBI would hopefully be of some |
| 20 | benefit to him, and that is why it was being administered |
| 21 | in January of 2000, correct? |
| 22 | A. Correct, correct. |
| 23 | Q. And in your opinion, the fact that there was a |
| 24 | change in a subtherapeutic dose did not in any way |
| 25 | negatively impact the intent of TBI being administered? |
| | |
| | |
| | MORSE, GANTVERG & HODGE |

| 1 | A. | It may have negatively a little, but it didn't |
|----|---------|--|
| 2 | mean tl | he difference between cure or prolonged survival. |
| 3 | Q. | Okay. |
| 4 | | Do you think he would have died of the causes that |
| 5 | he did | in June of 2000 had a therapeutic dose been |
| 6 | adminis | stered? |
| 7 | Α. | It would be speculation. If not June, it would |
| 8 | have be | een July or August. |
| 9 | Q. | What chance of survival do you believe Joshua had |
| 10 | for cu: | re? |
| 11 | | MR. GROEDEL: At what point? |
| 12 | | MR. MARGOLIS: January of 2000. |
| 13 | A. | After the restaging? We certainly put it at less |
| 14 | than f | ive percent, and probably realistically zero. |
| 15 | Q. | When did the restaging occur? |
| 16 | A. | On the 6th and the 10th of January. |
| 17 | Q. | Okay. |
| 18 | A. | Part of it. There may have been more. |
| 19 | Q. | Have you destroyed any medical records in this |
| 20 | case? | |
| 21 | Α. | I have not. |
| 22 | Q. | At any point in time, have you gone to the medical |
| 23 | records | s department to review medical records in this |
| 24 | case? | |
| 25 | A. | No, I have not. |
| | | |
| | | |

91

| 1 | Q. | So you have never gone to the medical records |
|----|---------|---|
| 2 | depart | ment to obtain Joshua Valdivieso's medical chart? |
| 3 | A. | No, I have not. |
| 4 | Q. | When you go to the medical records department, do |
| 5 | you ha | ve to sign the chart out? |
| 6 | A. | To be honest, I have never been to the medical |
| 7 | record | s department. |
| 8 | Q. | Have you asked that Joshua's chart, hospital |
| 9 | chart, | ever be brought to your office? |
| 10 | A. | No. The first time I saw the chart was earlier |
| 11 | this m | orning. |
| 12 | Q. | If you make a mistake in a medical record this |
| 13 | has haj | ppened to you in the past, has it not? I mean, if |
| 14 | a mista | ake is made in a medical record, isn't there a |
| 15 | specif | ic procedure that is to be followed? |
| 16 | Α. | Usually date it and record what was done. |
| 17 | Q. | And do you put error or cross it out and write |
| 18 | error, | and then write in what is correct? |
| 19 | Α. | That can be the case. |
| 20 | Q. | And you would have had occasion to do that prior |
| 21 | to Jul | y of 2001? |
| 22 | A. | In what, though? |
| 23 | Q. | In a medical record. |
| 24 | А. | Say those dose administrations that we talked |
| 25 | about, | if there is a misadministration, we will then go |
| | | |
| | 1 | |

back and alter the chart to reflect the right 1 administration, whether it was an underdose or overdose, 2 to then reflect what was given. 3 Ο. What about in patient care medical records, if a 4 5 mistake is made and you cross it out and you write error or void, is that something that you do, or do you just 6 cross it out and write in what you believe to be correct? 7 I usually would indicate an error, I wrote the 8 Α. wrong note in a patient's chart. 9 Ο. Okay. 10 So I had two charts there, and I wrote the wrong 11 Α. note, so I just reflected, put wrong patient, and then 12 wrote the correct note. 13 14 Ο. Would you agree with me, if a physician discovers that they have made a mistake in the treatment of a 15 patient, they should not take steps in an attempt to hide 16 17 or cover up that mistake? Α. Correct. 18 Would you agree that it would be inappropriate to 19 Ο. bill for medical services which in fact were not provided? 20 MR. GROEDEL: Objection. 21 22 You may answer. 23 Α. Correct. Who was responsible for the medical records that 24 Q . were utilized to bill for Joshua's TBI January 26th, 25

93

27th, 28th? 1 We have a billing agency that does that. 2 Α. Do you generate any records that they review? 3 Ο. No. Α. 4 Who does? 5 Ο. There is a billing specialist. 6 Α. 7 Who are they? Q. It is Walt Blackam. It is a company that we still Α. 8 9 use. Have you ever been sued for malpractice before 10 Q. this? 11 12 Α. No, I have not. 13 Ο. Do you have any enemies in the department that you can think of that would write Exhibit 19? 14 15 MR. GROEDEL: Objection. You may answer. 16 (Continuing) The reason I ask that is that you had 17 Q. indicated that whoever wrote that may have modified the 18 chart. 19 Not that I am aware of. 20 Α. Have there been any complaints that have been made 21 Ο. against you during your period at University Hospitals? 22 None that --23 Α. MR. GROEDEL: Objection. 24 Q. Either by residents or other staff? 25 MORSE, GANTVERG & HODGE

Α. None that have been brought to my attention. 1 Do you believe that Josh's period of event free 2 Ο. recurrence would have been at all altered had he received 3 a therapeutic dose of TBI, based upon what you knew in 4 2000? 5 I am not sure. 6 Α. Had the therapeutic dose of TBI been administered 7 Ο. to Joshua in January of 2000, would he have developed the 8 skull metastasis that he presented with in May of 2000? 9 MR. GROEDEL: Objection. 10 Α. I am not sure. 11 Doctor, would you go to this category, B. 12 Q. Do you want this back, or where does this go? 13 Α. MR. MARGOLIS: You can just give that to 14 15 the court reporter. 16 MR. MORIARTY: Unless you are pretty close, within moments of being done --17 MR. FINELLI: We are not. 18 MR. MORIARTY: When you get to the next 19 breaking point, let's take a break. 20 21 MR. MARGOLIS: We can take a break right 22 now. THE VIDEOGRAPHER: Off the record. End of 23 Tape 1. 24 (Short recess had.) 25

MORSE, GANTVERG & HODGE

BY MR. MARGOLIS: 1 Dr. Kinsella, would you please go to the 2 Q. prescription sheet in the original? 3 Α. (Witness complies). 4 This meeting that occurred where you may or may 5 Ο. not have made the alteration, where did the meeting occur 6 at? 7 Α. It was in my office. 8 How many people other than yourself were present? 9 Q. Two others. 10 Α. Were the two other people that were there 11 Ο. 12 attorneys? 13 Α. No. Were they employees of University Hospital? 14 Ο. 15 MR. GROEDEL: Objection. You may answer. 16 Α. One was. 17 Who was the other? 18 Q. Α. A physician. 19 Was it Dr. Wiersma? 20 Ο. MR. GROEDEL: Objection. 21 You may answer. 22 23 Α. Yes. Have you discussed with Dr. Wiersma whether or not 24 Q. she has any recollection of you altering the medical 25 MORSE, GANTVERG & HODGE

records at that meeting? 1 No, I haven't. 2 Α. It is nothing that the two of you have discussed? 3 Ο. Α. No. 4 5 Ο. Okay. You referred to the TBI dose sheet when you 6 7 treated the patient on 5-10 and 5-18, correct? I don't understand the question. Α. 8 Ο. This TBI dosage sheet which we have marked on the 9 back as Exhibit 102 --10 Right, yes, correct. 11 Α. 12 Ο. -- that is an ongoing sheet, correct? 13 Α. Correct. It is the same sheet that you utilized for his 14 Ο. prescription for the TBI on 1-17, correct? 15 16 Α. Correct, yes. So whatever notations would have been on the sheet 17 Q. 18 on 1-17 would have been present when you reviewed the sheet again to write the 5-10 dosage, correct? 1920 Α. Correct. And whatever notations would have been on the 21 Ο. sheet on 1-17 would have been present when you reviewed 22 23 the sheet for the 5-18 dosage, correct? 24 Α. Correct. Why didn't you see, on 5-10, that he was given 1 25 Ο.

| 1 | Gray, if in fact the change to 10 Grays didn't occur |
|----|---|
| 2 | until after the lawsuit was filed? |
| 3 | A. Well, I didn't I missed it. |
| 4 | Q. You looked right at the sheet and you didn't see 1 |
| 5 | Gray? |
| 6 | A. That is correct. |
| 7 | Q. Do you think 1 Gray for TBI in January should |
| 8 | have stood out like a flashing red light as being a |
| 9 | subtherapeutic dose to a man of your skill, education and |
| 10 | experience, true? |
| 11 | A. If I saw it, yes. |
| 12 | Q. Okay. |
| 13 | So your testimony is that you looked at Exhibit |
| 14 | 102 on 5-10 and you didn't see that on 1-17, 1 Gray was |
| 15 | given? |
| 16 | A. Correct. |
| 17 | Q. And you looked at Exhibit 102 on 5-18, and you |
| 18 | didn't see that 1 Gray was given? |
| 19 | A. Correct. |
| 20 | Q. Do you think it would be more probable for you to |
| 21 | have, quote unquote, missed it, if in fact by 5-10-2000 |
| 22 | the alteration had already been made? |
| 23 | MR. GROEDEL: Objection. |
| 24 | You may answer. |
| 25 | A. I don't know. |
| | |
| | |

Did you tell anybody else prior to today's Q. 1 deposition that you in fact are the one that made the 2 alterations on Exhibit 102? 3 Α. No. 4 I am not sure if I said that today. I said, you 5 know, during the meeting --6 Doctor, let me be nauseatingly clear. 7 Q. Did you make the alterations that appear on 8 Exhibit 102 where 1 Gray turned into 10 and 0.333 turned 9 into 3.333, were those made by your hand, yes or no? 10 MR. GROEDEL: Objection. 11 Α. I am not sure. I don't know. 12 They may have been, you don't know? 13 Ο. They may have been. I cannot recall exactly. 14 Α. And you will agree with me, if they would have 15 Q. been done by your hand, that would not have been the 16 proper thing to do? 17 Correct. I mean, I did it unintentionally. 18 Α. If you did it unintentionally, would you have had 1.9 Ο. 20 any follow-up corresponding record that you would have authored or dictated or generated to reflect that this 21 was something that was done unintentionally by you? 22 23 Α. I did not. 24 Q. All right. Do you know if these two people who were in the 25

99

| 1 | room actually saw you alter it, if you did? | | |
|----|---|--|--|
| 2 | A. One of the persons said, don't mark that chart, | | |
| 3 | keep that pen away. | | |
| 4 | Q. Before or after you before or after the | | |
| 5 | alteration? | | |
| 6 | A. I can't recall. It was a person I was explaining | | |
| 7 | what happened, or what I thought happened, in terms of | | |
| 8 | writing the wrong dose. | | |
| 9 | Q. It presumably would not have been Dr. Wiersma who | | |
| 10 | said, don't alter that, keep your pen away, it would have | | |
| 11 | been the other individual? | | |
| 12 | A. That is correct. | | |
| 13 | Q. The chart that is on the front, Doctor, what is it | | |
| 14 | marked, please, the exhibit number on the front; is it | | |
| 15 | 100 on the front of that? | | |
| 16 | A. Of the whole thing? | | |
| 17 | Q. Yes. | | |
| 18 | A. 101. | | |
| 19 | Q. 101. | | |
| 20 | Where is that chart normally kept in the regular | | |
| 21 | course of business? | | |
| 22 | A. Since he died, we send them out to some | | |
| 23 | contractor. | | |
| 24 | Q. Before his death? | | |
| 25 | A. Down in the department. | | |
| | | | |
| | | | |

Of radiation --Q. 1 Radiation oncology, correct. 2 Α. At some point in time, have you caused that chart Q. 3 that is marked 100 -- is it 101? 4 5 Α. 101. -- to be in your office under lock and key? 6 Ο. 7 Since I met with Marc Groedel in February of 2002, Α. he requested I keep the chart. 8 Ο. All right. 9 10 I am going to request that the chart remain in the offices of Reminger & Reminger and --11 Α. Sure. 12 -- be under the custody of Mr. Groedel --13 Ο. Where it has been since whenever you requested it. 14 A. I mean, I haven't had it recently. I don't know when I 15 sent it down there. It was a couple -- several weeks 16 17 ago. So the original chart has been here for several 18 Ο. weeks? 19 20 Α. Yes. MR. GROEDEL: A week or two. 21 THE WITNESS: Well, whenever, yes. 22 23 Somebody from your office picked it up. MR. GROEDEL: We will agree to keep it. 24 25 MR. MARGOLIS: Thank you.

BY MR. MARGOLIS: 1 2 Doctor, would you please go to Dr. Kinsella Ο. Exhibit B, and turn to Page 14. 3 Uh-huh, I am there. 4 Α. What is -- are those your initials up on the top 5 Ο. that says, radiation oncologist? 6 7 Α. Yes. Was this what you had indicated he needed before Ο. 8 it was decided that he was going to get TBI? 9 Yes, this was going to be part of what he needed. 10 Α. Okay. 11 Ο. Would this be rendered basically not part of his 12 radiation treatment because of the change --13 Α. Correct. 14 15 Ο. -- to TBI? 16 Ά. Correct. 17 Ο. Would you have expected -- strike that. A lot of this stuff, we have already gone over, 18 and I don't want to duplicate. 19 20 Would you please turn to Page 32. MR. WALTERS: Can I get a clarification? 21 Are we now on something that you are going to be 2.2 designating as an Exhibit B, or --23 MR. MARGOLIS: Yes, Steve, the front says 24 25 Exhibit B.

MR. WALTERS: Okay. 1 MR. MARGOLIS: And then --2 MR. WALTERS: And prior to this, we were 3 talking about one that says A? 4 5 MR. MARGOLIS: Yes, sir. MR. WALTERS: All right. 6 (Continuing) Page 32, sir, what is that? 7 Q. This is a physics check of the whole brain Α. 8 irradiation prescribed the day before. 9 Why was not a similar sheet done -- well, strike 10 Q. that. 11 12 Look at the bottom right-hand corner, it says, 13 physician. That is right. Α. 14 Is that your signature? 15 Q. Yes, it is. It is --16 Α. Why is it that you would have signed off on this 17 Q. physics check for his May treatment, but you would not 18 have signed off for the physics check of his January 19 treatment? 20 Well, that was the policy, we didn't sign off on 21 Α. the TBI. 22 Okay, but you signed off --23 Ο. Right. That is why I am saying that 99 percent of 24 Α. what we do, there is this interaction, so we see it 25 MORSE, GANTVERG & HODGE

different times. 1 Why is it different for TBI? 2 Ο. Ã. We detected a flaw after -- as a consequence of 3 this. 4 Was that a flaw that was systemic just to UH --5 Ο. MR. GROEDEL: Objection. 6 -- or is that the way the community of radiation 7 Q. oncology operates? 8 MR. GROEDEL: Objection. 9 You may answer. 10 I don't know. Α. 11 Would you please go to 33. 12 Ο. 13 Α. (Witness complies). What is this? Ο. 14 15 Α. This is the calculations for that brain boost that was prescribed on the 18th, and this is being done on the 16 19th. 17 And who were the folks -- it says, Calculated by 18 Q. J. Wright. Who is Checked by? 19 That is a good question. It must be a physicist, 20 Α. but I can't recognize the writing. 21 Ο. Okay. 22 When did you say he had another restaging in 23 January? 24 I would have to look at the records, but my 25 Α. MORSE. GANTVERG & HODGE

104

Ħ

| 1 | recollection is the MIBG scan was on the 6th or 7th and | | |
|----|--|--|--|
| 2 | the MRI scan was on the 10th or 11th | | |
| 3 | Q. | Okay. | |
| 4 | A. | of January, 2000. | |
| 5 | Q. | When you applied for privileges or employment at | |
| 6 | University Hospitals, what was involved in that process? | | |
| 7 | Α. | I can't recall exactly. I assume I filled out a | |
| 8 | series | s of forms. | |
| 9 | Q. | Okay. | |
| 10 | | And did you have meetings with anybody from UH? | |
| 11 | | MR. NORCHI: Objection. | |
| 12 | | MR. GROEDEL: You may answer. | |
| 13 | A. | I can't recall. I think I just submitted an | |
| 14 | application form. | | |
| 15 | Q. | All right, and you don't recall having any | |
| 16 | interviews with anybody at UH? | | |
| 17 | Α. | While I was being recruited, which is | |
| 18 | Q. | Well, that is what I | |
| 19 | Α. | Okay. | |
| 20 | Q. | Okay, maybe that is different | |
| 21 | A. | Right, it is. | |
| 22 | Q. | than the actual | |
| 23 | А. | It is different. | |
| 24 | Q. | Because you don't do the application until an | |
| 25 | offer | is extended | |
| | | | |
| | | | |

Α. Right. 1 2 -- predicated on being credentialed. Ο. And accepted. 3 Α. And accepted. 4 Ο. Who was -- who recruited you? 5 There was a search committee that was established 6 Ά. 7 by both the Dean and the CEO of the hospital. Ο. Can you give me names? 8 Jim Willson, who is the head of the Ireland Cancer 9 Α. Center, was the chair of the search committee. The other 10 members would have been, I think, Robert Ratcheson, who 11 is the head of neurosurgery; Marty Resnick, I think was 12 on the committee, who was the head chairman of urology; 13 and the chairman of neurosurgery. I think Tom Stellato 14 was on it, who is the division head of general surgery in 15 the department of surgery. I think someone from the 16 17 department, I think it was from the -- well, they were forming a new department, so it didn't exist, but I think 18 it was Nancy Oleinick, who is a Ph.D. radiation biologist. 19 20 I am pretty sure that is it. Ο. Okay. 21 After you met them and they met you and the 22 decision was made that they wanted to extend an offer to 23 vou --24 25 Α. Well, I then would have interviewed extensively

MORSE, GANTVERG & HODGE

with other hospital personnel, but they were the search 1 committee. So they were -- but I met with Mrs. Walters, 2 Mr. Jacobs, Mr. Gray, Alan Gray was -- and most of the 3 other chairs. 4 5 Ο. After they met you, you met them, you decided you wanted to work there, they decided that they wanted you, 6 did there come a point in time where you had to go 7 through a credentialing process? 8 Α. Correct. 9 What did that entail? 10 Ο. MR. NORCHI: Objection. 11 MR. GROEDEL: You may answer. 12 MR. WALTERS: Objection. 13 MR. GROEDEL: I will object. 14 You can answer. 15 Filling out standard forms for -- I think very 16 Α. similar to most -- many hospitals. 17 At any point in time in this process, did you 18 Ο. communicate to them the investigation that we discussed 19 20 earlier while you were at University of Wisconsin? They were aware of it. 21 Α. 22 Q. Okay. 23 How were they aware of that, sir? MR. GROEDEL: Objection. 24 You may answer, if you know. 25

107
MR. NORCHI: Objection. 1 MR. WALTERS: Objection. 2 I think direct questioning. I assume they called Α. 3 people. I don't know that for a fact. 4 5 Ο. Okay. So in the credentialing portion of your process, 6 UH was aware of the investigation that we discussed 7 earlier that involved you at University of Wisconsin? 8 Α. Correct. 9 10 Ο. Okay. Did you -- and you verbally discussed that with 11 12 them during the process of these interviews? Α. Correct, as well as with the search committee. 13 MR. MARGOLIS: Okay, I am going to just 14 take one break to confer with my partner, and then 15 I think I am done. 16 THE VIDEOGRAPHER: Off the record. 17 (Thereupon, a discussion was had off the 18 record.) 19 CROSS EXAMINATION 20 BY MR. NORCHI: 21 It is almost noon, Doctor. Good afternoon. My 22 Ο. 23 name is Kevin Norchi, I briefly introduced myself earlier. I represent University Hospitals of Cleveland, 24 and through that, I also represent David Abraham and the 25 MORSE, GANTVERG & HODGE

respiratory -- I am sorry -- the radiology therapists. I 1 2 would like to follow up on some of the responses you gave to questions earlier today. 3 Α. Uh-huh. Yes. 4 I understand that when you came to University 5 Ο. Hospitals of Cleveland, and really started practicing in 6 March of 1998, the radiation oncology department at 7 University Hospitals of Cleveland, albeit generally okay, 8 if I can use that phrase, required some further 9 development by someone of your stature to bring it in 10 line with what was going on in the rest of the medical 11 12 community in this country, correct? 13 Α. Correct. And I understand that you implemented a lot of Ο. 14 changes to improve the radiation oncology department at 15 University Hospitals? 16 Α. Correct. 17 If you don't mind, can you outline some of the 18 Ο. changes that you implemented in the program from, say, 19 1998 through the early part of 2001? 20 Well, we talked in terms of developing the system, 21 Α. and that was sort of the challenge that I was given, and 22 the responsibility, as well as developing the integration 23 of radiation oncology with the cancer center, which it 24 hadn't previously been felt to be an integral part, and 25

which it clearly should have been, and that was the
purpose of -- one of the purposes of recruiting me.

From the physician point of view, when I first arrived, there were four physicians, two of which were near retirement. Right now -- and today, we have 13 physicians. So it has increased at least threefold. And the fourteenth will start in July.

8 The number of patients treated, we were treating 9 between 75 to 90 a day. We are now treating about 300 a 10 day.

We have refurbished a lot of equipment in terms of 11 12 treatment planning. The decade of the '90s introduced CT scanning in radiation oncology, and this concept of three 13 dimensional conformal irradiation, which wasn't being 14 15 practiced here, but at that time, by the late '90s, it was more or less the standard of care, and I introduced 16 17 that system, some of which I helped develop when I was at Wisconsin under a federal grant. 18

And from the physician, I requested that we specialize in areas of expertise and work with multi-disciplinary cancer teams, and you know, we have accomplished that. So most of the physicians that have joined us since 1998 have one or two tumor sites that they have principal interest in, and interface on a day to day basis with surgeons, medical oncologists,

pathologists, diagnostic radiologists and cancer biologists, for that matter, and basically are responsible for contributing that part to the overall comprehensive cancer center.

When I came, we weren't a comprehensive cancer 5 center. I think I facilitated that award from the 6 National Cancer Institute. And you had to show -- I 7 mean, it was in the so-called pink sheet from the Cancer 8 Center Review, I think in '95, that they were clearly 9 10 deficient in radiation oncology, and by '98, they made us a comprehensive center, along with other things, but I 11 wasn't principally -- I wasn't solely responsible, but I 12 think I was a major player. So I think that is a case. 13

14 Nursing, we have a much better nursing system. I 15 think the nurses are now radiation oncology nurses and 16 are recognized as that, and work with individual team 17 members in terms of specific cancer sites.

So my nurse, Deb Harrp, interfaces with all the gastrointestinal tumor patients with a series of other nurses, as well as physicians. So there is a team approach, and that is how cancer care is delivered today. And that was my challenge.

And the other is to integrate the community sites so that what we do at the UHC and what we do at Southwest General or Mercy in Canton or now Community Health

Partners in Lorain or the Lake University Ireland Cancer
Center is, in a sense, the same, the same protocols are
available.

We have a system now that we can teleconference so we can have joint rounds, they can participate. All of the multi-disciplinary tumor boards occur in radiation oncology because we had space, but we have become the focus, I guess, of cancer care, as opposed to being an ill used accessory.

10 Q. Okay.

11 Who were the four physicians who were in the 12 radiation oncology department when you joined? Dr. Shina, Dr. Novak, Dr. Pham, and Dr. Atunez. 13 Α. And Dr. Atunez was retired shortly after I came. 14 And where is Dr. Pham, is he still --15 Ο. It is a woman, it is Houng Pham. She is from 16 A. 17 Viet Nam. She relocated to Seattle. Her husband is a physician, a physical medicine specialist, they got an 18 offer to go to the University of Washington. 19 20 Ο. And when did she go to Seattle? In January of 2001, I think, or December of 2000. 21 Α. And is Dr. Novak still affiliated with the Ireland 2.2 Ο. Cancer Center? 23 Yes, yes, he runs the facility at LUICC, at the 24 Α. Lake University Ireland Cancer Center. 25

| 1 | Q. And of course, we have heard Dr. Shurin's name, he | |
|----|---|--|
| 2 | is still affiliated | |
| 3 | A. No, Shina. | |
| 4 | Q. I am sorry, did I say | |
| 5 | A. Shurin is the pediatric | |
| 6 | Q. Medical oncology. | |
| 7 | A. Pediatric oncology. | |
| 8 | Q. Dr. Shina | |
| 9 | A. Yes. | |
| 10 | Q is affiliated still with the program? | |
| 11 | A. Right, he is leaving at the end of the month, or | |
| 12 | early June, I am not sure when his last day is. And he | |
| 13 | is taking a position in Albuquerque, where he has | |
| 14 | vacationed the last 20 years. But he has accepted a | |
| 15 | position there to become chairman of a department at a | |
| 16 | private hospital there, I think it is called St. Vincent's. | |
| 17 | Q. Okay. | |
| 18 | What is Dr. Shurin's does Dr. Shurin hold a | |
| 19 | position within the department? | |
| 20 | A. No, she is division head of pediatric oncology, so | |
| 21 | her appointment is in the department of pediatrics. | |
| 22 | Q. I misspoke. | |
| 23 | A. So that is her only appointment. She is not in | |
| 24 | the department of radiation oncology at all. | |
| 25 | Q. I am sorry, I misspoke. I meant Dr. Shina. | |
| | | |

Α. Dr. Shina. 1 2 Dr. Shina currently is the clinical director, and he was appointed the clinical director when Dr. Michael 3 Samuels left in, I think in -- I think we appointed him 4 in either March or April of 2000. 5 As part of the changes you have implemented at б Ο. 7 University Hospitals of Cleveland and the Ireland Cancer Center, did you also implement education strategies, if 8 you will, for the staff? You mentioned the nurses. 9 Α. Right. 10 Did you implement such --11 Q. 12 Α. Right, we have had ---- educational programs for radiation therapists, 13 Ο. physicists, dosimetrists? 14 15 Α. Yes. Can you tell me what they were and when you did 16 Ο. 17 that? Well, one, there is a budget now for travel to 18 Α. meetings that didn't exist. And the physicists, 19 20 dosimetrists and therapists have their own professional societies, some of which have local meetings, and some of 21 which have national meetings. So that the carrot is to 2.2 have them present at those meetings, and then obviously 23 then to -- and they are usually sent to a meeting, one 24 25 meeting a year, just for being on the staff, and if they

are going to present or have some type of committee 1 responsibility in the national organization, then we 2 obviously support that. And the same is obviously true 3 with the physicians. 4 5 Ο. Okay. You were asked earlier about the number of 6 pediatric total body irradiations that occurred at 7 University Hospitals of Cleveland since you arrived, and 8 you gave us a number. 9 I am not sure if I gave you that number. 10 Α. I thought it was 10 to 15. Ο. 11 That was 10 to 15 patients --12 Α. 13 Ο. Oh, that were referred ---- that Susan would refer to me --14 Α. 15 Ο. I am sorry. -- of pediatric oncology patients in a year, from 16 Α. her practice. 17 18 Q. Okay. If you could, then, I will ask the question, how 19 many total body irradiations on pediatric patients were 20 21 performed from the time you arrived in March of 1998 to January 26th, 2000? 22 This would be just an estimate, an educated guess, 23 Α. but I would say probably eight a year. 24 How many under your -- how many of those eight per 25 Ο.

MORSE, GANTVERG & HODGE

year would be under your direction as opposed to 1 Dr. Shina, for example? 2 The majority of them, in the pediatrics. Don did Α. 3 the adults. 4 Ο. Okay. 5 I was looking at one of the forms that were 6 7 prepared for the administration of total body irradiation, and it indicates that the -- maybe you can 8 help me, the dose rates --9 Α. This is A. 10 I am sorry, under A, Exhibit 13, for example. 11 Q. 12 Α. Okay. If you look at the top, it says, Dose Rate equals 13 Ο. 100 MU, I presume, per minute? 14 Monitor units -- I am sorry, 13? 15 Α. Yes. 16 Ο. 17 Α. Yes, monitor units per minute. Before January of 2000, had there been a typical 18 Ο. practice where the dose rate was higher, for example, 19 20 around 300, for pediatric total body irradiation? It shouldn't have been, I mean, because the dose Α. 21 rate is -- as we said, is 5 to 10 centiGray a minute. 22 These are just the monitor units based on the calculation 23 that day. We know above that, you get unacceptable acute 24 25 lung and GI toxicity. And that has been worked out at

| 1 | St. Jude's in Seattle, going back to the '70s. So I |
|----|---|
| 2 | mean, it is |
| 3 | Q. Is this dose rate, then, of a hundred, what was |
| 4 | always given, to your knowledge, for total body |
| 5 | irradiation in a pediatric patient? |
| 6 | A. I can't recall. But the dose rate in terms of |
| 7 | centiGray per minute should have been it can go up to |
| 8 | 15, but usually you try to keep it at 5 to 10. |
| 9 | Q. Okay. |
| 10 | You mentioned that there are nurses, individual |
| 11 | radiation oncology nurses that would be assigned to a |
| 12 | particular attending physician |
| 13 | A. Correct. |
| 14 | Q is that true? |
| 15 | A. Uh-huh. |
| 16 | Q. And you mentioned Deb Harrp? |
| 17 | A. Correct. |
| 18 | Q. How long had Deb Harrp been working with you? |
| 19 | A. In when? |
| 20 | Q. As of January, 2000. |
| 21 | A. She may have started around that time. I would |
| 22 | have to look. I know Jill what was Jill's last |
| 23 | name worked from when I started, and then she became |
| 24 | the head nurse |
| 25 | Q. Uh-huh. |
| | |
| | |

н

-- okay? And the head nurse is a supervisory Α. 1 2 position. So I interviewed Deb Harrp, and I can't recall 3 exactly when she started. But I think it was sometime 4 5 late 1999, and Jill was still there as a supervisor for all the nurses. But I have the busiest service, so a 6 supervisor couldn't work for me, just because they are 7 too busy. 8 With respect to Joshua Valdivieso, what were Deb 9 Ο. 10 Harrp's responsibilities in January of 2000? With the pediatric inpatients, there would be very 11 Α. 12 little responsibility. 13 With an outpatient, principally outpatient radiation oncology nurse, but the vast majority have just 14 had adult oncology experience. 15 So when the patients come down, there is a 16 pediatric anesthesiology -- anesthesiologist, and usually 17 18 a nurse anesthetist there. So any dosages, and things like that, are off -- are handled by them. 19 20 So our nurses have very little direct supervisory -supervisory nursing for those particular patients, just 21 because they are so complicated, and they often even will 22 23 come down with a nurse from the floor. 24 Ο. Okay. Would you have expected Deb Harrp to see Joshua at 25

anytime during his admission at University Hospitals from 1 January 20th through the end of the month? 2 Sometimes we would go up on the floor, you know, З Α. mostly for a visit. But she would have no direct 4 responsibilities, there is nothing in terms of her 5 nursing care that would need to be extended to the floor. 6 7 You would not expect her to report back to you as Ο. to whether the total body irradiation had actually gone 8 forward at that time, or where Joshua was in the process 9 of the total body irradiation that you prescribed? 10 Well, I see her every day, we talk, you know. 11 Α. Ι am not sure what that means. I mean, again, she is not --12 that Josh had his second treatment and had his third 13 treatment, we may have said that. But I mean in terms of 14 15 other things, no, she is not responsible for looking at the dose, for example. 16 I didn't suggest that she was. 17 Ο. The question was whether or not you would expect 18 her to at least follow the progress of Joshua during the 19 total body irradiation, not to establish that the dose 20 was appropriate or not, just to let you know that the 21 total body irradiation was occurring; is that something 22 you would expect her to do or not? 23 Correct. But as I mentioned before, with the long 24 Α. hours, the nursing oftentimes -- I principally see 25

MORSE, GANTVERG & HODGE

patients all day Monday, Tuesday and Wednesday, 1 oftentimes from 8:30 until 6:30 or 7:00. So Deb works 2 those three long days, and then sometimes she would work 3 shorter days or not work a Thursday or Friday, because 4 the hospital says work 40 hours and they can't pay -- no, 5 I mean, that is how we set it up, so, you know, she --6 she has agreed to that, which is --7 Q. Okay. 8 So the hours that she works conform with what your 9 schedule requires? 10 Α. Right. 11 12 Ο. And you essentially tell her what her hours will 13 be? No, no. She has a nurse supervisor. But it is 14 Α. fairly predictable from week to week, of when I see -- my 15 on treatment patients are typically on Mondays, and I see 16 follow-ups on Tuesdays, and Wednesdays I see follow-ups 17 and do patients, on Thursdays and Fridays I will see some 18 new patients. 19 But you know, there is less direct clinical 20 activity on Thursdays and Fridays, so oftentimes she may 21 work for someone else during those times, or may take her 22 23 comp time. Specifically with respect to Joshua, do you know 24 Ο. whether you or Deb, separately or together, visited 25

| 1 | Joshua | in the hospital? |
|----|--------|--|
| 2 | А. | I can't recall. |
| 3 | Q. | And of course, you know David Abraham, correct? |
| 4 | А. | Yes. |
| 5 | Q. | And he no longer works at the hospital? |
| 6 | А. | Right. |
| 7 | Q. | Do you recall him to be a competent dosimetrist? |
| 8 | Α. | Yes. |
| 9 | Q. | And you had worked with him for at least a couple |
| 10 | of yea | rs; is that true? |
| 11 | A. | I am not sure if he was there that long. I would |
| 12 | have t | o look at his record. I think he probably at |
| 13 | least | a year, it may have been longer. |
| 14 | Q. | Okay. |
| 15 | | Well, during the year that you recall him working |
| 16 | at UH, | he had prepared or calculated doses for patients, |
| 17 | some o | f your patients for whom you had given |
| 18 | prescr | iptions, correct? |
| 19 | Α. | Absolutely. |
| 20 | Q. | Okay. |
| 21 | | Have there ever been any occasions where he felt |
| 22 | that t | he dose was unusual and bring that to your |
| 23 | attent | ion? |
| 24 | A. | Possibly. I can't recall a specific, but possible. |
| 25 | Q. | Okay. |
| | | |
| | 1 | |

| 1 | Well, let's not make it specific with David |
|----|---|
| 2 | Abraham. Have there ever been any times when a |
| 3 | dosimetrist would bring to your attention what they |
| 4 | thought to be an unusual dose or an unusual prescription |
| 5 | that was written by you? |
| 6 | A. Yes. |
| 7 | Q. That is not an unusual occurrence, is it? |
| 8 | A. No, no. |
| 9 | Q. Because of your busy schedule, as you have just |
| 10 | described for us |
| 11 | A. I would call it uncommon. |
| 12 | Q. You would call it uncommon? |
| 13 | A. Yes. Usually my technique is to write and dictate |
| 14 | very detailed notes, and often the comment from the |
| 15 | dosimetrist and the therapist is they know a lot about |
| 16 | the patient by the time they end the note. And so I try |
| 17 | to get it right the first time in so many words. So you |
| 18 | know, usually there is not a discrepancy. |
| 19 | And I tend to see more complicated patients, and |
| 20 | some unusual patients that previously hadn't been treated |
| 21 | in the department because of they would be referred |
| 22 | elsewhere. |
| 23 | Q. Right. |
| 24 | Well, and because of the unusual patients you |
| 25 | might see, you would also have atypical treatment plans, |
| | |
| | |
| | |

| 1 | correct? |
|----|--|
| 2 | A. More complicated. Maybe not atypical. |
| 3 | Q. Well, more complicated in that the dosimetrists |
| 4 | may not have seen that particular type of prescription or |
| 5 | treatment plan in the past, fair? |
| 6 | A. Correct, correct. |
| 7 | Q. Let's go back to those situations that, I mean, |
| 8 | you described as uncommon, but where a dosimetrist would |
| 9 | have a question about the dose or the prescription. |
| 10 | Would the communication with you, between you and the |
| 11 | dosimetrist, be by a Post-It note or some note stuck to |
| 12 | the chart and then the chart would be put in your mailbox? |
| 13 | A. Possibly. |
| 14 | Q. Okay. |
| 15 | A. Not my mailbox. My office, everything occurs in |
| 16 | the clinic. |
| 17 | Q. Okay. |
| 18 | A. I am there throughout the work day, four of the |
| 19 | five days. So, you know, I am in there, so oftentimes |
| 20 | they just communicate it by orally. |
| 21 | Q. But you have been in situations where there would |
| 22 | be |
| 23 | A. Yes. |
| 24 | Q a communication with a Post-It note, or some |
| 25 | other note stuck to the chart, correct? |
| | |
| | |

| 1 | A. | Correct. |
|----|-------|--|
| 2 | Q. | And then you would respond and write on the note |
| 3 | and r | eturn it back to the dosimetrist? |
| 4 | A. | Possibly, or walk it back. |
| 5 | Q. | But that is one method that is one manner of |
| 6 | commu | nication that would occur between you and a |
| 7 | dosim | etrist, for example? |
| 8 | A. | Yes. |
| 9 | Q. | Is that the same well, would you also |
| 10 | commu | nicate in that same way with a physicist who had |
| 11 | quest | ions? |
| 12 | A. | Possibly, but more directly by mouth. |
| 13 | Q. | More typically by oral communication? |
| 14 | A. | Oral communication, yes. |
| 15 | Q. | Okay. |
| 16 | | Have you spoken to Deb Harrp about this lawsuit at |
| 17 | all, | the litigation? |
| 18 | Α. | No, I have not. |
| 19 | Q. | And has she spoken to you about it? |
| 20 | A. | No, she has not. |
| 21 | Q. | You are affiliated with a practice group, it is |
| 22 | Unive | rsity Radiology |
| 23 | Α. | Radiation Medicine Associates. |
| 24 | Q. | Is that a corporation? |
| 25 | Α. | Yes, it was one of the becoming a chair here in |
| | | |
| | | |

| 1998, you set up a corporation. It was pretty strange, |
|---|
| but anyway I had never done anything like that. But |
| subsequently, there is sort of a boiler plate, they are |
| all the same. But at that time, they weren't. |
| So I was responsible for it, and I actually used a |
| lawyer that had set up a practice plan before, and we |
| just sort of did it. But it was approved by the hospital |
| and the medical school. |
| Q. Sure. |
| Is it that practice plan through which you bill |
| patients? |
| A. Correct. |
| Q. Okay. |
| Are you an officer or shareholder in that? |
| A. The president. |
| Q. The president, okay. |
| Are there any other employees of the group, that |
| you are aware of? |
| A. Since we have gone into the UFPA, I think they |
| have called it now, the University Faculty Practice |
| Associates, and we have had to pick up employees, so I am |
| not sure how many there are. |
| Q. Okay. |
| A. It is a bone of contention, because we are paying |
| for things that seemingly we are |
| |
| |
| |

n

MORSE, GANTVERG & HODGE

| 1 | Q. | You don't want to have to pay for. |
|----|--------|--|
| 2 | | MR. GROEDEL: Doctor, just answer the |
| 3 | | question, okay? |
| 4 | А. | Okay, sorry. |
| 5 | Q. | What is your affiliation with UFPA, University |
| 6 | Family | Practice Associates? |
| 7 | А. | No, no, it is University Physicians Faculty |
| 8 | Associ | ation. |
| 9 | Q. | Okay. |
| 10 | A. | So the family practice would be part of it, and we |
| 11 | would | be part of it. So all the practice plans. |
| 12 | Q. | Okay. |
| 13 | | Do you, through your practice plan, provide any |
| 14 | benefi | ts to any of the nurses? |
| 15 | А. | No. |
| 16 | Q. | Okay. |
| 17 | | The dosimetrists? |
| 18 | Α. | No. |
| 19 | Q. | How about the physicists? |
| 20 | А. | No. |
| 21 | Q. | Mr. Margolis asked you a couple of questions about |
| 22 | well, | it is Exhibit A-1, the prescription note. Let me |
| 23 | just f | ollow up with a couple others. |
| 24 | Α. | Okay. |
| 25 | Q. | I apologize if they are repetitive. |
| | | |
| | | |
| | | MORSE, GANTVERG & HODGE |

Ĩ

| | بني جلي |
|----|--|
| | |
| 1 | Actually, Exhibit A-2, Bates stamp Number 2 on it, |
| 2 | this is a prescription or a therapy prescription, and |
| 3 | this was filled out primarily by you, correct? |
| 4 | A. Correct. |
| 5 | Q. Okay. |
| 6 | I see your signature on the upper the M.D. |
| 7 | signature on the 1-17-2000 box. |
| 8 | A. Uh-huh. |
| 9 | Q. Is that written over at all |
| 10 | A. No. |
| 11 | Q on your copy? |
| 12 | A. No. It looks like the T and the K are superimposed. |
| 13 | Q. Okay. |
| 14 | Which is a little dissimilar from the one below |
| 15 | it, correct? |
| 16 | A. Right, which is dissimilar from the one below |
| 17 | that, unfortunately. |
| 18 | Q. And then I saw another signature that you make, it |
| 19 | looks like a squiggly line, it looks almost like a W; do |
| 20 | you recall that? That was from the May therapy. |
| 21 | A. Yes, I think you can look throughout, my strength |
| 22 | is not in Palmer. |
| 23 | Q. Okay. |
| 24 | One of the things that I am interested in is, when |
| 25 | you did look at this on May 10th to write a new |
| | |
| | |
| | MORSE, GANTVERG & HODGE |

Г

| 1 | prescription |
|----|---|
| 2 | A. Correct. |
| 3 | Q what records and documents did you have |
| 4 | available for you when you wrote the therapy prescription |
| 5 | note here? |
| 6 | A. I would have that chart (indicating). |
| 7 | Q. Okay. |
| 8 | A. That would be it. I would have since Joshua is |
| 9 | an inpatient at that point, I would have his inpatient |
| 10 | records, or actually just his chart from that admission |
| 11 | from Rainbow Babies. |
| 12 | Q. From May? |
| 13 | A. From, yes, the May 10th. I assume he came in that |
| 14 | day. |
| 15 | Q. You wouldn't have the January admission? |
| 16 | A. No. |
| 17 | Q. Okay. |
| 18 | A. No. |
| 19 | MR. MARGOLIS: Excuse me, just so that the |
| 20 | record is clear, the witness motioned to that |
| 21 | chart, and I think he meant Exhibit 101. |
| 22 | THE WITNESS: 101, I am sorry. Thank you. |
| 23 | BY MR. NORCHI: |
| 24 | Q. Contained in would you have reviewed Exhibit |
| 25 | 101 to look at the prior total body irradiation |
| | |
| | |

п

MORSE, GANTVERG & HODGE

treatments that were given? 1 Well, I may have. But --2 Α. Is it your usual custom and practice, when a 3 Ο. patient comes in with a recurrence, to look to see what 4 prior treatment he has received? 5 Yes. 6 Α. 7 Ο. Okay. And the prior treatment would be reflected in your 8 chart, the Exhibit 101 that you have in front of you? 9 Correct, correct. 10 Α. And again looking at Exhibit 101, you would have 11 Q. seen the calculation done by the dosimetrist and checked 12 by the physicist? 13 14 Α. I would not have looked at that. 15 Q. Okay. Do you ever look at those forms? 16 Yes, I -- yes. 17 Α. Under what circumstances would you look at those 18 Q. 19 forms? Since I don't sign them, I have probably glanced 20 Α. at them. I don't -- I mean, they are important 21 documents, but again, I certainly will sign off on those 22 types of things in the future, but I don't think I did 23 24 that day. Q. Okay, I understand. 25

| 1 | | I am just wondering, what stage in the process |
|----|--------|--|
| 2 | А. | Right. |
| 3 | Q. | would you look at |
| 4 | A. | When I am writing a note |
| 5 | Q. | the calculation sheets? |
| 6 | A. | Rarely. |
| 7 | | Of an old calculation sheet? |
| 8 | Q. | Yes. Well, in a case such as this, Joshua |
| 9 | A. | I wasn't aware, I mean, I just assumed, because I |
| 10 | am wri | ting the note here, okay (indicating)? |
| 11 | Q. | On January 17th. |
| 12 | А. | Right, I am looking above I am writing the note |
| 13 | on 5-1 | 0, it says, see consult note, I am seeing that. If |
| 14 | you lo | ok in the front of the chart, on the face sheet, |
| 15 | you ca | n see 10 Gray. So I mean and obviously in the |
| 16 | hospit | al record, on January 26th, I wrote the right |
| 17 | thing, | I mean, it was a you know, an error, it was a |
| 18 | mental | mistake. |
| 19 | Q. | I understand. |
| 20 | Α. | And I carried unfortunately, I carried it |
| 21 | throug | h. |
| 22 | Q. | And I think you did answer this, but on 5-10 and |
| 23 | 5-18, | looking at Exhibit 2 on the therapy which is the |
| 24 | therap | y prescription note, if you would have looked at |
| 25 | the to | p line, you would have seen that only 1 Gray |
| | | |
| | | |

Ī

| 1 | A. Right. |
|----|---|
| 2 | Q was provided, correct? |
| 3 | A. Right. |
| 4 | Technically, I should have started prescription |
| 5 | Number 2 on 5-10, a separate sheet. So I mean, this |
| 6 | then this would have been folded back. |
| 7 | Q. Is there any reason why you didn't do that, that |
| 8 | you can think of? |
| 9 | A. It was an emergency, the child was there, probably |
| 10 | the people hadn't put the right form in. Usually one of |
| 11 | my the clerical people would have put a new |
| 12 | prescription in. So I open the chart, and I would see a |
| 13 | new prescription a whole new face sheet. And it |
| 14 | wasn't there. So it is either take down the chart and |
| 15 | ask them. The patient was under anesthesia, so I took |
| 16 | the path of least resistance. |
| 17 | Q. Was it your custom and practice to try and write a |
| 18 | note in your chart every time the patient had treatment, |
| 19 | or was it just to write a note at the beginning, and then |
| 20 | an ending note? |
| 21 | A. In patients getting weeks of treatment, we write a |
| 22 | note once a week. If there is a change or a |
| 23 | resimulation, that requires an additional note. But a |
| 24 | typical, every five fractions you write an update note. |
| 25 | Q. Okay. |
| | |

| 1 | And so the process you would have used in this is, |
|----|--|
| 2 | as you mentioned, you would write the January 17th note |
| 3 | that would identify the prescription, you would fill out |
| 4 | the prescription sheet |
| 5 | A. Right. |
| 6 | Q that would get passed on to the dosimetrist to |
| 7 | prepare |
| 8 | A. Correct. |
| 9 | Q the calculation? |
| 10 | A. Correct. |
| 11 | Q. And then that would be checked by the physicist? |
| 12 | A. Correct. |
| 13 | Q. And if either of them had problems or issues with |
| 14 | the dose, they would come to see you? |
| 15 | A. Correct. |
| 16 | Q. Okay. |
| 17 | And of course, you have testified you don't recall |
| 18 | any discussions with either? |
| 19 | A. Right. |
| 20 | Q. And then the physicist would then check that. |
| 21 | Who would be present at the time of the total body |
| 22 | irradiation, other than the respiratory I am sorry |
| 23 | the radiation therapist? |
| 24 | A. Sometimes the physicist would be there. I mean, |
| 25 | it is ongoing, so they would be there to check the setup |
| | |
| | |
| | MORSE, GANTVERG & HODGE |

1 and things.

2 Q. And what do you mean by setup?

Well, the patient is placed at three meters from 3 Α. the radiation beam, the linear accelerators, and it is 4 actually marked out, and there is a special shield that 5 is placed in the -- between the patient and the machine, 6 7 plus these things called diodes, which record the radiation dose, are placed on the patient at certain 8 locations. And either a dosimetrist or a physicist does 9 that, or both. 10 Ο. Okay. 11 12 Can you tell from the record who did that in this 13 case? Α. Let me see. 14 On the 26th, it looks like the physicist was Sam 15 Beddar, there is no dosimetrist, and it looks like the 16 same on the -- I am not sure who was on the 28th -- or 17 the 29th -- I am sorry, on the 28th. 18 I can't tell you that, those days, specific days, 19 besides it looks like it is Sam Beddar the first day. 20 I didn't have a copy of your CV, so I apologize, I 21 Ο. will have to ask this question blind, without reviewing 22 23 it. Have you ever written any articles or made any 24 presentations regarding treatment of children through 25

total body irradiation with 1 Gray or smaller doses? 1 Α. Yes. 2 And when? Do you want this (indicating)? 3 Ο. In 1983, there is an article in --Α. 4 5 MR. GROEDEL: He just asked you when. (Continuing) Oh, 1983, sorry. 6 Α. 7 MR. GROEDEL: There you go. I am going to follow up. 8 Q. Α. It has got low-dose TBI in the title, it is in 9 Ewing's sarcoma, '83 or '84. 10 Can you tell me which one it is, then? 11 Q. I think I am the first author. It has got 12 Α. low-dose -- Number 18. 13 And it is an article in which you are the first 14 Ο. author, and it says, Intensive combined modality therapy 15 including low-dose TBI in high-risk Ewing's sarcoma 16 patients, correct? 17 18 Α. Correct. Is there any -- well, is that article at all 19 Ο. 20 relevant to any of the issues in this case? Well, the doses, it was 15 centiGray twice a week 21 Α. for five weeks at a total dose of 150 centiGray. It was 22 23 an experimental study carried out at the National Cancer Institute of an approach using total body irradiation. 24 I see from your notes of 5-11, patient notes -- it 25 Ο.

11

is Page 4 of Exhibit A. 1 5-11. Α. 2 Ο. Yes, see it? 3 Α. I see a note from Deb Harrp. 4 Okay, that is Deb Harrp's note? 5 Ο. Right. Patient, mom and dad came down to Α. 6 7 radiation oncology, given teaching information, signed consent and schedule of treatments. Patient will be 8 outpatient starting tomorrow. Deb Harrp, R.N. 9 Okay. 10 Ο. 11 Was the brain therapy that Joshua received 12 outpatient therapy? It started as an inpatient, because they are 13 Α. 14 saying -- Deb's note says he is being discharged. 15 Q. Right. So his first two treatments on 5-10 and 5-11 must Α. 16 17 have been as an inpatient and subsequently as an outpatient. 18 Thank you, Doctor. I don't 19 MR. NORCHI: have any further questions. 20 CROSS EXAMINATION 21 22 BY MR. WALTERS: For the record, I am Steve Walters, I represent 23 Ο. Case Western Reserve University and the two physicists, 24 Dr. Barry Wessels and Dr. Sam Beddar. 25 MORSE, GANTVERG & HODGE

Doctor, I have very few questions at this point, 1 because most of them have been asked. 2 3 Α. Okay. Which is good news for everyone. Q. 4 5 If I understand, Dr. Kinsella, you do design protocols for radiation therapy that are experimental on 6 7 occasion? In the past, when I worked at the National Cancer Α. 8 Institute, all of the treatment we gave was experimental 9 by design. Only patients could be treated on 10 experimental protocols at the National Cancer Institute. 11 12 Ο. With regard to radiation therapy which you have caused to be performed at University Hospitals, as a 13 comprehensive cancer center as designated by the National 14 Cancer Institute, are you on what I will, for want of a 15 better term, use, cutting edge of radiation oncology? 16 Yes, I would consider it today. 17 Α. 18 Q. And I understand that that has been through a great deal of effort since you have arrived there some 19 four years ago --20 Right. 21 Α. -- four and a half years ago. 22 Ο. 23 There are protocols in which children, pediatric patients, are given total irradiation of 1 Gray? 24 Total body irradiation of 1 Gray? No, not today. 25 Α.

Not today. 1 Q.

| 2 | With regard to the involvement of the dosimetrist |
|----|--|
| 3 | and the physicist, I want to clarify some questions that |
| 4 | were already asked, I think by Mr. Margolis, but I will |
| 5 | try not to be repetitive. |
| 6 | Am I correct that neither a that a physicist is |
| 7 | not permitted to write a prescription for dosage? |
| 8 | A. Correct. |
| 9 | Q. The physicists do not determine what the dosage |
| 10 | should be, that is something that is exclusively the |
| 11 | province of the radiation oncologist? |
| 12 | A. Correct. |
| 13 | Q. And in the case of Joshua Valdivieso, that was |
| 14 | there was no difference in that arrangement? |
| 15 | A. Oh, correct. |
| 16 | Q. In fact, by law, as you understand it, physicists |
| 17 | are not permitted to make that determination? |
| 18 | A. Correct. |
| 19 | Q. You may not be familiar with the training of |
| 20 | physicists, but am I correct that they are not trained, |
| 21 | as you are trained, in determining what constitutes a |
| 22 | therapeutic dose for various cancers? |
| 23 | A. Correct. |
| 24 | Q. And if a physicist were to question your judgment |
| 25 | on what is therapeutic or subtherapeutic or, moving to |
| | |
| | |
| | MORSE, GANTVERG & HODGE |

| 1 | the other direction, toxic, that is not an appropriate |
|----------|---|
| 2 | thing for a physicist to do, is it? |
| 3 | A. They could question it. |
| 4 | Q. How would you receive them questioning your |
| 5 | judgment about what is appropriate dosage? |
| 6 | A. I would explain the reason why I prescribed that |
| 7 | dose. |
| 8 | Q. Has that happened since you have been at |
| 9 | University Hospitals, where either a physicist or a |
| 10 | dosimetrist have questioned your dosage, and you have |
| 11 | explained to them why that was the correct dosage? |
| 12 | A. Yes. |
| 13 | Q. Obviously you don't have the time to do that on |
| 14 | every case? |
| 15 | A. Oh, correct. |
| 16 | Q. It wasn't clear to me, but if I am correct, Joshua |
| 17 | was scheduled to receive his total body irradiation in |
| 18 | three fractions? |
| 19 | A. Correct. |
| 20 | Q. And they were scheduled to be done on January |
| 21 | 26th, 27 and 28? |
| 22 | A. Correct. |
| 00 | Q. Would you have seen Joshua on each occasion when |
| 23 | |
| 23 24 | he was there to receive a fraction? |
| | he was there to receive a fraction? A. I am not required to see him. I usually would see |
| 24 | |

| 1 | him. |
|----|---|
| 2 | Q. In this specific case, do you recall whether or |
| 3 | not you did? |
| 4 | A. I saw him on the 26th and wrote a note for sure. |
| 5 | Q. Okay. |
| 6 | And that is the note you referred to before that |
| 7 | is in apparently the University Hospitals chart? |
| 8 | A. Right. |
| 9 | Q. And you may have answered this, bear with me. |
| 10 | That was put in the University Hospitals chart rather |
| 11 | than in your departmental chart, Exhibit 101, for what |
| 12 | reason? |
| 13 | A. Joshua was an inpatient, and I am communicating to |
| 14 | the inpatient team what we are doing in the radiation |
| 15 | oncology clinic, which, as you know, is a long way from |
| 16 | and the expectation, so that they know they are |
| 17 | scheduling his bone marrow transplant three days from |
| 18 | now. |
| 19 | Q. And typically is that the way it works, when a |
| 20 | patient is being seen or treated in your department as an |
| 21 | outpatient, the record keeping is done in your |
| 22 | departmental record, such as Exhibit 101? |
| 23 | A. Correct. |
| 24 | Q. And when they are an inpatient, the records |
| 25 | record keeping or notations are made in the hospital |
| | |
| | |
| | MORSE, GANTVERG & HODGE |

| 1 | chart? |
|----|--|
| 2 | A. Sometimes both places. We are communicating to |
| 3 | different groups. If I am communicating the schedule |
| 4 | that is important for the floor and physicians on the |
| 5 | floor to know, I would give that information. If there |
| 6 | was another bit of information, say, scheduling a second |
| 7 | simulation, that the floor would not know what those |
| 8 | words meant, I would simply put it in our chart. |
| 9 | Q. Now, I noticed in the case of Joshua, you dictated |
| 10 | a lengthy note that was then typed up for your encounter |
| 11 | of January 6th, 2000, and I think you were asked |
| 12 | questions about it, correct? |
| 13 | A. Correct. |
| 14 | Q. And then I noted also that you dictated a note, |
| 15 | not quite as lengthy, but still a fairly lengthy note on |
| 16 | May 10th? |
| 17 | A. Correct. |
| 18 | Q. What is the criteria by which you decide when to |
| 19 | dictate a note as opposed to just write a note out? |
| 20 | A. Well, a consult note is often long, and I haven't |
| 21 | got the time to write it. So usually I will write |
| 22 | sometimes I will write a brief note, but say, full note |
| 23 | dictated. I will then give it to my secretary, and |
| 24 | usually we put it in the chart that day. So they |
| 25 | actually have that, and it is appreciated, because it is |
| | |

much more detail, and it can be read, it is legible. 1 In, I guess Plaintiff's Exhibit A that we have 2 Ο. been making reference to periodically in this deposition, 3 on Page 4, there is your handwritten note of January 4 5 17th? 6 Α. Correct. 7 Am I correct that the treatment plan as of January Q. 17th was different than the treatment plan contemplated 8 when you dictated your January 6th note? 9 10 Α. Correct. And I think you explained that, there had been Ο. 11 some additional staging, and to put it in layman's terms, 12 this was a worse situation than you had anticipated? 13 Correct. 14 Α. There are no other notes until there is one 15 Q. beginning 5-10? 16 Right, correct. 17 Α. Am I correct that when that says 5-10-99, that is Ο. 18 a mistake, of course? 19 20 Α. That is correct. It is 5-10-2000? 21 Ο. 2000, yes. 22 Α. 23 Ο. By 5-11, that -- somebody -- well, I guess you, pick up the mistake and begin using the proper year? 24 That is Deb Harrp's note, but that is the correct 25 Α.

| 1 | year, yes. |
|----|---|
| 2 | Q. Okay, all right. |
| 3 | A. By 5-16, I picked it up. |
| 4 | Q. All right. |
| 5 | Which is on Page 5 of Exhibit A? |
| 6 | A. On Page 4, 5-16 note. |
| 7 | Q. It is 4, okay. |
| 8 | Dr. Kinsella, turning to Page 1 of Exhibit A |
| 9 | A. Yes. |
| 10 | Q this is the prescription, there has been talk |
| 11 | about prescription. This is the prescription, correct? |
| 12 | A. Yes. |
| 13 | Q. And only a physician can write that? |
| 14 | A. Correct. |
| 15 | Q. And it is the prescription that then triggers the |
| 16 | calculations that the various people go through as far as |
| 17 | setting up the machine, calculating how to deliver the |
| 18 | radiation? |
| 19 | A. Right, correct. |
| 20 | Q. We talked a lot about the line for January 17th on |
| 21 | Exhibit 1, which you have indicated contains a total dose |
| 22 | of 1 Gray, and should have been 10 Gray, correct? |
| 23 | A. Correct. |
| 24 | Q. Down below that is the very next prescription |
| 25 | you wrote was on May 10th? |
| | |
| | |

Α. Correct. 1 2 Ο. And on Exhibit 1, that says 35 Gray? Α. Correct. 3 So -- and that is your signature or initials to 4 Ο. the right, correct? 5 6 Α. Yes, it is. 7 So when you wrote that, you would have seen your Q. earlier prescription, correct? 8 Should have. I mean, it was there. 9 Α. Ο. Understand. Yes, I am not quibbling with words. 10 Would that have been the first time you would have 11 had the occasion to see that 1 Gray prescription of 12January 17th? 13 Ά. Well, I saw that I wrote a note on the 26th in the 14 15 hospital chart, so this chart would have been available 16 during the treatment. But after the total body 17 irradiation was given, I did not see Joshua in follow-up at any time, so this would have been the next time I 18 would have seen this. 19 20 (Thereupon, Mr. Margolis left the room.) 21 Ο. Let me ask you this: Would there have been any -- have been any reason 22 23 for you to make reference to the therapy prescription 24 sheet between January 17th and May 10th? 25 Α. During the treatment itself, the TBI, I certainly

143

۶ľ
could have seen it and should have seen it. So while he 1 was getting treatment, and while I wrote the note in the 2 chart, the hospital chart, the patient and the radiation 3 oncology record are usually there in the outpatient 4 clinic. 5 Ο. Now --6 7 Α. I can't recall whether I specifically had this chart in front of me when I wrote that note in the 8 hospital chart. 9 10 But when you wrote the May 10th prescription, Ο. obviously since it is only two lines below, or an inch 11 away, you did have it front of you? 12 Α. Yes. 13 Q. Sure. 14 Exhibit A-2, which is the next page --15 Yes. Α. 16 -- there is -- and I think you have explained 17 Ο. this -- the 35 Gray for the May 10th prescription is 18 crossed out and there are some other numbers put in and 19 20 circled. That is your writing, correct? 21 Α. Yes. (Thereupon, Mr. Margolis reentered the 22 23 room.) And the total number of fractions are changed from 24 0. 25 14 to 7?

| 1 | A. Correct. | |
|----|--|--|
| 2 | Q. And that is your changes? | |
| 3 | A. Yes. | |
| 4 | Q. Those changes were made at the time and I am | |
| 5 | drawing the distinction between that and the situation | |
| 6 | you described earlier in response to Mr. Margolis' | |
| 7 | questions about something done after the lawsuit. | |
| 8 | That was done the changes for May 10th were | |
| 9 | done intentionally and at the time Joshua was under | |
| 10 | treatment? | |
| 11 | A. They were done on 5-18. | |
| 12 | Q. Okay. | |
| 13 | In doing that, you would have again had the | |
| 14 | opportunity to see the 1 Gray prescription that you had | |
| 15 | written back on January 17th? | |
| 16 | A. Correct. | |
| 17 | Q. If you compare Exhibit A-2 with Exhibit A-3 | |
| 18 | A. Yes. | |
| 19 | Q is there any change to the prescription sheet | |
| 20 | between those two, other than what you have already | |
| 21 | testified to, and that is the change that was made after | |
| 22 | the suit was filed on the January 17th prescription? | |
| 23 | A. Not that I can see. | |
| 24 | Q. I haven't seen any, either, but I thought maybe | |
| 25 | you might pick it up if I have missed it. | |
| | | |
| | | |

| 1 | A. (Witness shakes head). |
|----------------------------------|---|
| 2 | Q. Would you agree that a radiation oncologist is |
| 3 | more apt to recognize the inappropriateness of a |
| 4 | radiation dose than would be a nonphysician? |
| 5 | A. Oh, absolutely. |
| 6 | Q. Now, you gave testimony in response to questions |
| 7 | by Mr. Margolis with regard to the prognosis for this |
| 8 | young man. |
| 9 | A. Yes. |
| 10 | Q. Am I correct in my understanding of your testimony |
| 11 | that at least as of the time that Joshua was restaged in |
| 12 | early January of 2000, his prognosis was rather dismal? |
| 13 | A. Correct. |
| 14 | Q. And I think you already quoted some statistics |
| 15 | with regard to that. |
| 16 | A. I gave an estimate |
| 17 | Q. Yes. |
| 18 | A my estimate. |
| 19 | Q. Am I correct that in your practice as a radiation |
| 20 | oncology oncologist, the fact that a given patient's |
| 21 | chances of survival, even with cutting edge therapy, the |
| 22 | most appropriate therapy available, is poor, you will |
| 23 | not, on that basis alone, deny them the at least possible |
| 24 | benefit of receiving the therapy? |
| 25 | A. Correct. |
| | |
| 19 20 21 22 23 24 | Q. Am I correct that in your practice as a radiation oncology oncologist, the fact that a given patient's chances of survival, even with cutting edge therapy, the most appropriate therapy available, is poor, you will not, on that basis alone, deny them the at least possible benefit of receiving the therapy? |

And in the case of Joshua Valdivieso, it was that 1 Ο. view of giving him whatever chance, albeit small that he 2 had, that you agreed to provide him with total body 3 irradiation? 4 5 Α. Correct. Is there some rule of thumb as to the duration of 6 Ο. 7 time, or the period of time over which fractions must be given if they are to have any salutary effect on a 8 patient? 9 10 Α. Well, typically radiation is given once a day, in some settings, it is given twice a day. And we think the 11 delays in radiation -- and there is information to 12 suggest that, that intentional breaks can have an adverse 13 outcome. So prolonging a course of treatment for various 14 reasons, this is principally in adult cancers, cervix 15 cancer and lung cancer. 16 Am I correct that as you look at the case of 17 Ο. Joshua Valdivieso, at least from the standpoint of 18 radiation oncology, the dosage given, the time given, the 19 fractions given, in all probability made no difference in 20 terms of his ultimate outcome, which was to succumb to 21 his cancer? 22 23 Α. That is what I believe. Dr. Kinsella, both before Joshua Valdivieso and 24 Ο. after Joshua Valdivieso, have you had occasions to work 25

on cases in which either Dr. Barry Wessels or Dr. Sam 1 Beddar have been involved? 2 Yes. Ά. 3 Have you found them to be competent and Q. 4 5 conscientious physicists? 6 Α. Yes. 7 Q. Were your responses to any of the questions by Mr. Margolis intended to indicate that you believe that 8 in the case of Joshua Valdivieso, either Dr. Wessels or 9 10 Dr. Beddar fell below the standard for physicists? Absolutely not. Α. 11 MR. WALTERS: That is all I have. 12 MR. MORIARTY: Do you have more than five 13 minutes? 14 MR. SWEENEY: No, probably not, actually. 15 MR. MORIARTY: Do you have more than five 16 minutes? 17 MR. MARGOLIS: Yes. 18 MR. MORIARTY: Then I need five minutes. 19 20 (Thereupon, a discussion was had off the record.) 21 (Short recess had.) 22 23 MR. MARGOLIS: Doctor, did you indicate --MR. GROEDEL: Wait, Tim had questions. 24 25 MR. MARGOLIS: What?

MORSE, GANTVERG & HODGE

MR. WALTERS: Wait your turn. 1 DR. WIERSMA: Wait your turn. 2 MR. MARGOLIS: Oh, I am sorry, Tim, I 3 apologize. 4 MR. SWEENEY: That is okay, as it is going 5 to turn out, you might as well go ahead. After 6 looking at my notes, I am going to pass. 7 Thanks, Doctor. 8 (Thereupon, a discussion was had off the 9 record.) 10 RECROSS EXAMINATION 11 12 BY MR. MARGOLIS: Doctor, is it Dr. Shina who you said is leaving to 13 Q. go to Mexico? 14 15 Α. Correct. New Mexico. MR. MORIARTY: New Mexico. 16 (Continuing) New Mexico, Santa Fe. 17 Α. All right. 18 Ο. Going back to this meeting where you may or may 19 not have altered the record and Dr. Wiersma was present, 20 21 you were aware certainly prior to today that one of the allegations in this lawsuit involved an alteration of 22 records? 23 Uh-huh, right. 24 Ά. And Dr. Wiersma purportedly would have been a 25 Ο. MORSE, GANTVERG & HODGE

witness as to whether or not you would have altered the 1 record at this meeting after the lawsuit was filed. 2 You are testifying today that you have never 3 discussed with Dr. Wiersma what her recollection is of 4 whether or not you altered the records at this meeting 5 after the lawsuit was filed? 6 MR. GROEDEL: Objection. 7 First of all, any conversations that 8 Dr. Kinsella had with Dr. Wiersma would be 9 protected by spousal privilege. So I am going to 10 instruct him not to answer the question just based 11 on that basis alone. 12 MR. MARGOLIS: Except if she is going to 13 testify as to what she saw, then that portion of 14 the privilege is going to be abrogated by her, and 15 I can certainly ask him what his understanding is 16 of her knowledge. 17 (Continuing) Let me phrase the question this way: 18 Ο. Because you and Dr. Wiersma are married, there is 19 a legal privilege that applies. We will argue it in 20 21 front of the judge, and the judge will make a determination. For the purposes of my questioning today, do you 22 have knowledge as to whether or not Dr. Wiersma recalls 23 you altering the record, which is record 102, at this 24 meeting that occurred after the lawsuit was filed? 25

MR. GROEDEL: Objection. 1 You may answer, if you know. 2 Α. I am not sure if she was there at that time. 3 Okay, all right. Q. 4 You have been involved in pediatric oncology and 5 radiation oncology for how many years? 6 Since 1980, when I went to the National Cancer 7 Α. Institute. 8 9 Ο. Have you ever known children to beat the odds, that there are successes or miracles that medically you 10 just say, no chance, not going to happen? 11 12 MR. GROEDEL: Objection. 13 You may answer. MR. WALTERS: Objection. 14 MR. NORCHI: Objection. 15 Not really. I mean, unfortunately, they often are 16 Α. predicted by -- by the disease status. So we know pretty 17 well what will happen. 18 One hundred percent of the time? Ο. 19 MR. GROEDEL: Objection. 20 You may answer. 21 MR. WALTERS: Same objection. 22 23 MR. NORCHI: Objection. 24 We are pretty sure most of the time. Α. That isn't what I asked, though. 25 Ο.

151

Have there ever been children who you believe, 1 based upon your skill, education, knowledge and 2 experience, that they are not going to survive secondary 3 to their disease beyond a certain time period, and lo and 4 behold, they surprise everybody and they do? 5 6 MR. GROEDEL: Objection to the vagueness of the question --7 MR. WALTERS: Objection. 8 MR. GROEDEL: -- but you may answer. 9 10 MR. NORCHI: Objection. Theoretically. 11 Α. Have they lived longer than I might have guessed? 12 Have they been cured? Probably not, unfortunately. 13 Yes. Now, if a patient, a child, has an extremely poor 14 Ο. prognosis, and you don't really anticipate that the 15 medical treatment that you are providing is going to have 16 any meaningful impact upon the patient's prognosis either 17 for cure or survival, is that something that you are duty 18 19 bound to inform the parents of so they can make an informed choice of treatment? 20 In that setting, those -- as you have phrased the 21 Ά. question, I would say yes. 22 Ο. All right. 23 24 And your testimony is that after you saw Joshua and you had this detailed note of January 6th, that you 25

saw him again on January 17th where, based upon his 1 medical condition and modifications, that there was a 2 change from your perspective what would be most 3 appropriate treatment, and it would be TBI, correct? 4 Correct. Α. 5 And your only January 17th note is what is on Page 6 Ο. 4 of Exhibit A, correct? 7 Correct. Α. 8 At any point do you document that you informed 9 Ο. 10 Joshua's parents that you really didn't think that this treatment was going to have a snowball's chance in hell 11 in benefiting this child? 12 13 MR. GROEDEL: Objection. You may answer. 14 (Continuing) Is that documented anywhere in your 15 Q. January 17th note? Look at the note. 16 Α. No. 17 As a matter of fact, on January 20th -- if you 18 Ο. want to go to Dr. Wiersma, and look at Page 4. 19 MR. WALTERS: We don't have this. 20 MR. MORIARTY: What is the exhibit number? 21 MR. MARGOLIS: 4. 22 MR. GROEDEL: Is this going to be marked as 23 2.4 an exhibit? This is something we haven't seen. MR. MARGOLIS: Right, I am going to give --25

| 1 | I will mark it as an exhibit. Let me do this |
|----------------|---|
| 2 | MR. MORIARTY: I am just saying, the other |
| 3 | ones had a letter, A, page something |
| 4 | MR. MARGOLIS: Right. |
| 5 | MR. MORIARTY: B, page something. What |
| 6 | is this one? |
| 7 | MR. MARGOLIS: This does not have a letter, |
| 8 | because there is only one folder that is |
| 9 | delineated Dr. Wiersma. |
| 10 | MR. MORIARTY: Okay. |
| 11 | MR. MARGOLIS: It is marked Exhibits 1 |
| 12 | through 32. |
| 13 | Q. (Continuing) So I am handing you the Dr. Wiersma |
| 14 | folder, and asking you to refer to Page 4. |
| 15 | A. Yes. |
| 16 | Q. And at that point, was it not represented as |
| 17 | following to the parents: "It is hoped that this procedure |
| 18 | will benefit my child. There is no guarantee that my |
| 19 | child will experience a continued remission. It is hoped |
| 20 | that the radiation and high-dose chemotherapy will kill |
| | |
| 21 | tumor cells. It is hoped that the combined treatments |
| 21 22 | tumor cells. It is hoped that the combined treatments will increase my child's chance to remain well. It is |
| | |
| 22 | will increase my child's chance to remain well. It is |
| 22 23 | will increase my child's chance to remain well. It is hoped that the treatment will decrease the risk that the |
| 22 23 24 | will increase my child's chance to remain well. It is hoped that the treatment will decrease the risk that the tumor will return or relapse." And then that is signed |

154

2 Q. All right.

| 3 | So with everything that all the doctors knew |
|----|---|
| 4 | that were taking care of Joshua in January of 2000, |
| 5 | you never said to the parents, I think that this TBI |
| 6 | is hopeless, or we don't have any hope whatsoever that |
| 7 | this will benefit your child; it was represented that |
| 8 | this could have a potential benefit to this child, wasn't |
| 9 | it? |
| 10 | A. Yes. |
| 11 | Q. And if you would have thought in January of 2000 |
| 12 | that TBI had absolutely no chance of benefiting this |
| 13 | child, it would have been medically unethical for you to |
| 14 | administer that treatment? |
| 15 | A. I didn't say that. |
| 16 | Q. I didn't ask you what you said. I asked you to |
| 17 | answer what I asked. |
| 18 | Would you read the question back. |
| 19 | A. Yes, please. |
| 20 | (Record read.) |
| 21 | A. (Continuing) Yes, correct. |
| 22 | Q. And you would agree with me that it would have |
| 23 | been unethical for any other health care professional to |
| 24 | have recommended the treatment under these circumstances |
| 25 | if the consensus of opinion was there was no chance that |
| | |
| | |
| | MORSE, GANTVERG & HODGE |

this was going to help this child? 1 Α. Yes. 2 Has your status at University Hospital been 3 Ο. changed at all relative to the filing of this lawsuit, 4 have you been put on probation? 5 Α. No. 6 7 Are you aware as to whether or not there is any Ο. impending investigation surrounding your potential 8 summary suspension based upon the facts of this lawsuit 9 and deposition? 10 MR. GROEDEL: Objection. 11 12 Α. No, I do not. 13 Q. There was a physicist who you testified had left, or a dosimetrist, I believe, Mr. Abrams [sic]? 14 Α. Yes. 15 Where did he go? 16 Ο. I think he is at Akron City Hospital now. 17 Α. Have there been instances in the course of your 18 Q. practice where you have told patients' parents, I just 19 simply will not do any more treatment on this child 20 because it doesn't have any -- it is not medically 21 warranted --22 23 Α. Yes. -- if there is no chance of benefit? 24 Ο. Yes. 25 Α.

156

Ο. And that is something that you believe, as a 1 physician, you have the obligation to do if the situation 2 3 merits it? Α. Yes. 4 The last question I have, if you look at -- or 5 Ο. line of questioning. If you look at 10- I think it is 6 -2, which is the prescription sheet --7 Α. Yes. 8 9 Ο. Is it 102, sir? Let me see. 10 Α. MR. GROEDEL: Yes. 11 (Continuing) Yes. 12 Α. 13 Ο. I thought you said earlier that normally every time a prescription is written, that it is written on a 14 separate piece of paper, that it is not done 15 sequentially; is that accurate? Was that your testimony? 16 When I came, we would do -- when I started at UH 17 Α. in 1998, we would do it on the same, and then some 18 patients would carry over. It got to be very sloppy and 19 hard to follow. 20 So a policy was made that if a patient comes back 21 for a retreatment or a second treatment, then the 22 clerical staff, and things like that, should reorganize 23 the chart with a new prescription sheet, and then this 24 would go behind that. 25

| 1 | Q. All right. |
|----|---|
| 2 | And when did that change in policy take place? |
| З | A. I am not sure whether it was before or after this |
| 4 | time. |
| 5 | Q. All right. |
| 6 | A. But in today today, there would have been a |
| 7 | fresh sheet here that I would have then put, whole brain, |
| 8 | it would have been Number 2, and the stage would have |
| 9 | changed, it would be X, it would be relapse, so some |
| 10 | things would have changed. |
| 11 | Q. You indicated in answer to Mr. Norchi's questions |
| 12 | that in May, when you did additional prescriptions for |
| 13 | radiation, that you would have reviewed the child's chart |
| 14 | inclusive of the January treatment that he had received, |
| 15 | correct? |
| 16 | A. I may have. |
| 17 | Q. Well, what would be your standard operating |
| 18 | procedure under these circumstances? You have a child |
| 19 | with a remission, the child has |
| 20 | A. Right. |
| 21 | Q been previously treated with radiation. |
| 22 | Wouldn't you want to look at what the prior radiation |
| 23 | treatment was before you determined what treatment you |
| 24 | were going to recommend now? |
| 25 | A. Yes, yes. |
| | |

н

Q. All right. 1 And -- but my -- it was 10 Gray, and it was here 2 Α. (indicating), and it is on that note. So that is -- I 3 mean, that is how I saw it. I mean, it was a mental 4 5 lapse. I understand that. 6 Ο. 7 Α. And --And it is your testimony today under oath that had Ο. 8 anybody brought to your attention that Joshua Valdivieso 9 did not receive 10 Gray of radiation during his TBI on 10 January 26th, 27th and 28th, if anybody would have 11 12 brought that to your attention, you would have advised 13 the parents of the fact and evaluated whether or not a change in his medical treatment would have been 14 warranted? 15 Right. 16 Α. And the first time that you knew that this child 17 Q. 18 received 1 Gray was after the lawsuit in this case was filed? 19 20 Α. Correct. MR. MARGOLIS: Thank you. 21 MR. NORCHI: I have just one follow-up 22 23 question. MR. MORIARTY: 24 No. MR. NORCHI: Please? One subject. 25

MORSE, GANTVERG & HODGE

| 1 | RECROSS EXAMINATION |
|----|---|
| 2 | BY MR. NORCHI: |
| 3 | Q. Doctor, I would like to just follow up on an |
| 4 | answer you gave to a question by Mr. Walters. |
| 5 | A. Uh-huh. |
| 6 | Q. You told us that you have testified today that |
| 7 | you have no criticisms of the physicists who were |
| 8 | involved in the care of Joshua Valdivieso in January, |
| 9 | correct? |
| 10 | A. Correct. |
| 11 | Q. By the same token, would it also be true that you |
| 12 | have no criticisms of the care or the participation in |
| 13 | the care of Joshua Valdivieso by the dosimetrist, David |
| 14 | Abraham? |
| 15 | A. Correct. |
| 16 | Q. The radiation therapists? |
| 17 | A. Correct. |
| 18 | Q. And the nurses, in particular Deb Harrp? |
| 19 | A. Yes. |
| 20 | Q. Okay. |
| 21 | No criticisms of any of their participation? |
| 22 | A. No. |
| 23 | MR. NORCHI: Thank you. |
| 24 | MR. GROEDEL: Okay. |
| 25 | MR. WALTERS: I have no questions. |
| | |
| | |
| | MORSE, GANTVERG & HODGE |

| 1 | MR. GROEDEL: Oh, I am sorry, Steve. |
|----|--------------------------------------|
| 2 | MR. WALTERS: Well, I have none. |
| 3 | MR. GROEDEL: Oh, you have none. I am |
| 4 | sorry. |
| 5 | MR. MORIARTY: He will read and sign. |
| 6 | |
| 7 | (DEPOSITION CONCLUDED) |
| 8 | |
| 9 | |
| 10 | Timothy J. Kinsella, M.D. |
| 11 | |
| 12 | |
| 13 | |
| 14 | |
| 15 | |
| 16 | |
| 17 | |
| 18 | |
| 19 | |
| 20 | |
| 21 | |
| 22 | |
| 23 | |
| 24 | |
| 25 | |
| | |
| | |
| | MORSE, GANTVERG & HODGE |

CERTIFICATE 1 State of Ohio, 2 SS: County of Cuyahoga. 3 I, Ivy J. Gantverg, Registered Professional 4 Reporter and Notary Public in and for the State of Ohio, 5 duly commissioned and qualified, do hereby certify that 6 the above-named TIMOTHY J. KINSELLA, M.D., was by me 7 first duly sworn to testify to the truth, the whole 8 truth, and nothing but the truth in the cause aforesaid; 9 that the deposition as above set forth was reduced to 10 writing by me, by means of stenotype, and was later 11 transcribed into typewriting under my direction by 12 computer-aided transcription; that I am not a relative or 13 attorney of either party or otherwise interested in the 14 event of this action. 15 IN WITNESS WHEREOF, I have hereunto set my hand 16 and seal of office at Cleveland, Ohio, this 6th day of 17 May, 2002. 18 19 20 Ivy J. Gantverg, Notary Public in and for the State of Ohio.(Publiq 21 Registered Professional Reporter. 22 My commission expires November 5, 2003. 23 24 25

MORSE, GANTVERG & HODGE

| 3.4 | 84.0 | Th | TM |
|-----|------|------|-----------|
| VED | 1111 | -Pag | TO |

| 64 M 0.00 | | | | | [| | Iulti-Pa | | | | | | \$15,00 | <u>)0 - ab</u> |
|---------------------|------------------|------------------|----------------|-----------------|-----------------------|-----------------|-----------------|-----------------|------------------|-----------------------|-----------------|-----------------|---------|-----------------|
| \$15,000 | | 12:13 | 12:23 | | 52:25 116:15 | 53:6 | 53:8 | 110:5 | 116:11 | 27 [1] | 138:21 | | | |
| \$5,815 [| | 13:3 | | | 14 [12] | 53.16 | 52.20 | 50.00 | 50.05 | 27th [4] | | 83:17 | 94:1 | 159:11 |
| | 117:1 | | | | 53:6 | 52:16 53:9 | 52:20 53:10 | 52:23 64:15 | 52:25 64:23 | 28 [1] | 138:21 | | | |
| 83 [1] | 134:10 | | | | 81:8 | 102:3 | 144:25 | 07.15 | 04.20 | 28th [6] | | 83:17 | 94:1 | 133:17 |
| 84 [1] | 134:10 | | | | 1400 [1] | | | | | | 159:11 | | | |
| 87 [1] | 19:9 | | | | 15 [11] | 19:25 | 41:15 | 48:18 | 54:24 | | 133:18 | | | |
| 90 [1] | 19:10 | | | | 55:1 | 55:2 | 55:7 | | 115:12 | 2nd [1] | 2:23 | | | |
| 90s [2] | 110:12 | 110:15 | | | 117:8 | 134:21 | | | | 3 [1] | 67:25 | | | |
| 1 93 [1] | 19:4 | | | | 15,000 | 1] | 13:9 | | | 3.333 [1] | | | | |
| '95 [1] | 111:9 | | | | 150 [1] | 134:22 | | | | 30 [3] | 52:7 | 120:2 | 120:2 | |
| 97 [1] | 28:4 | | | | 16 [4] | 49:16 | 54:25 | 57:11 | 57:12 | 300 [2] | 110:9 | 116:20 | | |
| 98 [3] | 28:4 | 29:8 | 111:10 | | 1660 [1] | 2:23 | | | | 32 [3] | 102:20 | 103:7 | 154:12 | |
| 99 [1] | 29:9 | | | | 17 [3] | 50:8 | 50:11 | 79:24 | | 33 [1] | 104:12 | | | |
| -2 [1] | 157:7 | | | | 17.5 [7] | | 80:9 | 80:20 | 80:25 | 333 [3] | 40:24 | 67:6 | 68:1 | |
| 0.333 [2] | 83:19 | 99:9 | | | 81:8 | 81:10 | 82:10 | | | 35 [8] | 79:17 | 80:8 | 80:20 | 81:2 |
| 0.5 [1] | 29:24 | | | | 17th [19] | | 49:23 | 50:23 | 51:24 | 81:6 | 81:9 | 143:2 | 144:18 | |
| 00 [3] | 52:6 | 52:7 | 120:2 | | 62:22 | 83:4 | 83:16 | 130:11 | 132:2 | 350 [1] | 41:11 | | | |
| 1 [52] | 1:14 | 26:5 | 26:9 | 26:13 | 141:5 145:15 | 141.8 145-22 | 142:20 153:1 | 143:13 153:6 | 143:24 153:16 | 4 [12] | 40:13 | 49:24 | 49:25 | 62:18 |
| 26:21 | 31:1 | 31:4 | 49:19 | 49:20 | 18 [2] | 55:3 | 134:13 | 100.0 | 300.20 | 135:1 153:19 | 141:4 153:22 | 142:6 154:14 | 142:7 | 153:7 |
| 58:4 | 58:14 | 58:22 | 59:23 | 60:11 | 18 [2] 18th [12] | | 57:19 | 79:23 | 80:22 | 40 [1] | 120:5 | 1.277.177 | | |
| 62:9 71:8 | 63:13 78:16 | 63:18 78:23 | 64:10 78:24 | 64:22 79:11 | 80:24 | 81:7 | 81:24 | 82:6 | 80.22 | 400 [1] | 41:11 | | | |
| 83:5 | 83:15 | 83:19 | 83:24 | 87:24 | 82:18 | 82:24 | 104:16 | | | 44113 [2 | | 2:16 | 2:23 | |
| 88:7 | 88:18 | 89:7 | 89:23 | 95:24 | 18X [4] | 70:18 | 70:22 | 71:1 | 78:21 | 44114 [3 | | 2:10 | 2:12 | 1.20 |
| 97:25 | 98:4 | 98:7 | 98:14 | 98:18 | 19 [8] | 22:16 | 22:23 | 23:6 | 23:14 | 44115 [1 | | | 2:12 | 2:20 |
| 99:9 | 130:25 | 134:1 | 136:24 | 136:25 | 23:16 | 23:21 | 24:1 | 94:14 | | | | 2:8 | | |
| 142:8 145:14 | 142:21 154:11 | 142:22 159:18 | 143:2 | 143:12 | 1980 [1] | | | | | 443978 | | 1:7 | | |
| | 62:19 | 62:24 | 71:21 | 84:11 | 1980s [1] | | | | | 45 [1] | 64:21 | 00.14 | 114.00 | 1177.0 |
| 97:15 | 97:18 | 97:22 | 98:14 | 07.11 | 1982 [1] | 5:4 | | | | 5 [6] 142:5 | 64:12 162:22 | 80:16 | 116:22 | 117:8 |
| 1-17-20 | | 71:5 | 73:20 | 127:7 | 1983 [3] | 5:4 | 134:4 | 134:6 | | 5-10 [14] | | 79:14 | 79:17 | 80:2 |
| 1-19 _[1] | | 112 | , | 110,11, | 1987 [2] | 5:5 | 5:7 | | | 80:5 | 97:7 | 97:14 97:19 | 97:25 | 80:2 98:14 |
| 1-26 [11] | | 41:8 | 66:11 | 66:15 | 1990 [1] | 18:5 | | | | 130:13 | | 131:5 | 135:16 | 141:16 |
| 67:21 | 68:2 | 68:6 | 68:6 | 68:10 | 1993 [1] | | | | | 5-10-20 | | 98:21 | 141:21 | |
| 68:22 | 69:5 | | | | 1996 [1] | | | | | 5-10-99 | | 141:18 | | |
| 1-27 [2] | 41:8 | 69:6 | | | 1997 [2] | | 19:16 | | | 5-11 [4] | | 135:2 | 135:16 | 141:23 |
| 1-28 [3] | 41:8 | 68:2 | 69:6 | | 1998 [8] | 19:18 | 19:21 | 109:7 | 109:20 | 5-16 [2] | | 142:6 | | |
| 1-87 [1] | 3:3 | | | | 110:23 | 115:21 | 125:1 | 157:18 | 107.20 | 5-18 [13] | | 79:14 | 80:4 | 80:5 |
| 1.5 m | 36:2 | | | | 1999 [2] | 87:15 | 118:5 | | | 80:11 | | 80:17 | 80:18 | |
| 10 [31] | 26:5 | 26:10 | 26:14 | 26:22 | 19th [1] | | | | | 97:23 | 98:17 | 130:23 | | |
| 31:2 | 31:9 | 41:3 | 62:19 | 63:13 | 2 [6] | 79:11 | 80:1 | 127:1 | 130:23 | 5-31-20 | 00 [1] | 22:18 | | |
| 63:19 | 64:12 | 64:18 | 68:12 | 86:2 | 131:5 | 158:8 | | | | 6 [3] | 33:16 | 52:7 | 120:2 | |
| 86:3 90:2 | 88:7 98:1 | 88:18 99:9 | 89:7 115:11 | 89:24 115:12 | 2.5 [1] | 82:13 | | | | 630 [1] | 2:8 | | | |
| | 117:8 | 130:15 | 142:22 | 157:6 | 20 [3] | 28:22 | 41:15 | 113:14 | | 6th [12] | 33:13 | 35:18 | 36:23 | 36:24 |
| 159:2 | 159:10 | 100,10 | 1 | 107.0 | 2000 [39] | 15:24 | 16:10 | 29:12 | 29:15 | 51:22 | 90:10 | 91:16 | 105:1 | 140:11 |
| 100 [5] | 3:5 | 5:17 | 100:15 | 101:4 | 33:13 | 34:14 | 36:10 | 36:10 | 43:23 | 141:9 | 152:25 | 162:17 | | |
| 116:14 | | | | | 45:4 | 45:11 | 46:12 | 47:14 | 47:15 | 7 [6] | 52:6 | 52:7 | 80:20 | 81:7 |
| 1000 [1] | 40:25 | | | | 47:16 90:15 | 76:6 90:21 | 87:15 91:5 | 89:18 91:12 | 90:7 95:5 | 120:2 | 144:25 | | | |
| | 6:9 | 6:10 | 6:14 | 7:3 | 95:8 | 95:9 | 105:4 | 112:21 | 114:5 | 7.5 [1] | 64:13 | | | |
| 7:10 | 22:1 | 33:9 | 49:4 | 49:18 | 115:22 | 116:18 | 117:20 | 118:10 | 140:11 | 730 [1] | 2:4 | | | |
| 63:5 101:5 | 69:12 | 100:18 | 100:19 | 101:4 | 1 | 146:12 | 154:25 | 155:4 | 155:11 | 75 [1] | 110:9 | | | |
| | 128:21 139:11 | 128:22 139:22 | 128:25 | 129:9 | 2001 [11] | | 27:4 | 29:14 | 29:21 | 7th [2] | 90:10 | 105:1 | | |
| 102 [12] | 70:1 | 70:5 | 74:18 | 76:19 | 47:13 | 76:5 | 76:7 | 86:13 | 92:21 | 8 [1] | 120:2 | | | |
| 83:20 | 97:10 | 98:14 | 98:17 | 99:3 | | 112:21 | 5.10 | 12.14 | 22 17 | 9 [1] | 1:23 | | | |
| 99:9 | 150:24 | 157:9 | | | 2002 [7] 23:21 | 1:14 101:7 | 5:19 162:18 | 23:14 | 23:17 | 90 [1] | 110:9 | | | |
| 10th [19] | 81:5 | 81:25 | 82:5 | 82:9 | 2003 [1] | | 104.10 | | | 900 [1] | 2:23 | | | |
| 82:10 | 82:13 | 82:17 | 82:24 | 90:11 | | | 110.7 | 152.10 | 154.75 | 99 [2] | 48:11 | 103:24 | | |
| 91:16 | 105:2 | 127:25 | 128:13 | 140:16 | 20th [4] | | 119:2 | 153:18 | 104:20 | A-1 [1] | 126:22 | | | |
| | 143:24 | 144:10 | 144:18 | 145:8 | 21 [1] | 36:3 | | | | A-2 [3] | 127:1 | 144:15 | 145:17 | |
| 113 [2] | 1:22 | 2:19 | | | 2500 [1] | | 96.95 | (7 . 1 | 00.17 | A-3 [1] | 145:17 | | | |
| | 24:8 | 105:2 | | | 26th [12] 93:25 | 15:23 115:22 | 36:25 130:16 | 67:1 133:15 | 83:16 | a.m [2] | 1:23 | 67:25 | | |
| | 1:23 | | | | | | | 155:15 | 130:21 | ability [| | 47:25 | | |
| 12 [1] 13 [10] | 52:16 | 52:18 | 52:20 | 52:23 | 139:4 | 143:14 | 159:11 | | | and any f | -1 | 77.45 | | |

| | | | | | | | lulti-Pa | age | | | | ove - a | attentio |
|---------------------------|------------------------|---------------|---------------|--|------------------------|-----------------------|-----------------|----------------|----------------|--------------------------------|-----------------|------------|----------------|
| above [4 | [] | 1:24 | 116:24 | 130:12 | 11:5 40:10 | 21:14 47:13 | 29:16 53:15 | 34:9 | 39:9 54:9 | answered [6] 60:13 78:11 | 54:7 | 59:6 | 59:9 |
| | named [1 | | 162:7 | | 40:10 | 47:13 78:21 | 53:15 83:6 | 53:24 83:12 | 54:9 90:2 | 60:13 78:11 answers [1] | 139:9 | | |
| Abraha | | 1 51:8 | 51:8 | 108:25 | 97:19 | 119:12 | 129:11 | 129:22 | 145:13 | anticipate [1] | 84:13 152:15 | | |
| 121:3 | 122:2 | 160:14 | 51.8 | 108.25 | 153:1 | | | | | anticipated [1] | 132:13 | | |
| Abram | | 27:22 | 55:11 | 156:14 | against | | 14:7 | 20:23 | 94:22 | anyone's [1] | 70:12 | | |
| Abram | | 51:8 | | | age [1] | 32:8 | | | | anytime [1] | 119:1 | | |
| abrogat | | 150:15 | | | agency | | 94:2 | | | anyway [1] | 125:2 | | |
| absolut 155:12 | | 121:19 | 146:5 | 148:11 | ago [6] 136:20 | 10:2 136:22 | 23:12 | 25:12 | 101:17 | apologize [4] 149:4 | 86:17 | 126:25 | 133:21 |
| accelera | ator m | 64:5 | | | agree [18 | | 11:10 | 11:17 | 38:24 | apparent [1] | 76:4 | | |
| | ators [1] | | | | 42:23 84:13 | 43:2 84:20 | 43:6 84:21 | 83:2 87:24 | 84:2 93:14 | appear [2] | 74:19 | 99:8 | |
| accepte | | 106:3 | 106:4 | 113:14 | 93:19 | 99:15 | 101:24 | 146:2 | 155:22 | APPEARANCI | | 2:1 | |
| accesso | | 112:9 | | | agreed | 2] | 120:7 | 147:3 | | application [2] | 105:14 | 105:24 | |
| accomp | * | 52:2 | | | agreem | | 1:20 | | | applied [1] | 105:5 | 100.21 | |
| accomp | | 32:19 | | | ahead [5 | | 28:7 | 54:8 | 59:10 | applies [1] | 150:20 | | |
| | lished [1 |] | 110:22 | | 73:3 | 149:6 | | | | apply [1] 84:14 | 100.20 | | |
| accordi | | 49:23 | 50:22 | 62:21 | Akron [| [] | 156:17 | | | appointed [2] | 114:3 | 114:4 | |
| accurat | | 7:11 | 157:16 | | al [1] | 1:9 | | | | appointment [2] | | 113:23 | |
| acknow | ledged | 1] | 59:17 | | Alan [1] | | | | | appreciate [2] | 15:15 | 49:21 | |
| act [1] | 14:24 | | | | albeit [3] | | 109:8 | 147:2 | | appreciated [1] | 140:25 | | |
| action [4 | \$] | 15:17 | 20:22 | 26:14 | Albuqu | | - | 113:13 | | approach [4] | 40:7 | 41:25 | 111:21 |
| 162:15 | | | | | allegation | | 11:18 | 11:22 | 11:25 | 134:24 | | e see he | |
| activity | | 120:21 | | | 14:7 | 15:12 | 149:22 | | | | 34:15 | 35:21 | 86:18 |
| actual [] | | 105:22 | | | allow [1] | | 1 | | | | 138:1 | 138:5 | 146:22 |
| acute [3] | | 68:3 | 116:24 | | allowing | | 15:15 | | | 153:4 | | 01.14 | |
| addition | | 52:23 | | | allows p almost p | | 16:5 108:22 | 127:19 | | appropriately [1 | | 81:14 | |
| addition | | 36:25 | 37:4 | 131:23 | 1 | - | | 127:19 | | approval [1] | 62:3 | | |
| 141,12 admini s | | 64.10 | 65:14 | 155:14 | alone [2] along [3] | | 150:12 25:25 | 111:11 | | approved [1] April [2] 5:19 | 125:7 114:5 | | |
| | ster [3] stered [2' | 64:19 | 15:23 | 155:14 26:5 | alter [3] | | 100:1 | 100:10 | | apt [1] 146:3 | 114:5 | | |
| 26:9 | 26:13 | 43:20 | 49:9 | 20.3 52:3 | alteratio | | 73:6 | 76:4 | 77:9 | area [7] 15:3 | 15:15 | 17:16 | 45:18 |
| 52:4 | 56:24 | 58:16 | 61:24 | 64:3 | 84:21 | 84:25 | 85:5 | 96:6 | 98:22 | 45:21 46:17 | 77:5 | 17.10 | 43.10 |
| 67:22 | 80:3 | 81:25 | 82:1 | 83:16 | 100:5 | 149:22 | | | | areas [1] 110:20 | | | |
| 83:24 90:14 | 87:25 90:20 | 89:1 90:25 | 89:23 91:6 | 90:7 95:7 | alteratio | DNS [4] | 74:17 | 76:19 | 99:3 | argue [1] 150:20 | | | |
| | stering p | | 14:8 | 46:5 | 99:8 | | | | | arrangement [1] | 137:14 | | |
| 53:1 | 80:3 | *) | 14.0 | 40.0 | altered | | 8:10 | 36:7 | 72:10 88:6 | arrived [4] | 110:4 | 115:8 | 115:21 |
| adminis | stration | [5] | 28:23 | 53:20 | 75:24 | 81:11 149:20 | 81:13 150:1 | 84:18 150:5 | 00:0 | 136:19 | | | |
| 64:2 | 93:2 | 116:7 | | | altering | | 96:25 | 150:24 | | article [3] | 134:4 | | 134:19 |
| | strations | | 92:24 | | always | | 18:8 | 74:15 | 86:3 | articles [2] | 18:1 | 133:24 | |
| | strative | | 9:3 | 19:16 | 117:4 | .1 | | | | aspects [1] | 61:20 | | |
| 28:18 30:5 | 28:21 | 28:24 | 29:17 | 30:2 | amongs | t [1] | 39:3 | | | assessing [1] | 90:11 | | |
| | strator's | 111 | 9:5 | | amount | | 30:7 | | | assigned [1] | 117:11 | | |
| admissi | | 119:1 | 128:10 | 128:15 | anatom | | 50:13 | | | Associates [4] 126:6 | 87:17 | 124:23 | 125:21 |
| admit [2 | | 31:1 | 31:4 | ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | Anderso | | 13:24 | | | Association [1] | 126:8 | | |
| adult [4] | | 58:19 | 118:15 | 147:15 | anesthe | | 32:7 | 41:23 | 131:15 | assume [6] | 120:8 | 50:21 | 55:12 |
| adults [2 | | 32:9 | 116:4 | | anesthe | | | 10:24 | 118:17 | 105:7 108:3 | 128:13 | لایک. ان ا | nd at a te har |
| adverse | | 4:18 | 147:13 | | anesthe | | | 118:17 | | assumed [3] | 29:22 | 50:25 | 130:9 |
| adverse | | 89:22 | | | anesthe | | 118:18 | | | assurance [1] | 85:25 | | |
| advised | •/ | 26:21 | 159:12 | | ankle [1] | | | | | assurance/peer | | 72:1 | |
| advises | | 71:19 | | | anonym | | 76:23 | 77:3 | 77:13 | attachments [1] | | | |
| advisor | | 30:13 | | | answer | [57] 11:24 | 9:23 13:1 | 10:10 14:3 | 10:21 14:15 | attempt [3] | 88:23 | 89:12 | 93:16 |
| affected |] [1] | 89:23 | | | 23:23 | 31:8 | 38:7 | 43:24 | 44:17 | attend [5] | 37:24 | 37:25 | 38:2 |
| affiliate | ed [4] | 112:22 | 113:2 | 113:10 | 45:15 | 46:11 | 47:24 | 53:22 | 55:23 | 38:21 39:16 | | | |
| 124:21 | | | | | 56:6 | 58:11 | 59:12 | 60:1 | 61:6 | attendant [1] | 28:17 | | |
| affiliati | | 29:6 | 126:5 | | 65:3 73:13 | 65:16 75:10 | 71:20 75:17 | 71:24 77:22 | 73:1 84:24 | attendees [1] | 72:8 | | |
| aforesa | | 162:9 | | | 85:8 | 86:9 | 88:3 | 93:22 | 94:16 | attending [2] | 12:5 | 117:12 | |
| afterno | | 108:22 | | | 96:16 | 96:22 | 98:24 | 104:10 | 105:12 | attends [1] | 37:10 | | . |
| n . | rdem | 66:13 | | | 107:12 | 107:15 | 107:25 | 126:2 | 130:22 | attention [27] | 26:4 | 26:8 | 26:13 |
| afterwa again [24 | | 10:4 | 10:14 | 10:25 | 150:11 | 151:2 | 151:13 | 151:21 | 152:9 | 58:8 59:23 | 60:10 | 61:3 | 61:12 |

| | | | | | Iulti-Pa | age | | | | attorn | ey - cells |
|--------------------------------|-----------------|-----------------|-------------------|-------------------------------|------------------|--------------------------|------------------|--------------------------------------|---------------------|------------------|------------------|
| 76:8 76:12 | 76:14 | 76:15 | 76:16 | benefit [9] | 62:18 | 88:1 | 88:5 | 59:22 61:12 | 61:13 | 62:8 | 62:11 |
| 77:19 78:2 121:23 122:3 | 78:7 159:9 | 86:25 159:12 | 95:1 | 90:20 146:24 156:24 | 154:18 | 155:7 | 155:8 | 74:23 75:6 76:15 76:16 | 76:8 77:18 | 76:11 78:2 | 76:14 78:6 |
| attorney [1] | 162:14 | 109.12 | | benefiting [3] | 90:14 | 153:12 | 155:12 | 86:25 92:9 | 95:1 | 159:9 | 159:12 |
| attorneys [1] | 96:12 | | | benefits [1] | 126:14 | 155.12 | 1.00.1.2 | Brunette [2] | 11:1 | 11:2 | |
| Atunez [2] | 112:13 | 112:14 | | best [4] 5:7 | 35:7 | 39:5 | 47:25 | Brzytwa [1] | 2:22 | | |
| atypical [2] | 122:25 | 123:2 | | better [2] | 111:14 | 136:16 | (1.202) | BS [1] 53:12 | | | |
| audible [1] | 64:7 | | | between [14] | 48:12 | 62:25 | 79:10 | budget [1] | 114:18 | | |
| August [1] | 91:8 | | | 80:5 82:10 | 82:17 | 91:2 | 110:9 | Building [5] | 1:22 | 2:4 | 2:8 |
| author [3] | 73:19 | 134:12 | 134:15 | 123:10 124:6 | 133:6 | 143:24 | 145:5 | 2:11 2:19 | | | |
| authored [5] | 18:1 | 24:1 | 54:12 | 145:20 | | | | busiest [1] | 118:6 | | |
| 66:22 99:21 | 10.1 | 21.1 | 51.12 | beyond [1] | 152:4 | | | business [1] | 100:21 | | |
| available [6] | 68:20 | 68:22 | 112:3 | bill [4] 12:1 | 93:20 | 93:25 | 125:10 | busy [3] 51:25 | 118:8 | 122:9 | |
| 128:4 143:15 | 146:22 | | | billed [1] 11:20 | | | | bylaws [1] | 8:15 | | |
| award [1] | 111:6 | | | billing [4] 94:6 | 11:13 | 14:9 | 94:2 | calculated [3] | 55:10 | 104:18 | 121:16 |
| aware [19] | 8:19 | 8:23 | 11:21 | billings [2] | 7:18 | 13:3 | | calculating [1] | 142:17 | | |
| 27:5 27:21 46:13 63:21 | 41:18 76:18 | 44:22 94:20 | 46:7 107:21 | binder [1] | 49:22 | 13:3 | | calculation [11] | 51:3 | 55:2 | 55:3 |
| 107:23 108:7 | 125:18 | 130:9 | 149:21 | biologist [1] | 49:22 | | | 56:10 57:2 | 62:20 | 116:23 | 129:12 |
| 156:7 | | | | biologists [1] | 106:19 | | | 130:5 130:7 calculations [7] | 132:9 57:20 | 57:21 | 62:2 |
| away [3] 100:3 | 100:10 | 144:12 | | bit [2] 63:7 | 111:2 | | | 62:17 64:13 | 57:20 104:15 | 57:21 142:16 | 04:2 |
| B [6] 3:3 | 95:12 | 102:3 | 102:23 | black [1] 74:15 | 1-0.0 | | | calibration [3] | 32:15 | 32:19 | 48:1 |
| 102:25 154:5 | | | | Blackam [1] | 94:8 | | | campus [1] | 87:19 | | / * |
| Babies [1] | 128:11 | | | blankly [1] | 94:8 21:13 | | | cancer [29] | 5:5 | 29:1 | 29:7 |
| backup [1] | 16:5 | | | blind [1] 133:22 | 21.15 | | | 29:10 30:12 | 106:9 | 109:24 | 110:21 |
| balance [3] | 46:19 | 47:3 | 47:16 | blindly [1] | 65:13 | | | 111:1 111:4 | 111.5 | 111:7 | 111:8 |
| balances [10] | 43:10 | 43:16 | 43:20 | blocking [1] | 13:16 | | | 111:17 111:21 112:25 114:7 | 112:1 134:23 | 112:8 136:8 | 112:23 136:11 |
| 44:25 45:9 55:5 55:6 | 46:8 | 47:22 | 48:4 | blue [1] 79:20 | 15.10 | | | 136:14 136:15 | 147:16 | 147:16 | 147:22 |
| Barb [2] 27:11 | 53:12 | | | BMT [1] 68:2 | | | | 151:7 | | | |
| Barbara [1] | 27:15 | | | board [19] | 18:11 | 18:14 | 18:17 | cancers [5] | 21:18 | 21:19 | 39:13 |
| Barry [5] | 2:13 | 3:21 | 27:24 | 18:20 18:21 | 18:22 | 18:22 | 30:13 | 137:22 147:15 | | | |
| 135:25 148:1 | | | | 36:20 37:2 | 37:6 | 37:11 | 37:14 | candidate [1] | 34:15 | | |
| based [20] | 12:2 | 21:5 | 36:16 | 38:3 38:9 86:1 | 38:21 | 39:20 | 49:11 | cannot [3] | 50:6 | 72:19 | 99:14 |
| 38:11 45:13 | 57:20 | 59:2 | 61:17 | boards [5] | 30:16 | 30:17 | 38:25 | Canton [2] | 29:15 | 111:25 | ĺ |
| 64:22 73:11 89:7 95:4 | 80:19 116:23 | 81:11 150:11 | 86:6 152:2 | 86:4 112:6 | 50.10 | 50.17 | 56.25 | capacity [2] | 4:23 | 5:8 | |
| 153:1 156:9 | LLCraw | 150.11 | L . I have a here | body [25] 15:22 | 31:14 | 34:20 | 36:14 | care [24] 7:13 42:16 42:25 | 7:18 43:4 | 31:6 43:21 | 42:11 49:8 |
| basis [6] 19:24 | 64:20 | 64:23 | 110:25 | 50:13 55:3 | 71.6 | 89:13 | 115:7 | 51:14 52:11 | 58:7 | 89:12 | 89:17 |
| 146:23 150:12 | | | | 115:20 116:7 119:10 119:20 | 116:20 119:22 | 117:4 | 119:8 | | 111:21 | 112:8 | 119:6 |
| Bates [1] 127:1 | | | | | 136:25 | 128:25 138:17 | 132:21 143:16 | 155:4 155:23 | 160:8 | 160:12 | 160:13 |
| beam [3] 48:11 | 70:20 | 133:4 | | 147:3 | 100120 | 100117 | 1 /0/10 | career [1] | 45:25 | 100.00 | 100.00 |
| bear [1] 139:9 | | | | boiler [1] | 125:3 | | | carried [4] 134:23 | 60:7 | 130:20 | 130:20 |
| beat [1] 151:9 | | | | bone [4] 68:2 | 82:21 | 125:24 | 139:17 | carrot [1] | 114:22 | | |
| became [1] | 117:23 | | | Bonezzi [1] | 2:11 | | | carry [1] 157:19 | س <i>د س</i> ر ۲۰۱۱ | | |
| become [2] | 112:7 | 113:15 | | boost [3] 80:20 | 81:3 | 104:15 | | carrying [1] | 65:5 | | |
| becoming [1] | 124:25 | | | bottom [1] | 103:12 | | | case [47] 1:7 | 2:13 | 3:20 | 4:24 |
| Beddar [27] 27:13 55:16 | 2:13 55:19 | 3:21 55:20 | 25:16 56:14 | bound [2] | 22:10 | 152:19 | | 5:24 14:24 | 24:4 | 24:16 | 28:10 |
| 56:15 56:20 | 56:23 | 55:20 57:4 | 50:14 57:8 | box [7] 53:13 | 54:4 | 54:5 | 71:10 | 30:10 30:22 | 37:1 | 37:16 | 39:10 |
| 58:3 58:7 | 59:4 | 59:17 | 59:17 | 74:4 74:18 | 127:7 | 104 15 | 105 | 39:13 39:19 61:2 61:21 | 55:21 62:7 | $56:24 \\ 62:18$ | 57:7 63:9 |
| 62:8 62:17 | 70:23 | 78:22 | 133:16 | brain [5] 82:21 158:7 | 103:8 | 104:15 | 135:11 | 63:21 66:10 | 73:6 | 73:9 | 76:1 |
| 133:20 135:25 | 148:2 | 148:10 | | breach [1] | 31:6 | | | 78:8 89:25 | 91:20 | 91:24 | 92:19 |
| Beddar's [2] beforehand [2] | 56:4 38:17 | 61:21 | | break [6] | 48:21 | 66:20 | 67:9 | 111:13 130:8 | 133:13 | 134:20 | 135:24 |
| begin [1] 141:24 | 30:17 | 48:5 | | 95:20 95:21 | 108:15 | | V.12 | 137:13 138:14 147:17 148:9 | 139:2 159:18 | 140:9 | 147:1 |
| beginning [2] | 131:19 | 141:16 | | breaking [1] | 95:20 | | | cases [4] 20:14 | 38:18 | 38:25 | 148:1 |
| behalf [8] | 2:2 | 2:6 | 2:9 | breaks [1] | 147:13 | | | Casey [1] | 11:7 | | |
| 2:13 2:17 | 2:21 | 210 25:1 | 2:9 87:6 | brief [3] 27:7 | 27:9 | 140:22 | | category [1] | 95:12 | | |
| behind [1] | 157:25 | | | briefly [2] | 85:24 | 108:23 | | caused [2] | 101:3 | 136:13 | |
| behold [1] | 152:5 | | | bring [17] | 5:21 | 7:17 | 8:2 | causes [1] | 91:4 | | |
| below [6] | 70:23 | 127:14 | 127:16 | 9:6 15:20 | 26:4 | 26:8 | 37:19 | caveat [2] | 21:12 | 21:13 | |
| 142:24 144:11 | 148:10 | | | 44:8 58:8 66:21 109:10 | 60:10 121:22 | 61:2 122:3 | 66:18 | CCG [1] 34:16 | | | |
| beneficial [1] | 34:21 | | | brought [23] | 5:24 | 26:12 | 27:5 | cells [1] 154:21 | | | |
| | | | | Stonent [23] | J.47 | <i>44</i> √,1 <i>4</i> 4 | ليه د بيد | | | | |

| | | | | Μ | lulti-Pa | age [™] | | | cente | er - Co | ntinuing |
|-------------------------------|-----------------|------------------|------------------|--|----------------|------------------|-----------------|--------------------------------------|----------------|----------------|----------|
| center [15] | 29:2 | 29:7 | 29:11 | checking [1] | 68:16 | | | 107:2 108:13 | 115:1 | | |
| 30:12 106:10 | 109:24 | 111:4 | 111:6 | checks [12] | 43:10 | 43:16 | 43:20 | common [3] | 1:4 | 21:19 | 89:11 |
| 111:9 111:11 114:8 136:14 | 112:2 | 112:23 | 112:25 | 44:25 45:9 | 46:8 | 46:18 | 47:21 | communicate [4 |) | 61:1 | 107:19 |
| centers [1] | 29:18 | | | 48:3 55:5 | 55:6 | 57:2 | | 123:20 124:10 | | | |
| centiGray [11] | 40:25 | 40:25 | 64:12 | chemotherapy | | 154:20 | | communicating | [3] | 139:13 | 140:2 |
| 64:14 64:14 | 40.25 67:6 | 68:1 | 116:22 | child [22] 34:23 65:24 81:15 | 36:17 89:22 | 51:20 90:13 | 64:18 90:19 | 140:3 | | | |
| 117:7 134:21 | 134:22 | | | 131:9 152:14 | 153:12 | 90:15 154:18 | 90:19 154:19 | communication | | 123:10 | 123:24 |
| CEO [2] 10:4 | 106:7 | | | 155:7 155:8 | 155:12 | 156:1 | 156:20 | 1 | | a o 1 | 46.10 |
| certain [5] | 9:6 | 28:18 | 65:11 | 158:18 158:19 | 159:17 | | | community [7] 104:7 109:12 | 30:1 111:23 | 30:1 111:25 | 46:18 |
| 133:8 152:4 | | | | child's [4] | 63:23 | 154:22 | 154:25 | comp [1] 120:23 | 111.23 | 111.20 | |
| certainly [21] | 8:4 | 9:17 | 10:1 | 158:13 | | | | company [1] | 94:8 | | |
| 21:14 21:18 | 27:21 | 33:8 | 34:21 | children [4] | 133:25 | 136:23 | 151:9 | compare [1] | 145:17 | | |
| 35:8 38:23 59:18 66:23 | 41:16 86:17 | 49:17 91:13 | 52:3 129:22 | 152:1 | 1.50.00 | | | competent [2] | 145.17 | 148:4 | |
| | 150:16 | 91.15 | 127.22 | choice [1] | 152:20 | | | complaints [1] | 94:21 | 140.4 | |
| CERTIFICAT | | 162:1 | | choose [3] | 12:12 | 35:8 | 56:3 | complete [2] | 7:10 | 73:5 | |
| certification [1] | | | | chosen [1] | 62:24 | | | complicated [4] | | | 100.0 |
| certified [7] | 3:10 | 18:11 | 18:14 | circle [2] 78:25 | 79:3 | | | 123:3 | 118:22 | 122:19 | 123:2 |
| 18:17 18:21 | 18:22 | 18:23 | ~~! A (| circled [1] | 144:20 | | | complies [4] | 23:8 | 48:19 | 96:4 |
| certify [1] | 162:6 | | | circumstances | | 5:11 | 31:5 | 104:13 | <i></i> | 10.12 | 20.4 |
| cervix [1] | 147:15 | | | 31:14 32:14 61:16 65:7 | 58:23 65:21 | 59:21 85:21 | 60:10 86:16 | comprehensive | [4] | 111:4 | 111:5 |
| Chagrin [1] | 29:21 | | | 129:18 155:24 | 158:18 | 57.21 | 00.10 | 111:11 136:14 | | | |
| chair [5] 13:23 | 13:24 | 56:7 | 106:10 | City [1] 156:17 | | | | computation [1] | | | |
| 124:25 | | | | Civil [1] 1:18 | | | | computations [1] |] | 61:17 | |
| chairman [10] | 9:2 | 13:22 | 28:11 | claims [1] | 15:1 | | | computer-aided | [1] | 162:13 | |
| 28:13 41:17 | 56:2 | 59:3 | 106:13 | Clair [2] 1:22 | 2:19 | | | | 110:13 | | |
| 106:14 113:15 | | 141 | | clarification [1] | | | | CONCLUDED | [1] | 161:7 | |
| chairmanship | | 14:1 | | clarify [1] | 137:3 | | | conclusion [2] | 12:24 | 32:1 | |
| chairs [2] | 14:4 | 107:4 | | clean [1] 83:13 | | | | conclusions [1] | 10:19 | | |
| challenge [2] | 109:22 | 111:22 | 1 | clean-up [1] | 69:17 | | | concur [1] | 40:1 | | |
| chance [8] 153:11 154:22 | 91:9 155:12 | 147:2 155:25 | 151:11 156:24 | clear [5] 29:9 | 73:18 | 99:7 | 128:20 | concurred [1] | 39:24 | | |
| Chancellor [1] | 10:12 | 100.20 | 130.24 | 138:16 | , 0.10 | | 120120 | condition [3] | 35:15 | 39:5 | 153:2 |
| chances [2] | 90:12 | 146:21 | | clearly [5] | 21:19 | 61:3 | 75:25 | conduct [1] | 56:4 | | |
| change [25] | 12:5 | 37:18 | 69:10 | 110:1 111:9 | | | | conducted [1] | 12:20 | | |
| 72:21 73:19 | 73:25 | 74:22 | 75:5 | clerical [2] | 131:11 | 157:23 | | confer [1] | 108:15 | | |
| 75:6 79:10 | 79:13 | 79:13 | 80:2 | Cleveland [22] | 1:9 | 1:23 | 2:5 | conferences [1] | 39:16 | | |
| 80:2 80:7 | 81:24 | 90:24 | 98:1 | 2:6 2:8 2:23 3:18 | 2:12 19:15 | 2:16 29:1 | 2:20 29:4 | conform [1] | 120:9 | | |
| 102:13 131:22 158:2 159:14 | 145:19 | 145:21 | 153:3 | 30:9 55:25 | 87:14 | 108:24 | | conformal [1] | 110:14 | | |
| changed [12] | 8:10 | 79:15 | 79:22 | 109:8 114:7 | 115:8 | 162:17 | 10010 | connecting [1] | 47:20 | | |
| 80:22 81:5 | 82:6 | 85:2 | 79:22 88:11 | clicks [2] 63:15 | 64:2 | | | conscientious [1] | | 148:5 | |
| 144:24 156:4 | 158:9 | 158:10 | 00.11 | clinic [5] 25:15 | 68:23 | 123:16 | 139:15 | consensus [1] | 155:25 | | |
| changes [7] | 74:3 | 109:15 | 109:19 | 144:5 | | | | | 135:8 | | |
| 114:6 145:2 | 145:4 | 145:8 | | clinical [6] | 11:19 | 28:4 | 30:14 | consequence [1] | | | |
| chart [68] | 6:3 | 6:19 | 6:22 | 114:2 114:3 | 120:20 | | | - | 36:22 | 136:17 | |
| 7:15 15:25 | 16:2 | 17:1 | 17:2 | clinics [1] | 52:6 | | | consolidative [1] | | | |
| 17:10 17:11 17:19 17:21 | 17:11 17:22 | 17:14 17:22 | 17:18 17:23 | close [1] 95:16 | | | | | 137:21 | | |
| 33:5 52:15 | 54:1 | 66:3 | 68:19 | closed [2] | 29:5 | 79:15 | | | 74:11 | | |
| 68:21 76:5 | 79:14 | 83:3 | 87:8 | closer [1] | 44:9 | | | | 20:5 | 130:13 | 140:20 |
| 92:2 92:5 | 92:8 | 92:9 | 92:10 | colleagues [3] | 14:7 | 37:8 | 45:21 | consultation [3] | | 33:25 | 34:25 |
| 93:1 93:9 100:20 101:3 | 94:19 101:8 | 100:2 101:10 | 100:13 101:18 | collective [4] | 39:1 | 39:4 | 40:6 | | 7:10 | | |
| 123:12 123:12 | 123:25 | 128:6 | 128:10 | 42:21 | 52.05 | 70 2 · | | | 128:24 | | |
| 128:21 129:9 | 130:14 | 131:12 | 131:14 | column [2] | 53:25 | 70:21 | | (| 142:21 | | |
| 131:18 139:7 | 139:10 | 139:11 | 140:1 | combined [2] | 134:15 | 154:21 | | contemplated [1] | | 141:8 | |
| 140:8 140:24 144:3 144:8 | 143:15 144:9 | 143:15 157:24 | 144:3 158:13 | commenced [1] | | | | contemporaneo | | 52:25 | |
| charted [1] | 144:9 | 131,24 | 100.10 | commencing [1] | | 100 | | 1 7 | 125:24 | | |
| charts [2] | 68:20 | 02.11 | | comment [2] | 66:14 | 122:14 | | | 71:25 | | |
| check [13] | 08:20 12:23 | 93:11 47:3 | 47:16 | commission [1] | | 117 - | | | 72:24 | 80:6 | |
| 56:10 57:12 | 12:23 57:16 | 47:3 68:20 | 47:16 68:22 | commissioned [| | 162:6 | | | 154:19 | 2010 | |
| | 103:19 | 132:20 | 132:25 | commit [1] | 60:18 | | | | 19:14 | 22:7 | 38:8 |
| checked [4] | 55:13 | 104:19 | 129:12 | commitment [1] | | | | | 46:23 | 47:23 | 54:19 |
| 132:11 | | | | committee [6] | 106:6 | 106:10 | 106:13 | | 75:4 | 75:11 | 77:3 |
| | | | | | | | | - | | | |

| | | | | | Μ | lulti-Pa | age™ | | | contra | ctor - a | lifferent |
|--|------------------|-----------------|------------------|------------------|-----------------------------------|-----------------|-----------------|------------------|--------------------------|--------------|----------------|-----------------|
| 78:12 | 88:17 | 94:17 | 103:7 | 134:6 | criticisms [3] | 160:7 | 160:12 | 160:21 | 111:21 | | | |
| 149:17 | 150:18 | 153:15 | 154:13 | 155:21 | cross [7] 4:6 | 49:5 | 92:17 | 93:5 | delivering [1] | 36:2 | | |
| 157:12 | | 100 44 | | | 93:7 108:20 | 135:21 | | | delivers [1] | 64:13 | | |
| contract | | 100:23 | | | crossed [3] | 71:2 | 71:9 | 144:19 | delivery [5] | 31:23 | 32:16 | 32:19 |
| contradi | | | | | CT [2] 48:13 | 110:12 | | | 48:2 65:24 | | | |
| contribu | | 111:3 | | | cure [4] 89:5 | 91:2 | 91:10 | 152:18 | demonstrates [1 | 1 | 83:24 | |
| control | | 47:23 | 56:3 | 64:4 | cured [1] 152:13 | | | | denied [1] | 87:25 | | |
| convenie | ent [3] | 48:20 | 48:23 | 48:24 | current [1] | 5:17 | | | deny [1] 146:23 | | | |
| conversa | ation [3] | 25:18 | 27:7 | 77:23 | curriculum [1] | 5:17 | | | department [40] | 6.17 | 6:25 | 7:12 |
| convers | ations [1 |] | 150:8 | | curve [1] 41:2 | | | | 9:2 9:9 | 13:22 | 14:1 | 17:11 |
| coordina | ator [1] | 38:9 | | | custody [1] | 101:13 | | | 21:24 23:20 | 28:11 | 28:13 | 38:21 |
| copy [8] | | 7:11 | 23:11 | 24:10 | custom [2] | 129:3 | 131:17 | | 41:17 51:7 | 56:2 | 59:3 | 60:23 |
| 25:6 | 79:2 | 127:11 | 133:21 | | cutting [2] | 136:16 | 146:21 | | 76:20 76:21 92:2 92:4 | 77:6 92:7 | 77:8 94:13 | 91:23 100:25 |
| corner [2 | 2] | 70:5 | 103:12 | | | | 140.21 | | 106:16 106:17 | 106:18 | 94:15 109:7 | 100:25 |
| corollar | V [1] | 77:3 | | | Cuyahoga [2] | 1:2 | 102:5 | | 112:12 113:15 | 113:19 | 113:21 | 113:24 |
| corpora | • | | 125:1 | | CV [2] 17:25 | 133:21 | | | 122:21 139:20 | | | |
| correct | | 5:10 | 11:13 | 11:16 | D _[1] 2:14 | | | | departmental [6 | 1 | 17:14 | 17:19 |
| 18:13 | 18:16 | 26:1 | 26:3 | 26:23 | DA [1] 55:12 | | | | 17:22 17:23 | 139:11 | 139:22 | |
| 28:12 | 30:4 | 32:6 | 32:24 | 33:20 | dad [1] 135:6 | | | | dependent [1] | 57:21 | | |
| 33:22 | 34:17 | 34:18 | 34:23 | 35:10 | daily [5] 36:1 | 36:3 | 64:20 | 64:23 | depending [1] | 39:9 | | |
| 35:16 | 37:7 | 37:12 | 39:6 | 39:22 | 66:10 | | | | deposed [1] | 3:10 | | |
| 45:22 52:20 | 45:25 53:4 | 46:5 62:14 | 46:6 63:3 | 47:12 63:20 | Dan [3] 4:4 | 6:3 | 6:6 | | deposition [12] | 1:13 | 1:16 | 4:8 |
| 67:2 | 69:1 | 62:14 69:2 | 74:2 | 75:12 | Daniel [1] | 2:3 | | | 4:17 5:16 | 21:23 | 22:11 | 99:2 |
| 75:18 | 78:15 | 79:17 | 79:24 | 80:22 | date [6] 1:24 | 23:14 | 24:5 | 50:21 | 141:3 156:10 | 161:7 | 162:10 | |
| 82:7 | 89:6 | 89:19 | 89:24 | 90:21 | 69:5 92:16 | | | | Derzon [2] | 10:3 | 10:6 | |
| 90:22 | 90:22 | 92:18 | 93:7 | 93:13 | dated [3] 57:13 | 57:18 | 58:2 | | described [3] | 122:10 | 123:8 | 145:6 |
| 93:18 97:13 | 93:23 97:15 | 97:7 97:16 | 97:11 97:19 | 97:12 97:20 | dates [4] 11:21 | 29:9 | 33:6 | 66:8 | describes [1] | 87:14 | | |
| | 97:15 97:24 | 97:16 98:6 | 97:19 98:16 | 97:20 98:19 | David [11] | 2:18 | 3:24 | 10:12 | description [1] | 86:5 | | |
| 99:18 | 100:12 | 101:2 | 102:14 | 102:16 | 10:17 27:22 | 51:8 | 55:11 | 108:25 | design [2] | 136:5 | 136:10 | |
| 107:9 | 108:9 | 108:13 | 109:12 | 109:13 | 121:3 122:1 | 160:13 | 100.0 | 100 | designated [1] | 136:14 | | |
| | | 117:17 | 119:24 | 121:3 | days [8] 36:2 123:19 133:19 | 38:17 133:19 | 120:3 139:17 | 120:4 | designating [1] | 102:23 | | |
| | 123:1 | 123:6 | 123:6 | 123:25 | | 100:19 | 139:17 | | designed [3] | 43:11 | 45:24 | 46:8 |
| 124:1 128:2 | 125:12 129:10 | 127:3 129:10 | 127:4 131:2 | 127:15 132:8 | | 104.5 | | | desk [1] 25:3 | 72.11 | 7,2,2,7 | 10.0 |
| | | 132:15 | 134:17 | 134:18 | Dean [2] 9:24 | 106:7 | | | destroyed [1] | 91:19 | | |
| 137:6 | 137:8 | 137:12 | 137.15 | 137:18 | death [3] 86:19 | 88:24 | 100:24 | | detail [1] 141:1 | 91:19 | | |
| 137:20 | 137:23 | 138:11 | 138:15 | 138:16 | Deb [15] 51:14 | 111:18 | 117:16 | 117:18 | 1 | 100.14 | 150.05 | |
| | 138:22 | 139:23 | 140:12 | 140:13 | 118:3 118:9 124:16 135:4 | 118:25 135:5 | 120:2 135:9 | 120:25 141:25 | detailed [2] | 122:14 | 152:25 | |
| | 141:6 141:18 | 141:7 141:20 | 141:10 141:25 | 141:14 142:11 | 160:18 | 155.5 | 155.9 | 141.20 | details [1] | 85:24 | | |
| | 141.18 | 141.20 | 141.23 142:23 | 142.11 | Deb's [1] 135:14 | | | | detected [1] | 104:3 | | |
| 143:3 | 143:5 | 143:8 | 144:20 | 145:1 | decade [1] | 110:12 | | | determination [| | 32:23 | 36:16 |
| 145:16 | 146:10 | 146:13 | 146:19 | 146:25 | December [1] | 112:21 | | | 36:17 40:8 | 137:17 | 150:21 | 25 (|
| | | 149:15 | 153:4 | 153:5 | decide [1] | 140:18 | | | determine [6] | 16:14 | 34:14 | 35:6 |
| | 153:8 | 155:21 | 158:15 | 159:20 | decided [5] | | 26.7 | 102.0 | 68:18 69:1 | 137:9 | 24.10 | 05.10 |
| 1 | | 160:15 | 160:17 | 71.10 | decided [5] 107:5 107:6 | 25:4 | 36:7 | 102:9 | determined [4] 158:23 | 13:4 | 34:19 | 85:19 |
| correcte | | 59:16 | 62:13 | 71:15 | decision [5] | 39:4 | 39:20 | 40:6 | determining [1] | 137-01 | | |
| correspo | | | 5:23 | 00.00 | 49:11 106:23 | コフパ | J7.40 | 40.0 | develop [1] | 137:21 | | |
| correspo | 0 | | 33:10 | 99:20 | decisions [2] | 9:16 | 36:7 | | A | | | 1 |
| costs [2] | | 12:19 | | | decrease [1] | 154:23 | wind + 1 | | developed [1] | 95:8 | 100.01 | 100.00 |
| counsel | | 1:20 | 3:12 | 4:2 | defendant [4] | 2:6 | 2:9 | 3:8 | developing [3] | 29:18 | 109:21 | 109:23 |
| L Contraction of the second se | 13:12 | 13:15 | 22:12 | | 24:19 | <i>4.</i> 0 | 4.7 | 3.0 | development [1] | | | |
| counsel' | | 73:12 | | | Defendants [3] | 1:10 | 2:13 | 2:17 | diagnoses [1] | 11:19 | | |
| country | | 109:12 | | | defer [2] 21:9 | 21:12 | / 1 . سم | ، د . سد | diagnostic [5] | 36:25 | 37:4 | 37:20 |
| County | | 1:2 | 162:3 | | deficient [1] | 111:10 | | | 37:22 111:1 | 50 · C | | |
| couple 16 | | 38:17 | 48:21 | 101:16 | define [1] | 85:1 | | | diameter [1] | 50:12 | | |
| E | | 126:23 | | | | | 12,10 | | Diane [2] | 28:1 | 53:12 | |
| course [1 | | 6:23 | 22:11 | 37:18 | defray [2] | 12:13 | 12:19 | | dictate [2] | 122:13 | 140:19 | |
| | | 113:1 | 121:3 | 132:17 | delay [2] 88:23 | 89:12 | | | dictated [6] | 68:5 | 99:21 | 140:9 |
| 141:19 | | 156:18 | 74.10 | 05.15 | delays [1] | 147:12 | | | 140:14 140:23 | 141:9 | | |
| court [4] | | 22:12 | 74:13 | 95:15 | delineated [1] | 154:9 | | | died [2] 91:4 | 100:22 | | |
| cover [1] | | | | | delineating [1] | 44:14 | | | difference [4] | 90:4 | 91:2 | 137:14 |
| credenti | | | | | deliver [7] | 16:7 | 61:19 | 62:16 | 147:20 | | | |
| credenti | | | 108:6 | | 63:13 67:6 | 81:2 | 142:17 | | different [8] | 21:15 | 48:10 | 104:1 |
| criteria _l | [1] | 140:18 | | | delivered [4] | 62:12 | 62:14 | 63:16 | 104:2 105:20 | 105:23 | 140:3 | 141:8 |
| | | | | | 1 | | | | <u> </u> | | | |

| | | | | | N | Iulti-P | age [™] | | dime | ensional | l - exar | nination |
|-------------------------------|----------------|-----------------|----------------|--------------------|------------------|------------------|------------------|------------------|---------------------------------------|----------------|------------------|----------------------------|
| dimensional [1] | | | | 75:25 | 84:15 | 86:11 | 87:1 | 90:10 | 57:14 94:22 | 99:6 | 108:12 | 119:1 |
| diminishing [1] | 41:14 | | | 92:16 | 95:17 | 99:16 | 99:22 | 103:10 | 119:19 120:22 | 121:15 | 143:16 | 143:25 |
| diodes [1] | 133:7 | | | 104:16 139:21 | 108:16 145:7 | 125:2 145:8 | 129:12 145:9 | 138:20 145:11 | 159:10 | | | |
| direct [4] | 108:3 | 118:20 | 119:4 | 157:15 | 140.7 | 145.0 | 145.5 | 14,0.11 | duties [12] | 28:9 | 28:18 | 28.21 |
| 120:20 | | | | dosage | 161 | 51:3 | 58:22 | 62:8 | 28:24 30:2 43:7 58:7 | 30:6 59:20 | 32:18 86:15 | 42:24 |
| direction [5] | 30:23 | 56:8 | 116.1 | 63:16 | 63:18 | 63:19 | 64:2 | 64:3 | duty [3] 43:3 | 61:2 | 152:18 | |
| 138:1 162:12 | | | | 64:9 | 80:4 | 97:9 | 97:19 | 97:23 | early [5] 36:9 | 52:6 | 109:20 | 112.10 |
| directly [2] | 15:1 | 124:12 | | 137:7 | 137:9 | 138:5 | 138:10 | 138:11 | 146:12 | 52:0 | 109:20 | 113:12 |
| director [4] | 28:25 | 30:12 | 114:2 | 147:19 | | | | | easier [3] | 22:9 | 33:11 | 54:21 |
| 114:3 | | | | dosages | | 118:18 | | | edge [2] 136:16 | | 55.11 | ا ست ۳۰ |
| directorship [1] | | | | dose [73] | | 16:6 | 16:7 | 17:3 | educate [1] | 31:11 | | |
| discharged [1] | 135:14 | | | 31:1 57:24 | 31:9 57:25 | 32:23 58:4 | 36:3 58:9 | 48:2 59:23 | educated [1] | | | |
| discharging [2] | 58:6 | 58:7 | | 61:4 | 62:14 | 58.4 62:16 | 63:10 | 64:5 | education [6] | 115:23 | 20.1 | ¢0.10 |
| disciplinary [2] | 15:17 | 20:22 | | 64:11 | 64:16 | 65:8 | 65:11 | 65:13 | 98:9 114:8 | 21:6 152:2 | 39:1 | 59:18 |
| discovers [1] | 93:14 | | | 67:7 | 68:11 | 68:13 | 68:18 | 71:7 | educational [2] | 37:15 | 114:13 | |
| discovery [3] | 14:19 | 14:21 | 72:2 | 71:22 | 73:19 | 74:18 | 75:18 | 76:9 | effect [3] 16:10 | 47:17 | 14:15 | |
| discrepancy [4] | 62:25 | 85:22 | 86:5 | 77:19 81:2 | 78:3 84:3 | 78:7 84:7 | 80:20 | 80:21 | effects [1] | | 147.0 | |
| 122:18 | | | | 86:5 | 84:5 87:6 | 84:7 88:19 | 84:9 90:24 | 85:22 91:5 | | 41:7 | | |
| discuss [5] | 20:1 | 20:9 | 20:15 | 92:24 | 95:4 | 95:7 | 90:24 97:6 | 98:9 | effort [1] 136:19 | 110.00 | | |
| 39:3 58:3 | | | | 100:8 | 116:9 | 116:13 | 116:19 | 116:21 | eight [2] 115:24 | 115:25 | | <i>(</i>) <i>(</i> |
| discussed [12] | 15:16 | 36:20 | 38:19 | 117:3 | 117:6 | 119:16 | 119:20 | 121:22 | either [16] 88:18 94:25 | 50:21 | 57:19 131:14 | 69:6 132:13 |
| 39:18 41:6 107:19 108:7 | 72:9 108:11 | 96:24 150:4 | 97:3 | 122:4 137:22 | 123:9 138:7 | 132:14 | 133:8 | 134:22 | 132:18 133:9 | 114:5 138:9 | 131:14 145:24 | 132:13 |
| | | | 27.2 | 1 | | 142:21 | 146:4 | 134.01 | 148:9 152:17 | 162:14 | 1 1 2 , 647 | * **** |
| discussion [9] 27:10 37:15 | 25:13 85:16 | 25:19 108:18 | 27:3 148:20 | doses [4] | | 121:16 | 134:1 | 134:21 | element [1] | 36:12 | | |
| 149:9 | 05.10 | 100.10 | 140.20 | dosimet 54:10 | 54:12 | 31:18 121:7 | 41:22 122:3 | 49:25 122:15 | elsewhere [1] | 122:22 | | |
| discussions [5] | 26:24 | 63:22 | 72:7 | 123:8 | 123:11 | 121.7 | 122.5 | 122:13 | emergency [1] | 131:9 | | |
| 88:22 132:18 | 20.21 | 00.22 | , 2., | 132:6 | 133:9 | 133:16 | 137:2 | 138:10 | employed [2] | 51:6 | 55:21 | |
| disease [10] | 21:10 | 21:14 | 34:1 | 156:14 | 160:13 | | | | employees [3] | 96:14 | | 125:21 |
| 35:1 35:22 | 36:21 | 37:19 | 39:3 | dosimet | | 42:10 | 51:6 | 114:14 | employees [3] | 90.14 87:15 | 123.17 | 143.41 |
| 151:17 152:4 | | | | 114:20 | | 126:17 | | | employee [1] employment [1] | | | |
| dismal [1] | 146:12 | | | dosing [| | 43:16 | 44:24 | 46:9 | | | | |
| dispute [1] | 73:9 | | | 47:4 | 47:17 | 48:6 | 69:1 | 80:25 | encounter [1] end [4] 95:23 | 140:10 | 110.0 | 100.17 |
| dissimilar [2] | 127:14 | 127:16 | | 85:20 | | E2 10 | 70.00 | 00.7 | | 113:11 | 119:2 | 122:16 |
| distinction [1] | 145:5 | | | down [10 100:25 | 101:16 | 53:19 118:16 | 70:23 118:23 | 80:7 131:14 | ending [1] | 131:20 | | |
| dive [1] 35:3 | | | | 135:6 | 142:24 | 110.10 | 110.25 | 1,01,14 | enemies [1] | 94:13 | | |
| division [2] | 106:15 | 113:20 | | Dr [107] | 2:9 | 2:13 | 2:13 | 2:17 | energy [1] | 70:20 | | |
| Doc [2] 33:10 | 63:6 | | | 2:17 | 2:21 | 2:21 | 3:16 | 3:16 | entail [1] 107:10 | | | |
| Doctor [38] | 4:8 | 5:15 | 6:13 | 3:21 | 3:21 | 3:23 | 3:25 | 3:25 | enter [1] 16:6 | | | |
| 16:22 18:1 | 21:22 | 22:9 | 23:6 | 7:22 | 10:23 | 18:4 | 18:8 | 18:11 | entire [1] | 82:21 | | |
| 24:3 31:11 | 35:4 | 41:9 | 45:17 | 18:25 21:5 | 19:3 21:9 | 19:7 22:15 | 19:20 25:9 | 19:23 25:16 | equals [1] | 116:13 | | |
| 47:25 49:3 67:21 69:3 | 54:20 69:15 | 55:1 70:4 | 58:3 78:6 | 25:16 | 26:4 | 26:19 | 26:24 | 27:2 | equipment [3] | 16:23 | 64:1 | 110:11 |
| 82:6 83:12 | 90:13 | 95:12 | 99:7 | 27:3 | 27:17 | 27:19 | 33:21 | 38:3 | error [9] 69:1 | 85:20 | 86:12 | 86:13 |
| 100:13 102:2 | 108:22 | 126:2 | 135:19 | 40:1 | 49:10 | 55:16 | 56:15 | 56:20 | 92:17 92:18 | 93:5 | 93:8 | 130:17 |
| 136:1 148:23 | 149:8 | 149:13 | 160:3 | 56:23 58:7 | 57:4 59:4 | 57:8 59:17 | 57:11 61:21 | 58:3 62:8 | Esq [8] 2:3 2:14 2:18 | 2:3 2:18 | 2:7 2:22 | 2:10 |
| doctors [1] | 155:3 | | | 62:17 | 39:4 70:23 | 73:15 | 61:21 77:18 | 62:8 77:23 | essentially [1] | 2:18 120:12 | ta . In ta | |
| document [17] | 17:6 | 23:10 | 23:13 | 77:24 | 78:1 | 78:22 | 80:15 | 87:6 | establish [1] | | | |
| 33:14 33:16 | 33:25 | 52:10 | 52:13 | 88:15 | 96:2 | 96:20 | 96:24 | 100:9 | established [5] | 119:20 | 20-10 | 20.12 |
| 52:18 52:20 74:8 81:13 | 54:11 85:12 | 72:10 153:9 | 72:25 | 102:2 | 112:13 | 112:13 | 112:13 | 112:13 | established [5] 29:14 106:6 | 29:6 | 29:10 | 29:12 |
| documentation | | 52:22 | | 112:14 | 112:15 113:18 | 112:22 113:25 | 113:1 114:1 | 113:8 114:2 | estimate [3] | 115:23 | 146:16 | 146:18 |
| documentation | | 52:22 54:23 | | 113.18 | 116:2 | 135:25 | 135:25 | 136:5 | et [1] 1:9 | 110.43 | 170.10 | 170.10 |
| documented [2] | | 153:15 | | 142:8 | 147:24 | 148:1 | 148:1 | 148:9 | etc _[1] 1:6 | | | |
| | 5:22 | 8:3 | 8:5 | 148:10 | 149:2 | 149:13 | 149:20 | 149:25 | evaluate [1] | 66.6 | | |
| 8:6 8:11 | 5:22 9:6 | 8:3 9:10 | 8:5 9:14 | 150:4 | 150:9 | 150:9 | 150:19 | 150:23 | | 66:6 | 150.10 | |
| 11:1 11:4 | 11:7 | 15:21 | 16:25 | t | 154:9 | 154:13 | | | evaluated [2] | 66:11 | 159:13 | 20.3 |
| 31:12 128:3 | 129:22 | - | | dramati | | | | | evaluation [3] | 19:1 | 19:23 | 20:1 |
| doesn't [4] | 48:4 | 65:20 | 79:3 | drawing | | 145:5 | | | event [2] 95:2 | 162:15 | | |
| 156:21 | | | | | 4:2 | | | | everybody [2] | 47:10 | 152:5 | |
| Don [1] 116:3 | | | | duly [3] | | 162:6 | 162:8 | | Ewing's [3] | 21:21 | 134:10 | 134:16 |
| done [40] 13:7 | 15:3 | 22:9 | 37:1 | duplicat | | 102:19 | | | exactly [6] | 16:12 | 41:4 | 68:23 |
| 37:4 41:12 | 42:4 | 46:3 | 46:17 | duratio | | 147:6 | | | 99:14 105:7 | 118:4 | | |
| 48:16 48:17 67:21 68:25 | 50:25 74-24 | 57:14 75:8 | 62:12 75:15 | during | | 9:9 | 16:18 | 22:11 | examination [8] | | 3:9 149:11 | 4:6 160:1 |
| 67:21 68:25 | 74:24 | 75:8 | 75:15 | 26:5 | 26:9 | 42:2 | 42:16 | 51:18 | 34:11 108:20 | 135:21 | 147,11 | 100.1 |
| | | | | ì | | | | | | | | |

| | | | | M | lulti-Pa | age | | | ł | examin | e - gon |
|---------------------------|---------------|-----------------|-----------------|--|-----------------|------------------|-----------------|------------------|--------|--------|---------|
| examine [1] | 11:20 | | | 146:20 153:18 | 159:13 | | | form [6] 53:23 | 85:23 | 86:5 | 86:5 |
| example [5] | 116:2 | 116:11 | 116:19 | Factor [1] | 55:4 | | | 105:14 131:10 | | | |
| 119:16 124:7 | | | | facts [1] 156:9 | | | | formalities [1] | 1:21 | | |
| except [2] | 78:21 | 150:13 | | faculty [3] | 14:5 | 125:20 | 126:7 | format [1] | 8:24 | | |
| excessive [1] | 14:9 | | | fail-safe [4] | 46:13 | 46:25 | 47:8 | forming [1] | 106:18 | | |
| exchange [1] | 47:1 | | | 47:11 | | | | forms [5] | 105:8 | 107:16 | 116:6 |
| exclusively [1] | 137:10 | | | failure [1] | 88:23 | | | 129:16 129:19 | | | |
| excuse [2] | 44:3 | 128:19 | | fair [3] 15:6 | 49:13 | 123:5 | | forth [11] | 1:24 | 7:3 | 20:6 |
| execute [1] | 32:18 | | | fairly [2] 120.15 | 140:15 | | | 23:21 49:22 | 52:23 | 74:17 | 81:15 |
| exercise [1] | 56:3 | | | Fallon [1] | 2:15 | | | 83:3 83:15 | 162:10 | | |
| exhibit [63] | 3:5 | 5:16 | 6:8 | familiar [1] | 137:19 | | | forward [4] | 65:13 | 74:10 | 80:22 |
| 6:10 6:14 | 7:3 | 7:10 | 22:1 | family [8] | 34:10 | 86:15 | 86:24 | 119:9 | | | |
| 22:16 23:6 | 23:14 | 23:16 | 23:21 | 87:2 87:4 | 87:11 | 126:6 | 126:10 | forwarded [3] | 9:14 | 10:16 | 17:1 |
| 24:1 33:7 | 33:9 | 48:18 | 49:4 | far [3] 14:13 | 14:17 | 142:16 | 120.10 | found [2] | 36:21 | 148:4 | |
| 49:19 49:20 | 49:22 | 57:11 | 62:18 | Farrell [2] | | 9:21 | | four [11] 4:25 | 5:1 | 33:25 | 38:19 |
| 63:5 69:12 | 70:1 | 70:5 | 74:18 | | 9:15 | 9:21 | | 48:15 53:24 | 110:4 | 112:11 | 123:18 |
| 76:19 83:20 98:17 99:3 | 94:14 99:9 | 97:10 100:14 | 98:13 102:3 | Fe [1] 149:17 | | | | 136:20 136:22 | | | |
| 102:23 102:25 | 116:11 | 126:22 | 102.5 | February [3] | 19:17 | 28:4 | 101:7 | fourteenth [1] | 110:7 | | |
| 128:21 128:24 | 129:9 | 120.22 | 130:23 | federal [1] | 110:18 | | | fraction [5] | 57:25 | 68:3 | 84:8 |
| 135:1 139:11 | 139:22 | 141:2 | 142:5 | fell [1] 148:10 | | | | 84:9 138:24 | | | |
| 142:8 142:21 | 143:2 | 144:15 | 145:17 | Fellows [1] | 37:23 | | | fractionated [1] | | | |
| 145:17 153:7 | 153:21 | 153:24 | 154:1 | felt [2] 109:25 | 121:21 | | | fractions [10] | 36:2 | 40:25 | 67:6 |
| exhibits [3] | 3:2 | 22:10 | 154:11 | few [1] 136:1 | | | | 67:25 80:20 | 131:24 | 138:18 | 144:24 |
| exist [6] 44:20 | 46:19 | 65:20 | 65:22 | field [1] 82:22 | | | | 147:7 147:20 | | | |
| 106:18 114:19 | | | | fields [1] 80:19 | | | | frame [1] | 12:3 | | |
| existed [6] | 22:8 | 23:16 | 44:18 | file [3] 5:22 | 7:7 | 22:14 | | framing [1] | 77:1 | | |
| 46:12 46:24 | 47:4 | | | | | | 76.1 | free [1] 95:2 | | | |
| existing [1] | 37:17 | | | filed [12] 24:8 76:10 78:8 | 26:20 98:2 | 71:14 145:22 | 76:1 150:2 | fresh [1] 158:7 | | | |
| expect [10] | 58:6 | 59:3 | 60:9 | 150:6 150:25 | 159:19 | 143:22 | 100.2 | Friday [1] | 120:4 | | |
| 63:9 64:25 | 65:6 | 90:13 | 119:7 | filing [1] 156:4 | 157.17 | | | Fridays [2] | 120:18 | 120:21 | |
| 119:18 119:23 | | | | - | | | | front [10] | 23:1 | 100:13 | 100:14 |
| expectation [1] | 139:16 | | | | 105 5 | 107.0 | | | 129:9 | 130:14 | 144:8 |
| expected [3] | 59:22 | 102:17 | 118:25 | filled [3] 54:5 | 105:7 | 127:3 | | 144:12 150:21 | | | |
| expecting [1] | 24:15 | | | Filling [1] | 107:16 | | | FTE [1] 29:24 | | | |
| experience [9] | 21:6 | 21:6 | 21:19 | findings (1) | 11:19 | | | full [1] 140:22 | | | |
| 39:2 59:19 | 98:10 | 118:15 | 152:3 | fine [3] 49:20 | 67:18 | 69:24 | | funding [1] | 30:25 | | |
| 154:19 | | | | Finelli [5] | 2:3 | 2:4 | 4:4 | future [1] | 129:23 | | |
| experimental [4] | 134:23 | 136:6 | 136:9 | 22:22 95:18 | | | | | 147.43 | | |
| 136:11 | | | | finish [1] 15:15 | | | | | | | 169.90 |
| expert [7] | 4:13 | 4:16 | 4:24 | first [31] 3:9 | 4:11 | 5:2 | 22:4 | Gantverg [3] | 1:18 | 162:4 | 162:20 |
| 5:3 5:9 | 21:2 | 45:17 | | 23:9 24:11 | 25:7 | 31:16 | 33:12 | gastrointestinal | | 30:17 | 111:19 |
| expertise [3] | 39:1 | 46:16 | 110:20 | 33:18 51:19 | 54:24 | 56:24 | 57:7 | general [5] | 29:11 | 39:13 | 44:13 |
| expires [1] | 162:22 | | | 66:9 66:10 | 67:7 | 68:3 | 71:21 | 106:15 111:25 | | | |
| explain [1] | 138:6 | | | 87:5 92:10 134:12 134:14 | 110:3 135:16 | 122:17 143:11 | 133:20 150:8 | generality [3] | 42:7 | 43:19 | 46:15 |
| explained [3] | 138:11 | 141:11 | 144:17 | 159:17 162:8 | 155.10 | 143.11 | 120.0 | generally [3] | 39:16 | 46:2 | 109:8 |
| explaining [2] | 75:18 | 100:6 | * * * * * * * | five [9] 10:2 | 56:25 | 91:14 | 123:19 | generate [1] | 94:3 | | |
| expressed [1] | | 100.0 | | 131:24 134:22 | 148:13 | 91:14 148:16 | 123:19 | generated [10] | 7:12 | 9:7 | 9:11 |
| | 26:3 | | | flashing [1] | 98:8 | 1.0.10 | 1.0.17 | 16:25 17:7 | 31:12 | 52:18 | 55:7 |
| extend [1] | 106:23 | | | flaw [2] 104:3 | 104:5 | | | 86:6 99:21 | | | |
| extended [2] | 105:25 | 119:6 | | | | 110.4 | 140 4 | generates [1] | 85:22 | | |
| extensive [1] | 36:21 | | | floor [6] 118:23 140:5 140:7 | 119:3 | 119:6 | 140:4 | gentleman [1] | 4:4 | | |
| extensively [1] | 106:25 | | | : | | | | GI [1] 116:25 | | | |
| extent [1] | 36:21 | | | focus [1] 112:8 | 377.17 | | | given [27] | 5:12 | 6:2 | 20:8 |
| external [1] | 48:11 | | | focuses [1] | 37:16 | | | 22:12 43:11 | 46:15 | 58:14 | 76:9 |
| extremely [1] | 152:14 | | | folded [1] | 131:6 | | | 86:3 93:3 | 97:25 | 98:15 | 98:18 |
| eyewitness [1] | 73:10 | | | folder [3] | 67:14 | 154:8 | 154:14 | 109:22 117:4 | 121:17 | 129:1 | 135:7 |
| face [3] 60:9 | 130:14 | 131:13 | | folks [1] 104:18 | | | | 136:24 143:17 | 146:20 | 147:8 | 147:10 |
| | | 191:19 | | follow [8] | 33:11 | 63:6 | 109:2 | | 147:19 | 147:20 | |
| facilitated [1] | 111:6 | 40 10 | 10.00 | 119:19 126:23 | 134:8 | 157:20 | 160:3 | giving [2] | 31:4 | 147:2 | |
| facilities [3] | 29:4 | 45:10 | 46:20 | follow-up [3] | 99:20 | 143:17 | 159:22 | glanced [1] | 129:20 | | |
| facility [8] | 29:5 | 29:10 | 29:12 | follow-ups [2] | 120:17 | 120:17 | | Gleason [1] | 27:15 | | |
| 29:13 29:14 | 29:21 | 29:25 | 112:24 | followed [2] | 88:9 | 92:15 | | goals [2] 32:19 | 58:15 | | |
| fact [17] 11:20 | 20:8 | 46:15 | 49:20 | following [2] | 36:4 | 154:17 | | gone [6] 14:17 | 91:22 | 92:1 | 102:18 |
| 77:25 78:6 | 90:18 | 90:23 | 93:20 137-16 | follows [1] | 3:11 | 1.57.27 | | 119:8 125:19 | | | |
| 98:1 98:21 | 99:2 | 108:4 | 137:16 | 10110 # 5 [1] | 5.11 | | | | | | |
| | | | | 1 | | | | 1 C | | | |

| | | · · · · · | | | | | lulti-P | age [™] | | | go | od - in | patien |
|----------------------------|-----------------|------------------|------------------|------------------|-----------------|-----------------|----------------|------------------|----------------|--|----------------|----------------|-----------------------|
| good [5] | 25:4 | 44:10 | 104:20 | 108:22 | handled | | 118:19 | | | hundred [4] | 64:14 | 64:17 | 117:3 |
| 136:4 Gordon | | 10.2 | 10.7 | | handwr | | | 74:19 | 83:14 | 151:19 | | | |
| | | 10:3 B-21 | 10:6 | | handwr | | | | | Hurd [1] 2:15 | 110.10 | | |
| govern [: | | 8:21 | | | handwr | | 68:7 | | | husband [1] | 112:17 | | |
| governn | | 29:24 | | | Hanna | | 2:8 | | | i.e [1] 26:13 | | | |
| graduat | | 30:7 | | | hard [3] | | 56:18 | 157:20 | | idea [4] 19:22 | 25:4 | 28:9 | 79:1 |
| grant [1] | | | | | Harrp | | 51:14 | 111:18 | 117:16 | identification [5 5:16 6:11 |] 70:2 | 3:4 | 3:6 |
| G ray [66] 26:22 | 31:1 | 26:5 31:4 | 26:9 31:9 | 26:13 36:2 | 117:18 135:9 | 118:3 160:18 | 118:25 | 124:16 | 135:4 | identified [8] | 41:21 | 49:10 | 49:11 |
| 36:3 | 41:3 | 58:4 | 58:14 | 58:22 58:22 | Harrp's | | 118:10 | 135:5 | 141:25 | 49:12 54:10 | 41:21 54:12 | 49:10 65:25 | 49:11 66:23 |
| 59:23 | 60:11 | 62:9 | 63:13 | 63:18 | head [10] | | 50:15 | 106:9 | 141:23 | identifies [1] | 67:23 | 00.20 | 00.25 |
| | 64:22 | 78:23 | 78:24 | 80:6 | 106:13 | | 113:20 | 117:24 | 118:1 | identify [5] | 3:13 | 6:16 | 72:19 |
| | 80:20 81:9 | 80:20 82:11 | 80:25 82:13 | 81:2 83:5 | 146:1 | | | | | 73:2 132:3 | 0.10 | 0.10 | /2:15 |
| | 83:19 | 83:19 | 83:24 | 86:3 | health [4 | 1] | 29:2 | 30:1 | 111:25 | identifying [1] | 49:21 | | |
| 87:25 | 88:7 | 88:18 | 89:7 | 89:23 | 155:23 | | | | | identity [1] | 72:4 | | |
| 90:2 | 98:1 | 98:5 | 98:7 | 98:14 | heard [2 | 1 | 75:4 | 113:1 | | ill [1] 112:9 | | | |
| | 99:9 | 107:3 | 107:3 | 130:15 | heart [1] | 90:5 | | | | impact [2] | 90:25 | 152:17 | |
| | 134:1 143:2 | 136:24 143:12 | 136:25 144:18 | 142:22 145:14 | hearts [] |] | 90:5 | | | impending [1] | 156:8 | | |
| | 159:10 | 159:12 | 144.10 | 140.14 | held [1] | 13:20 | | | | implement [2] | 114:8 | 114:11 | |
| Grays [6] | | 26:6 | 62:19 | 64:19 | hell [1] | 153:11 | | | | implemented [3] | | 109:19 | 114:6 |
| | 86:2 | 98:1 | | ~ | help [4] | 12:13 | 34:23 | 116:9 | 156:1 | important [2] | 129:21 | 140:4 | 11110 |
| great [1] | 136:19 | | | | helped [| 1] | 110:17 | | | improper [1] | 12:8 | 110.1 | |
| Groedel | [117] | 2:18 | 3:15 | 3:15 | hemato | | gists [1] | 37:22 | | improve [1] | 109:15 | | |
| | 7:21 | 9:22 | 10:9 | 10;18 | hereby | | 162:6 | | | inadvertent [1] | 79:7 | | |
| | 11:14 | 11:23 | 12:15 | 12:21 | herein p | | 3:8 | | | inappropriate p | | 13:4 | 93:19 |
| | 13:5 15:18 | 14:2 22:6 | 14:11 23:11 | 15:4 23:22 | hereina | | 3:10 | | | inappropriaten | | 13.4 | <i>JJ.</i> 1 <i>J</i> |
| | 38:6 | 40:16 | 40:18 | 43:12 | hereunt | | 162:16 | | | inception [1] | 31:24 | 140.5 | |
| | 43:22 | 43:24 | 44:16 | 45:12 | hers [1] | | | | | inch [1] 144:11 | 51:24 | | |
| | 46:10 | 46:21 | 47:19 | 47:24 | hide [2] | | 93:16 | | | | 5.00 | 174.16 | |
| | 54:6 | 54:16 | 54:18 | 55:22 | high-do | | 154:20 | | | including [2] inclusive [1] | 5:23 | 134:16 | |
| | 58:10 60:12 | 59:5 60:20 | 59:9 61:5 | 59:24 65:2 | high-ris | | 134:16 | | | | 158:14 | 154.00 | |
| | 66:18 | 67:11 | 67:13 | 67:17 | higher [| | 116:19 | | | increase [2] | 89:4 | 154:22 | |
| 69:22 | 70:16 | 71:18 | 71:19 | 71:23 | Highlan | | 29:21 | | | increased [2] | 30:25 | 110:6 | 00.04 |
| | 72:14 | 72:17 | 72:21 | 74:25 | hip [1] | 50:15 | 49.41 | | | indeed [3] | 80:8 | 81:6 | 82:24 |
| | 75:16 79:2 | 77:2 79:7 | 77:21 81:16 | 78:10 84:23 | history | | 34:1 | 34:6 | 34:9 | independent [5] 87:12 87:21 | 42:24 | 43:3 | 59:20 |
| | 86:8 | 88:2 | 91:10 | 93:21 | 34:10 | 4] | .,4.1 | 54.0 | J4.7 | indicate [5] | 42:21 | 68:10 | 93:8 |
| 94:15 | 94:24 | 95:10 | 96:15 | 96:21 | hold [1] | 113:18 | | | | 148:8 148:23 | 42.21 | 08.10 | 93.0 |
| | 99:11 | 101:7 | 101:13 | 101:21 | honest [| | 92:6 | | | indicated [9] | 11:21 | 16:25 | 35:14 |
| | 104:6 107:24 | 104:9 | 105:12 | 107:12 | hope [1] | | | | | 67:4 74:21 | 94:18 | 102:8 | 142:21 |
| | 107:24 | 126:2 151:1 | 134:5 151:12 | 134:7 151:20 | hoped [4 | | 154:17 | 154:19 | 154.21 | 158:11 | | | |
| | 152:9 | 153:13 | 153:23 | 156:11 | 154:23 | 1 | 1.5 1.1.7 | 101.10 | 101101 | indicates [1] | 116:8 | | |
| | 160:24 | 161:1 | 161:3 | | hopeful | V [2] | 89:3 | 90:19 | | indicating [9] | 54:20 | 69:14 | 75:23 |
| group [5] | | 30:22 | 39:8 | 42:22 | hopeles | • | 155:6 | | | 78:17 80:7 | 128:6 | 130:10 | 134:3 |
| 124:21 | 125:17 | | | | hoping | | 90:8 | | | 159:3 | < | GO O | 100 11 |
| groups (1 | | 140:3 | | | hospital | | 8:14 | 8:18 | 8:20 | individual [5] 111:16 117:10 | 65:23 | 73:2 | 100:11 |
| guarante | | 154:18 | | | 10:4 | 17:18 | 20:16 | 22:5 | 26:16 | individuals [1] | 49:19 | | |
| uess (8) | | 72:6 | 80:15 | 81:23 | 29:7 | 29:11 | 29:15 | 29:23 | 66:16 | indulgence [1] | 49:19 | | |
| | 115:23 | 141:2 | 141:23 | | 66:18 107:1 | 67:24 113:16 | 92:8 120:5 | 96:14 121:1 | 106:7 121:5 | inform [1] | 15:2 | | |
| guessed | | 152:12 | | | 125:7 | 130:16 | 120:3 | 143:15 | 121:3 | | | 14.00 | 26:12 |
| uidelin | es [4] | 8:15 | 8:21 | 44:2 | 144:9 | 156:3 | 156:17 | 4 107.107 | 111.5 | 72:23 73:10 | 135:7 | 14:20 140:5 | 20:12 140:6 |
| 85:6 | 20.0 | | | | hospital | | 1:9 | 2:6 | 3:18 | 147:12 | ****** | 1,0.0 | 1 10.0 |
| uise [1] | | 31 0 | 74.10 | | 19:15 | 29:1 | 29:4 | 29:22 | 30:9 | informed [3] | 87:5 | 152:20 | 153:9 |
| • | 71:7 | 71:8 | 74:18 | | 45:2 | 55:24 | 87:12 | 87:14 | 87:19 | inherent [3] | 43:21 | 44:25 | 45:9 |
| • • • | 79:17 | | | | 94:22 109:8 | 105:6 | 107:17 | 108:24 | 109:6 | initial [4] | 8:7 | 33:24 | 53:7 |
| | 2:18 | | | | 109:8 | 109:16 138:9 | 114:7 139:7 | 115:8 139:10 | 119:1 | 62:2 | | | |
| | 38:1 | 79:24 | 136:22 | | Houng | | 112:16 | 107.10 | | initials [7] | 53:9 | 53:14 | 54:5 |
| and [4] | | 99:10 | 99:16 | 162:16 | hours [5] | | 112.10 | 120:5 | 120:9 | 54:13 55:12 | 102:5 | 143:4 | |
| anded | 4] | 5:15 | 7:7 | 74:8 | 120:12 | 52.0 | 117.43 | ر.∪… د | 140.9 | initiate [1] | 25:22 | | |
| 85:12 | | | | | Howley | [1] | 2:15 | | | inpatient [9] | 37:24 | 67:24 | 128:9 |
| nanding | [4] | 6:13 | 23:6 | 70:4 | human | | 9:9 | 13:22 | | 128:9 135:13 | 135:17 | 139:13 | 139:14 |
| 154:13 - 1andle [1 | | 24:25 | | | humblin | | 90:11 | ڪريند ۽ جي ۾ | | 139:24 | | | |
| | 1 | 24:23 | | | an anna Ayall | | | | | inpatients [1] | 118:11 | | |

| | | | | | N | /Iulti-P | age™ | | | in | quired | - linea | | | |
|---|---|-----------------------|--------|-----------------|--------------------------------|----------|--------|--------|-----------------|--------|--------|----------|--------|-------|-------|
| Instances (n) 156.18 issue (n) 12.23 15.14 77.20 Kid (n) 16.23 16.10 16.32 16.10 16.32 16.10 16.32 16.10 16.32< | inquired [1] | 4:17 | | | | | 143:17 | 147:4 | Kevin [3] | 2:7 | 3:17 | 108:23 | | | |
| nstead [] 26.10 26.21 issue [] issue [] 19.17 VIII 19.17 VIII 19.17 VIII 19.17 VIII 19.17 VIII 19.17 | | 16:16 | | | irradiations [2] | 115:7 | 115:20 | | key [1] 101:6 | | | | | | |
| | instances [1] | 156:18 | | | issue [3] 12:23 | 15:14 | 77:20 | | kid [1] 41:2 | | | | | | |
| | instead [4] | 26:10 | 26:14 | 26:22 | issued [1] | 19:17 | | | kill [1] 154:20 | | | | | | |
| nstitute gn 5.5 35:12 13:12 13:42 13:62 13:12 13:14 13:16 | 31:2 | | | | | | 21:9 | 23:21 | | 49.5 | 54.11 | | | | |
| | institute [8] | | | | | | | | | | | 2.17 | | | |
| | | 136:11 | 136:15 | 151:8 | itself [2] 67:23 | 143:25 | | | | | | | | | |
| | | 46:7 | | | IV _[1] 34:16 | | | | | 22:15 | | 57:11 | | | |
| | institutions [1] | 18:9 | | | 1 | 6:8 | 162:4 | 162:20 | | | | | | | |
| Jpr 1/2 Jpr 1/2 <th 2<="" th=""> <th 2<="" th=""> <th 2<="" th=""></th></th></th> | <th 2<="" th=""> <th 2<="" th=""></th></th> | <th 2<="" th=""></th> | | instruct [3] | 14:14 | 71:23 | 150:11 | | | 1021 | | | 147:24 | 150:9 | 161:9 |
| | instructed [1] | 62:15 | | | | | 1.18 | 3.7 | | | | | | | |
| | instruction m | | | | 104:19 161:9 | | | 162:20 | | 27:17 | | | | | |
| | | | | | 1 | | | | | | | | | | |
| nterdedig 31:9 43:14 35:18 36:10 36:25 39:20 14:14 35:18 36:10 36:25 39:20 13:11 40:11 45:13 59:2 13:14 45:13 59:2 13:14 45:13 59:2 13:15 59:2 13:17 13:0:11 13:0:17 | 0 | | | | | | 16.10 | 33.13 | | | 155:3 | 159:17 | | | |
| | | | | | 34:14 35:18 | | | | | | | | | | |
| 8.19148.8147.38.71097.1397.1397.14150.23< | | | 60.12 | 01.0 | | 45:4 | | | | | | | | | |
| | | 31:9 | 00:15 | 01:0 | | | | | | 59:2 | 117:4 | 150:17 | | | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | | 134-15 | | | | | | | | | 20.2 | <u></u> | | | |
| 85:1 88:22 89:82 89:82 130:11 130:16 132:2 138:20 140:11 Known III 151:9 ntentional III 84:25 147:13 141:4 141:9 141:4 141:4 141:4 141:4 141:4 141:2 151:9 Known III 151:9 intentional III 84:25 147:13 141:4 141:51 145:22 142:01 143:24 153:16 153:16 153:16 153:16 153:16 153:16 153:16 153:16 123:12 112:12 112:12 112:12 112:12 113:14 117:22 127:16 113:14 117:22 127:16 113:14 117:22 127:16 133:16 133:16 133:16 133:16 133:16 143:14 117:22 133:14 117:22 133:14 117:22 133:14 117:22 123:14 113:14 117:22 123:14 113:14 117:22 123:14 113:14 117:22 123:14 113:14 117:22 123:14 113:14 117:22 123:14 113:14 117:22 123:14 113:14 117:22 123:14 | | | Q1.10 | Q1.15 | | | | | | [3] | 39:2 | 41:17 | | | |
| 90:2 90:25 141:4 141:7 141:9 142:20 146:12 152:36 Intentional p 84:25 147:13 143:24 146:15 145:24 146:15 145:25 147:13 166:18 153:46 153:46 153:46 153:46 153:46 153:46 153:46 153:46 153:46 153:46 153:46 153:46 122:25 137:12 166:76 29:7 121:11 166:78 141:47 141:17 | | | | | | | | | | 1010 | | | | | |
| Intention µ ntentional µ ntentional µ ntertaction µ ntertaction µ ntertaction µ 1022 143:224 145:12 153:1 145:22 153:1 145:22 153:1 145:22 153:1 145:22 153:1 145:22 153:1 145:22 153:1 145:22 153:1 145:22 153:1 153:12 153:1 32:4 153:1 32:4 122:25 133:1 32:4 122:12 133:14 32:4 132:12 132:14 32:4 133:15 32:4 133:14 32:4 132:15 32:4 133:13 32:12 132:14 123:14 132:14 123:14 132:14 123:14 132:15 123:14 132:14 123:14 132:15 123:14 132:15 123:14 132:15 123:14 132:15 123:14 132:15 123:14 132:15 123:14 132:15 123:14 132:15 123:14 132:15 123:15 132:14 123:15 132:15 123:14 133:15 123:14 133:14 123:12 133:15 < | | 30.23 | 02.0 | <i>ندي. د</i> ي | | | | | | | | | | | |
| | | 77:1 | | | | | | | | | | <u>.</u> | | | |
| $ \begin{array}{ c c c c c c c c c c c c c c c c c c c$ | | | 147.12 | | 153:1 153:6 | | 153:18 | 154:25 | | | | | | | |
| $ \begin{array}{c c c c c c c c c c c c c c c c c c c $ | | | 141,13 | | 1 | | 159:11 | 160:8 | | 29:7 | 112:1 | 112:25 | | | |
| $ \begin{array}{c c c c c c c c c c c c c c c c c c c $ | • · · | | 102.25 | | | 118:5 | | | | | | | | | |
| $ \begin{array}{c c c c c c c c c c c c c c c c c c c $ | | | | | Jill's [1] 117:22 | | | | | | | | | | |
| $ \begin{array}{ c c c c c c c c c c c c c c c c c c c$ | | | 48:16 | | | | | | | | 70:20 | 113:12 | | | |
| | | | | | Joann [1] | 51:11 | | | | | | | | | |
| | | | | | | | | | | 52:6 | 110:15 | 118:5 | | | |
| $ \begin{array}{ c c c c c c c c c c c c c c c c c c c$ | | | | | | | | | | | | | | | |
| $ \begin{array}{ c c c c c c c c c c c c c c c c c c c$ | | 86:23 | 110:24 | | | 110.23 | 112-12 | | | | | | | | |
| $ \begin{array}{ c c c c c c c c c c c c c c c c c c c$ | interfaces [1] | 111:18 | | | | 110.23 | 112.12 | | | | | | | | |
| Intervisit (i)18:21Josh (i) $119:13$ $124:16$ $145:7$ $149:22$ $150:2$ $150:6$ Interveing (i) $36:19$ Josh's (ii) $95:2$ Joshua [67] $6:18$ $6:24$ $7:2$ $150:25$ $156:4$ $156:9$ $159:18$ Interveiws (i) $106:12$ $106:12$ $110:12$ $10:16$ $10:12$ $110:16$ $113:13$ $33:3$ $33:12$ $31:12$ $110:12$ $110:1$ | internal [1] | 30:13 | | | | 4 - 4 | 20.2 | | | | | | | | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | internist [1] | 18:21 | | | | 4:4 | 20:2 | | | | | | | | |
| $ \begin{array}{c c c c c c c c c c c c c c c c c c c $ | | | | | | | | | | | | 10.0 | | | |
| $ \begin{array}{c c c c c c c c c c c c c c c c c c c $ | | | | | | | | | 1 | | 109.10 | | | | |
| $ \begin{array}{c c c c c c c c c c c c c c c c c c c $ | | | 118-3 | | | | | | | | | | | | |
| $ \begin{array}{c c c c c c c c c c c c c c c c c c c $ | | | | | | | | | | | | | | | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | | | | 110.16 | | | | | | | 0.11 | | | | |
| $ \begin{array}{ c c c c c c c c c c c c c c c c c c c$ | | | 110:12 | 110:10 | | | | | | | | 06.10 | | | |
| $\begin{array}{ c c c c c c c c c c c c c c c c c c c$ | | | 0 7 | 0.42 | 57:4 58:8 | | 66:11 | | | /5:14 | 80:11 | 80:13 | | | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | | | | | | | | | | 41.0 | | | | | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | | | | | | | | | | | 101.0 | 101 10 | | | |
| $ \begin{array}{c c c c c c c c c c c c c c c c c c c $ | | | 14.44 | 10.10 | | | | | | | | 121:13 | | | |
| nvolve $[3]$ 21:228:2451:2140:9143:17145:9146:11147:1147:17142:17142:17nvolved $[29]$ 26:1528:2031:1331:1631:1231:2232:732:1033:236:1140:540:2240:2235:132:1033:236:1140:540:2240:2258:2463:569:1369:1670:8166:13166:13166:13Joshua's $[13]$ 32:837:139:1958:2463:569:1369:1670:8166:17141:4143:20156:13105:6108:8148:2149:22151:5Jude's $[1]$ 117:1160:8160:13141:1160:16160:13nvolvement $[4]$ 30:1933:1949:1249:12138:5150:21150:2116gible $[1]$ 141:1141:1160:8137:237:2173:6July $[9]$ 19:2124:724:876:5137:24163:1991:13110:16120:20137:2112:1112:22112:2112:1212:2076:686:1391:892:21110:7168:8140:10140:15140:15106:9112:1112:22112:25114:7Jume $[3]$ 91:591:7113:1216ers $[3]$ 19:1720:1920:23106:9112:1112:2215:2331:1434:1591:7113:1216ers $[3]$ 19:1720:1920:23106:9112:1 <th></th> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>140:23</td> <td>147:10</td> <td></td> | | | | | | | | | | 140:23 | 147:10 | | | | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | • | | 28.24 | 51.0 | | | | | | 110 | 140.10 | | | | |
| $ \begin{array}{ c c c c c c c c c c c c c c c c c c c$ | | | | | 147:18 147:24 | | | | , Ç | | 149:13 | | | | |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | | | | | | 160:8 | 160:13 | | | | | | | | |
| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | | | | | | | | | | | | 41:23 | | | |
| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | 41:10 41:22 | 48:7 | 49:8 | 51:14 | | | | | [| | 156:13 | | | | |
| 160:8judge [3] 1:8 $150:21$ $150:21$ $1engthy$ [3] $140:10$ $140:15$ $140:15$ $nvolvement$ [4] $30:19$ $33:19$ $49:12$ $judgment$ [4] $34:21$ $35:6$ $137:24$ $lengthy$ [3] $140:10$ $140:15$ $140:15$ $nvolves$ [2] $37:21$ $73:6$ $July$ [9] $19:21$ $24:7$ $24:8$ $76:5$ $77:13$ $154:3$ $154:7$ $nvolving$ [3] $9:9$ $11:12$ $12:20$ $76:6$ $86:13$ $91:8$ $92:21$ $110:7$ $letter$ [7] $22:19$ $23:2$ $76:24$ $77:4$ $reland$ [8] $29:7$ $29:10$ $30:11$ $June$ [3] $91:5$ $91:7$ $113:12$ $letters$ [1] $9:14$ $106:9$ $112:1$ $112:22$ $112:25$ $114:7$ K [1] $127:12$ $level$ [1] $46:16$ $106:9$ $15:22$ $31:14$ $34:15$ $36:22$ $55:3$ $101:24$ $117:8$ $100:3$ $100:10$ $101:8$ $34:20$ $35:1$ $35:22$ $36:22$ $55:3$ $101:24$ $117:8$ $139:25$ $139:25$ $169:14$ $71:6$ $71:21$ $16:20$ $117:5$ $119:8$ $119:10$ $119:20$ $139:21$ $139:25$ $139:25$ $142:20$ $157:6$ | 51:17 57:1 | 57:8 | 65:23 | | | | 93:25 | 153:10 | 1 | | | | | | |
| nvolvement [4] $30:19$ $33:19$ $49:12$ $30:19$ $33:19$ $49:12$ $30:10$ $10:11$ | | 148:2 | 149:22 | 151:5 | • | | | | | | | | | | |
| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | | 00.10 | 00.10 | 10.10 | | | | | | | | | | | |
| $ \begin{array}{c ccccccccccccccccccccccccccccccccccc$ | | 30:19 | 33:19 | 49:12 | | 34:21 | 35:6 | 137:24 | | | | 120:20 | | | |
| $ \begin{array}{c ccccccccccccccccccccccccccccccccccc$ | | ar a - | 70 / | | | | | | | | 76:24 | 77:4 | | | |
| $ \begin{array}{c c c c c c c c c c c c c c c c c c c $ | | | | | | | | | 1 | 154:7 | | | | | |
| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | | | | | | | | 110.7 | | 9:14 | | | | | |
| $ \begin{array}{c ccccccccccccccccccccccccccccccccccc$ | | | | | | 91:7 | 113:12 | | level [1] 46:16 | | | | | | |
| rradiation [28]15:22 $31:14$ $34:15$ keep [6]9:1100:3100:10101:8light [2] $40:22$ $98:8$ $34:20$ $35:1$ $35:22$ $36:22$ $55:3$ $101:24$ $117:8$ $100:3$ $100:10$ $101:8$ light [2] $40:22$ $98:8$ $71:6$ $89:13$ $103:9$ $110:14$ $116:8$ keeping [2] $139:21$ $139:25$ line [8] $69:14$ $71:6$ $71:21$ $109:11$ $16:20$ $117:5$ $119:8$ $119:10$ $119:20$ 622 624 $120:20$ $127:19$ $130:25$ $142:20$ $157:6$ | | | | | 1 | | | | | 19:17 | 20:19 | 20:23 | | | |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | | | | | | 100:3 | 100:10 | 101:8 | | | | | | | |
| 116:20 117:5 119:8 119:10 119:20 Keeping [2] 139:21 139:25 127:19 130:25 142:20 157:6 | | | | | | | | | | | 71.21 | 109:11 | | | |
| | | | | | keeping [2] | 139:21 | 139:25 | | | | | | | | |
| | | | | | kept [3] 6:22 | 6:24 | 100:20 | | 1 | | | | | | |
| | | | * | | | | | | | | | | | | |

| | | | | | 101:25 | 102:1 | 100.04 | 103.0 | 100 0 | | 14.0 | | |
|-----------------------------------|--------|-----------------|------------------|------------------|------------------|------------------------|------------------|-----------------|------------------|-----------------------------|--------------------|-----------------|-----------------|
| ist [1] 3 | [1:1 | | | | | | 102:24 | 103:2 | 103:5 | medically [5] | 14:9 | 35:14 | 151:10 |
| | | 11:2 | | | 108:14 144:22 | 126:21 146:7 | 128:19 148:8 | 137:4 148:18 | 143:20 148:23 | 155:13 156:21 | | | |
| sted (2) | 38:18 | | | | 144:22 | 140:7 | 146.8 | 140:10 | 148:23 | medicine [6] | 36:11 | 65:10 | 65:11 |
| | | 55:2 | | | 153:25 | | 154:7 | 154:11 | 159:21 | 87:16 112:18 | 124:23 | | |
| itigation | i [1] | 124:17 | | | Margol | is' m | 145:6 | | | meet [2] 18:4 | 40:10 | a , | 71.00 |
| ived [1] | 152:12 | | | | mark [5] | | 6:9 | 69:19 | 100:2 | meeting [22] 71:25 72:3 | 71:14 72:3 | 71:16 72:5 | 71:20 72:7 |
| 0 [1] | 152:4 | | | | 154:1 | | | | | 75:23 76:6 | 77:24 | 78:1 | 96:5 |
| ocal [5] 3 | 34:25 | 35:21 | 36:22 | 40:23 | marked | [15] | 3:3 | 3:6 | 5:15 | 96:6 97:1 | 99:6 | 114:24 | 114:25 |
| 114:21 | | | | | 6:11 | 6:13 | 22:14 | 23:5 | 70:2 | 149:19 150:2 | 150:5 | 150:25 | |
| ocate [1] | | 17:14 | | | 70:4 | 97:9 | 100:14 | 101:4 | 133:5 | meetings [9] | 38:4 | 38:10 | 38:22 |
| ocations | [2] | 30:3 | 133:9 | | | 154:11 | a . 16 | 71.1 7 | 5 1 01 | 78:4 105:10 | 114:19 | 114:21 | 114:22 |
| ock [1] 1 | 101:6 | | | | marks [| | 71:15 | 71:16 | 71:21 | 114:23 | | | |
| onger [4] | | 64:21 | 121:5 | 121:13 | married | | 18:6 | 20:8 | 150:19 | members [3] | 14:5 | | 111:17 |
| 152:12 | | | | | marrow | | 68:2 | 139:17 | | mental [2] | 130:18 | 159:4 | |
| ook [27] - 2 | 22:14 | 23:4 | 33:7 | 34:25 | Marty (: | | 106:12 | | | mentioned [5] | 114:9 | 117:10 | 117:16 |
| | | 80:1 | 83:23 | 103:12 | Matt [1] | | | | | 119:24 132:2 | | | |
| | | 117:22 | 121:12 | 127:21 | matter | | 8:4 | 8:8 | 8:12 | Mercy [2] | 29:15 | 111:25 | |
| | | 129:4 147:17 | 129:16 153:16 | 129:18 153:19 | 8:16 | 13:13 | 14:14 | 111:2 | 153:18 | merits [1] | 157:3 | | |
| | 157:6 | 158:22 | 199.10 | 100.19 | matters | | 12:8 | | | met [12] 33:12 | 40:15 | 40:21 | 71:13 |
| ooked [6] | | 17:13 | 98:4 | 98:13 | Matthe | W [1] | 2:22 | | | 87:2 87:3 | 101:7 | 106:22 | 106:22 |
| 98:17 I | | 130:24 | 70.4 | 20.15 | may [100 | 1 | 1:14 | 5:4 | 9:17 | 107:2 107:5 | 107:5 | | |
| ooking 🛛 | | 6:4 | 17:15 | 33:14 | 9:23 | 10:10 | 10:21 | 11:15 | 11:24 | metastases [1] | 82:22 | | |
| | 53:5 | 74:17 | 116:6 | 119:15 | 13:1 31:8 | 13:7 33:7 | 14:3 38:7 | 20:15 42:15 | 23:23 43:24 | metastasis [1] | 95:9 | | |
| 129:11 | 130:12 | 130:23 | 149:7 | | 44:17 | 45:15 | 46:11 | 42:15 | 43:24 52:5 | meter [1] | 63:15 | | |
| ooks [8] 🤈 | | 83:18 | 127:12 | 127:19 | 52:5 | 53:22 | 54:21 | 55:23 | 56:6 | meters [1] | 133:3 | | |
| 127:19 | | 133:16 | 133:20 | | 57:16 | 58:11 | 60:1 | 61:6 | 65:3 | method [1] | 124:5 | | |
| lorain [2] | | 29:25 | 112:1 | | 65:16 | 72:21 | 73:25 | 74:6 | 74:21 | Mexico [4] | 149:14 | 149:15 | 149:16 |
| ow-dose | [3] | 134:9 | 134:13 | 134:16 | 75:5 | 75:5 | 75:24 | 76:13 | 76:25 | 149:17 | | | |
| ower [1] 7 | 70:5 | | | | 77:12 84:24 | 77:22 85:8 | 79:7 85:10 | 84:15 86:9 | 84:15 88:3 | MIBG [4] | 36:11 | 40:23 | 90:9 |
| JUICC II | l] | 112:24 | | | 91:1 | 91:18 | 93:22 | 94:16 | 94:18 | 105:1 | 10.10 | | |
| ung [2] | 16:25 | 147:16 | | | 95:9 | 96:5 | 96:5 | 96:16 | 96:22 | Michael [2] | 13:19 | 114:3 | |
| Ģ | | 2:7 | | | 98:24 | 99:13 | 99:14 | 103:18 | 104:10 | mid [1] 36:10 | | | |
| A.D [10] 1 | | 1:16 | 2:25 | 3:7 | 105:12 | 107:12 | 107:25 | 117:21 | 119:14 | | 122:25 | 145:25 | 149:6 |
| | | 54:5 | 127:6 | 161:9 | 120:21 127:25 | 120:22 128:12 | 121:13 128:13 | 123:4 129:2 | 127:20 137:19 | 152:12 | | | |
| 162:7 | | | | | 139:9 | 140:12 | 142:25 | 143:24 | 144:10 | mike [1] 44:7 | | | |
| nachine | | 16:7 | 32:15 | 48:1 | 144:18 | 145:8 | 149:19 | 149:19 | 151:2 | mind [2] 72:22 | 109:18 | | |
| | | 142:17 | | | 151:13 | 151:21 | 152:9 | 153:14 | 158:12 | mine [1] 78:24 | | | |
| nailbox [| [2] | | 123:15 | | 158:16 | | | | | minute [8] | 44:4 | 48:21 | 64:12 |
| najor [1] | | 111:13 | | | McCrys | | 2:22 | | | | 116:17 | 116:22 | 117:7 |
| najority | [4] | 14:6 | 21:20 | 116:3 | mean [32 | | 27:20 | 47:24 | 48:1 | minutes [8] 64:21 64:23 | 38:10 148:14 | 38:12 148:17 | 64:15 148:19 |
| 118:14 | | | | | 60:4 | 72:21 | 76:20 | 77:5 | 77:12 | miracles [1] | | 140.17 | 140.17 |
| nalignar | | | 58:20 | | 78:1 101:15 | 83:18 111:8 | 91:2 116:21 | 92:13 117:2 | 99:18 119:12 | | 151:10 | 00.05 | |
| nalpract | | | 94:10 | | 119:14 | 120:6 | 123:7 | 129:21 | 130:9 | misadministrat | | 92:25 | 145.05 |
| nan [2] 9 | | 146:8 | | | | 130:17 | 131:5 | 132:24 | 133:2 | missed [3] | 98:3 | 98:21 | 145:25 |
| nanagen | | | | | 143:9 | | 159:4 | 159:4 | | missing [1] | 82:3 | 110.07 | |
| Aannen (| [1] | 1:8 | | | meanin | | 40:24 | | | | 113:22 | 113:25 | a |
| nanner p | 1] | 124:5 | | | meanin | gful (1) | 152:17 | | | | 27:6 | 27:8 | 31:2 |
| Aarc [10] | | 2:18 | 3:15 | 7:6 | means [| 9] | 41:2 | 119:12 | 162:11 | 62:13 92:12 93:17 130:18 | 92:14 141:19 | 93:5 141:24 | 93:15 |
| | | 23:11 | 67:9 | 69:18 | meant 15 | | 43:14 | 77:16 | 113:25 | mistaken [2] | 76:9 | 87:6 | |
| | 101:7 | | | | 128:21 | | | | | modality [1] | 134:15 | 07.0 | |
| Aarch [8] | | 19:18 | 23:13 | 23:17 | measur | | | 41:7 | 50:3 | modification [1] | | | |
| | | 109:7 | 114:5 | 115:21 | 50:7 | 50:11 | 50:12 | 50:13 | 57:12 | modification [1] | | 152.0 | |
| /Iargolis 4:3 4 | | 2:3 4:7 | 2:4 6:5 | 3:12 6:12 | 57:20 | ******* | 50 FC | | | | | 153:2 | 01.14 |
| | | 7:9 | 7:24 | 8:1 | mediast | | | 0.11 | 0.0 | modified [4] 94:18 | 80:19 | 81:14 | 82:24 |
| | | 22:18 | 22:23 | 23:1 | medical 9:24 | [43] 11:12 | 4:24 | 8:11 12:19 | 9:8 13:21 | modify [2] | 82:22 | 82:22 | |
| 23:3 4 | 40:20 | 44:3 | 44:12 | 48:22 | 9:24 | 11:12 | 11:12 20:19 | 20:23 | 21:22 | • | O have a have have | 02:22 | |
| | | 54:17 | 59:11 | 66:20 | 34:6 | 35:6 | 46:3 | 49:8 | 58:15 | mom [1] 135:6 | 05 11 | | |
| | | 67:18 70:17 | 67:20 72:6 | 69:15 | 73:6 | 75:22 | 75:24 | 76:5 | 91:19 | moment [1] | 85:11 | | |
| | | 70:17 73:4 | 72:6 73:14 | 72:12 74:6 | 91:22 | 91:23 | 92:1 | 92:2 | 92:4 | moments [1] | 95:17 | 2 H ~ | |
| 1 60.20 | | 73:4 74:14 | 75:3 | 79:5 | 92:6 | 92:12 | 92:14 | 92:23 | 93:4 | Monday [2] | 51:25 | 120:1 | |
| | | | | | 93:20 | 93:24 | 96:25 | 109:11 | 110:25 | Mondays [1] | 120:16 | | |
| 74:9 7 | 31:19 | 83:8 | 83:11 | 85:18 | 113:6 | 125:8 | 152:16 | 153:2 | 159:14 | money [1] | 12:18 | | |

| monitor [3] | 116:15 | 116:17 | 116:23 | news [1] 136:4 | | 0 | | 118:21 119:6 | 119:25 | | |
|----------------------|----------|--------|---------------|------------------------|-------------|--------|---------------|------------------|----------------|----------|--------|
| | | | | • | 10.10 | 00.16 | 07.10 | | | | |
| month [8] | 23:12 | 24:6 | 24:13 | next [7] 40:8 | 40:10 | 82:16 | 95:19 | o'clock [1] | 52:8 | | |
| 24:22 25:3 | 25:12 | 113:11 | 119:2 | 142:24 143:18 | 144:15 | | | oath [6] 4:12 | 4:14 | 5:12 | 77:7 |
| Moriarty [23] | 2:22 | 4:1 | 4.1 | night [2] 38:17 | 52:8 | | | 89:21 159:8 | | | |
| 22:25 48:20 | 48:23 | 61:7 | 61:10 | none [4] 94:23 | 95:1 | 161:2 | 161:3 | object [3] | 10:18 | 45:12 | 107:14 |
| 85:10 85:13 | 85:14 | 95:16 | 95:19 | nonphysician [] | 1 | 146:4 | | objection [85] | 9:22 | 10:9 | 10:20 |
| 148:13 148:16 | | 149:16 | 153:21 | | -1 | 140.4 | | 11:14 11:23 | 12:15 | 12:21 | 12:25 |
| 154:2 154:5 | 154:10 | 159:24 | 161:5 | noon [1] 108:22 | | | | 13:5 14:2 | 12.13 14:11 | 12:21 | 15:18 |
| morning [3] | 22:4 | 52:7 | 92:11 | nor [1] 18:18 | | | | 23:22 31:7 | 38:6 | 43:12 | 43:22 |
| Moscarino [1] | 2:7 | | | Norchi [21] | 2:7 | 3:17 | 3:17 | 43:25 44:16 | 45:14 | 46:10 | 46:21 |
| most [9] 36:13 | 73:8 | 107.2 | 107:17 | 19:12 59:8 | 60:2 | 60:15 | 105:11 | 47:19 53:21 | 54:6 | 55:22 | 56:5 |
| | | 107:3 | | 107:11 108:1 | 108:21 | 108:23 | 128:23 | 58:10 58:12 | 59:5 | 59:7 | 59:8 |
| 110:22 136:2 | 146:22 | 151:24 | 153:3 | 135:19 151:15 | 151:23 | 152:10 | 159:22 | 59:24 59:25 | 60:2 | 60:12 | 60:14 |
| mostly [1] | 119:4 | | | 159:25 160:2 | 160:23 | | | 60:15 60:20 | 61:5 | 65:2 | 65:4 |
| mother [14] | 33:12 | 34:4 | 34:7 | Norchi's [1] | 158:11 | | | 65:15 65:17 | 71:18 | 74:25 | 75:9 |
| 34:10 36:1 | 36:23 | 40:10 | 40:15 | | | | | 75:16 77:2 | 77:21 | 78:10 | 84:23 |
| 40:21 41:7 | 50:1 | 50:2 | 51:21 | normal [1] | 6:22 | | | 85:7 86:8 | 88:2 | 93:21 | 94:15 |
| 63:23 | | | | normally [3] | 17:10 | 100:20 | 157:13 | 94:24 95:10 | 96:15 | 96:21 | 98:23 |
| motioned [1] | 128:20 | | | Notary [3] | 1:19 | 162:5 | 162:20 | 99:11 104:6 | 104:9 | 105:11 | 107:11 |
| 1 | | | | notations [3] | 97:17 | 97:21 | 139:25 | 107:13 107:24 | 104.9 | 103.11 | 150:7 |
| motivation [1] | 77:8 | | | | | | | 151:1 151:12 | 151:14 | 151:15 | 151:20 |
| mouth [1] | 124:12 | | | note [69] 22:7 | 40:12 | 40:15 | 40:19 | 151:22 151:23 | 151:14 | 152:8 | 152:10 |
| moving [1] | 137:25 | | | 49:23 50:22 | 62:19 | 62:24 | 66:15 | 151:22 151:25 | 1.22.0 | 0، شەرىد | 195.10 |
| MRI [8] 36:13 | 36:14 | 40:23 | 80:19 | 67:2 67:4 | 67:5 | 67:21 | 67:24 | i | 167.0 | | |
| 81:11 82:20 | 90:9 | 105:2 | 00.17 | 68:6 68:6 | 68:11 | 69:9 | 78:21 | obligation [1] | 157:2 | | |
| 1 | 10.7 | 105.2 | | 79:10 80:12 | 93:9 | 93:12 | 93:13 | obtain [1] | 92:2 | | |
| Mrs [1] 107:2 | | | | 122:16 123:11 | 123:11 | | 123:25 | obtained [2] | 34:3 | 34:9 | |
| MU [1] 116:14 | | | | 124:2 126:22 | 128:5 | 130:4 | 130:10 | obviously [9] | 26:17 | 27:20 | 46:13 |
| multi-disciplir | 1ary 131 | 30:16 | 110:21 | 130:12 130:13 | 130:24 | 131:18 | 131:19 | 114:23 115:3 | 115:3 | 130:15 | 138:13 |
| 112:6 | , , | | | 131:20 131:22 | 131:23 | 131:24 | 132:2 | 144:11 | 115.5 | 150.15 | 138.15 |
| multiple [1] | 35:23 | | | 135:4 135:5 | 135:14 | 139:4 | 139:6 | | 00.00 | 100 7 | 120.02 |
| - | | | | 140:10 140:14 | 140:15 | 140:19 | 140:19 | occasion [4] | 92:20 | 136:7 | 138:23 |
| Murphy [1] | 2:11 | | | 140:20 140:22 | 140:22 | 141:4 | 141:9 | 143:12 | | | |
| must [3] 104:20 | 135:16 | 147:7 | | 141:25 142:6 | 143:14 | 144:2 | 144:8 | occasions [3] | 5:1 | 121:21 | 147:25 |
| MV [1] 55:3 | | | | 152:25 153:6 | 153:16 | 153:16 | 159:3 | occur [5] 91:15 | 96:6 | 98:1 | 112:6 |
| Nagy [1] 11:7 | | | | noted [2] 79:12 | 140:14 | | | 124:6 | | | |
| | | | | notes [12] | 20:5 | 38:3 | 38:8 | occurred [5] | 25:13 | 25:15 | 96:5 |
| Nam [1] 112:17 | | | | 38:10 48:2 | 52:10 | 54:1 | 122:14 | 115:7 150:25 | 23:15 | 25.15 | 90.5 |
| name [13] | 3:15 | 3:17 | 3:19 | 134:25 134:25 | | 149:7 | | | | | |
| 3:22 13:15 | 13:16 | 49:6 | 51:12 | nothing [7] | 10:25 | 12:8 | 15:12 | occurrence [1] | 122:7 | | |
| 64:1 87:13 | 108:23 | 113:1 | 117:23 | 26:2 97:3 | 10:25 | 12:8 | 15:12 | occurring [2] | 11:25 | 119:22 | |
| named [8] | 13:23 | 24:14 | 24:18 | | | 102.9 | | OCCUTS [2] | 40:8 | 123:15 | |
| 25:12 25:16 | 25:17 | 25:23 | 25:24 | notice [1] | 1:21 | | | October [1] | 27:5 | | |
| names [2] | 54:14 | 106:8 | | noticed [1] | 140:9 | | | | <i>4.1.3</i> | | |
| | | 100.0 | | notification [1] | 15:17 | | | odds [1] 151:9 | | | |
| Nancy [1] | 106:19 | | | notified [3] | | 26:16 | 87.3 | off [16] 45:6 | 53:20 | 85:14 | 85:15 |
| national [9] | 5:5 | 111:7 | 114:22 | | | 20.10 | 07.5 | 85:16 95:23 | 103:17 | 103:19 | 103:21 |
| 115:2 134:23 | 136:8 | 136:11 | 136:14 | notify [1] | 26:17 | | | 103:23 108:17 | 108:18 | 118:19 | 129:22 |
| 151:7 | | | | Novak [2] | 112:13 | 112:22 | | 148:20 149:9 | | | |
| nationally [1] | 45:17 | | | November [3] | 19:16 | 28:3 | 162:22 | offer [3] 105:25 | 106:23 | 112:19 | |
| nauseatingly [] | 1 99.7 | | | now [29] 6:4 | 13:16 | 17:15 | 31:11 | office [14] | 5:22 | 6:3 | 9:1 |
| near [1] 110:5 | 1 22.1 | | | 40:6 47:6 | 48:22 | 53:13 | 55:10 | 9:5 17:10 | 17:11 | 17:21 | 79:8 |
| | | | | 67:10 69:3 | 69:12 | 72:24 | 95:22 | 92:9 96:8 | 101:6 | 101:23 | 123:15 |
| necessarily [2] | 69:10 | 78:4 | | 102:22 110:5 | 110:9 | 111:15 | 111:25 | 162:17 | | | |
| neck [2] 39:13 | 50:15 | | | 112:4 114:18 | 125:20 | 139:18 | 140:9 | officer [1] | 125:14 | | |
| need [6] 49:18 | 54:20 | 67:12 | 72:23 | 144:6 146:6 | 152:14 | 156:17 | 158:24 | | | | |
| 119:6 148:19 | | | | nuclear [1] | 36:11 | | | offices [2] | 1:22 | 101:11 | |
| needed [2] | 102:8 | 102:10 | | | | 10.00 | | often [7] 37:23 | 37:25 | 52:8 | 118:22 |
| | | | | number [22] | 40:13 | 40:22 | 41:14 | 122:14 140:20 | 151:16 | | |
| negatively [2] | 90:25 | 91:1 | | 49:21 49:25 | 50:8 | 52:16 | 54:24 | oftentimes [4] | 119:25 | 120:2 | 120:21 |
| negligent [1] | 85:5 | | | 54:25 55:1 | 80:16 | 100:14 | 110:8 | 123:19 | | | |
| neither [1] | 137:6 | | | 115:6 115:9 | 115:10 | 127:1 | 131:5 | Ohio [15] 1:1 | 1:17 | 1:20 | 1:23 |
| neuroblastom | | 18:2 | 21:3 | 134:13 144:24 | 153:21 | 158:8 | | 2:5 2:8 | 2:12 | 2:16 | 2:20 |
| 21:7 34:17 | 36:13 | 3.0.2 | المسلم المسلم | numbers [1] | 144:19 | | | 2:23 19:17 | 162:2 | 162:5 | 162:17 |
| | | 20.10 | 106.10 | nurse [10] | 38:1 | 51:16 | 51:16 | 162:21 | 102.2 | 1.04.0 | 102.17 |
| neurosurgery | [3] | 39:12 | 106:12 | 111:18 117:24 | 118:1 | 118:14 | 118:18 | | | | |
| 106:14 | | | | 118:23 120:14 | | | | old [1] 130:7 | | | |
| never [7] 53:15 | 62:8 | 92:1 | 92:6 | nurses [15] | 32:10 | 37:25 | 41:22 | Oleinick [1] | 106:19 | | |
| 125:2 150:3 | 155:5 | | | 43:6 65:10 | | 111:15 | 111:20 | once [4] 25:12 | 48:6 | 131:22 | 147:10 |
| new [18] 29:18 | 29:25 | 37:16 | 37:20 | 114:9 117:10 | 117:11 | 118:6 | 118:20 | oncologist [20] | 18:12 | 18:15 | 18:15 |
| 37:20 79:16 | 80:4 | 82:25 | 106:18 | 126:14 160:18 | 4 4 7 4 Å Å | 110.0 | 4. 1. 0 . 200 | 18:18 18:21 | 18:12 | 18:23 | 31:22 |
| 120:19 127:25 | | 131:13 | 131:13 | 1 | 57.0 | 111.14 | 111.14 | 32:5 32:21 | 35:4 | 56:11 | 58:9 |
| 149:15 149:16 | | 157:24 | | nursing [6] | 52:8 | 111:14 | 111:14 | 61:3 61:14 | 87:3 | 102:6 | 137:11 |
| 1 | | | | 1 | | | | 01.17 | 57.5 | *0#.0 | 1 |

Multi-PageTM

MORSE, GANTVERG & HODGE

monitor - oncologist

| | | | | | | Iulti-Pa | age™ | | | onco | logists | - place |
|------------------------------------|---------------|----------------|---------------|-----------------------|------------------|----------------|----------------|----------------|-------------------------------|-----------------|----------------|----------------|
| 146:2 146:20 | | | | Paisley | | 2:15 | | | 118:11 118:17 | 136:23 | 151:5 | |
| oncologists [2] | 21:20 | 110:25 | | Palmer | [1] | 127:22 | | | pediatrics [2] | 113:21 | 116:3 | |
| oncology [53] | 6:17 | 6:25 | 9:9 | panel [1] | 64:4 | | | | pen [4] 74:15 | 75:22 | 100:3 | 100:10 |
| 13:22 19:1 | 21:25 | 22:3 | 28:14 | paper [2] | 1 | 31:13 | 157:15 | | pending [1] | 15:1 | | |
| 28:15 28:25 | 29:23 | 30:15 | 30:18 | parenth | | 68:1 | | | people [12] | 31:13 | 37:19 | 42:22 |
| 35:5 35:13 37:23 37:23 | 36:20 38:1 | 37:6 38:20 | 37:9 45:24 | parents | | 26:18 | 90:19 | 152:19 | 78:5 78:13 | 96:9 | 96:11 | 99:25 |
| 46:4 46:18 | 65:21 | 58.20 67:24 | 101:2 | 153:10 | | 154:25 | 155:5 | 156:19 | 108:4 131:10 | 131:11 | 142:16 | |
| 104:8 109:7 | 109:15 | 109:24 | 110:13 | 159:13 | | | | | per [8] 42:18 | 57:25 | 84:7 | 84:9 |
| 111:10 111:15 | 112:7 | 112:12 | 113:6 | part [20] | 17:22 | 29:17 | 29:22 | 30:2 | 115:25 116:14 | 116:17 | 117:7 | |
| 113:7 113:20 | 113:24 | 115:16 | 117:11 | 34:16 | 36:3 | 36:13 | 42:11 | 64:5 | percent [5] | 28:22 | 48:11 | 91:14 |
| 118:14 118:15 | 135:7 | 136:16 | 139:15 | 76:9 | 89:14 | 91:18 | 102:10 | 102:12 | 103:24 151:19 | | | |
| 144:4 146:20 | 147:19 | 151:5 | 151:6 | 109:20 | 109:25 | 111:3 | 114:6 | 126:10 | performed [4] | 9:8 | 36:15 | 115:21 |
| one [41] 6:1 20:15 37:10 | 6:6 44:4 | 14:5 44:22 | 15:2 56:25 | | ato m | 110.5 | | | 136:13 | | | |
| 60:19 67:14 | 44:4 68:1 | 44:22 73:15 | 76:8 | particip | | 112:5 | 1/0 01 | | period [6] | 63:12 | 89:3 | 94:22 |
| 76:11 85:11 | 96:17 | 99:2 | 100:2 | particip | | | 160:21 | | 95:2 147:7 | 152:4 | | |
| 103:4 108:15 | 110:2 | 110:23 | 114:18 | particul 123:4 | ar [5] 160:18 | 30:18 | 117:12 | 118:21 | periodically [1] | 141:3 | | |
| 114:24 116:6 | 124:5 | 124:5 | 124:25 | | | 100.15 | | | permitted [2] | 137:7 | 137:17 | |
| 127:14 127:16 | 127:24 | 131:10 | 134:11 | partner | | 108:15 | | | person [9] | 50:3 | 50:4 | 50:5 |
| 141:15 149:21 159:22 159:25 | 151:19 | 154:6 | 154:8 | Partner | | 30:1 | 112:1 | | 72:4 72:19 | 73:15 | 75:21 | 77:13 |
| ones [2] 35:23 | 154:3 | | | parts [1] | | a | | | personal [2] | 4.1 | 20.14 | |
| | | 120.05 | | party [3] | | 24:18 | 162:14 | | • | 4:1 | 20:16 | 52.15 |
| ongoing [2] | 97:12 | 132:25 | | pass [1] | | | | | personally [3] | 2:21 | 13:7 | 53:15 |
| open [1] 131:12 | ac - | A. / | | passed [] | - | 132:6 | | | personnel [2] | 30:20 | 107:1 | |
| opened [2] | 29:5 | 29:21 | | past [5] | 34:6 | 81:13 | 92:13 | 123:5 | persons [1] | 100:2 | | |
| operates [1] | 104:8 | | | 136:8 | | | | | perspective [1] | 153:3 | | |
| operating [3] | 44:13 | 87:12 | 158:17 | path [1] | | | | | Ph.D [5] 56:15 | 56:15 | 56:16 | 56:18 |
| operative [1] | 42:17 | | | patholog | | 37:21 | 111:1 | | 106:19 | | | |
| opinion [5] | 21:15 | 60:4 | 65:21 | patholog | gy [1] | 37:20 | | | Pham [3] | 112:13 | 112:15 | 112:16 |
| 90:23 155:25 | | | | patient | 71] | 6:24 | 8:22 | 26:17 | phantoms [1] | 57:15 | | |
| opinions [1] | 4:17 | | | 26:21 | 32:24 | 33:12 | 35:5 | 35:7 | Phillip [2] | 9:15 | 9:21 | |
| opportunity [2] | 88:1 | 145:14 | | 35:9 | 35:13 | 36:9 | 39:17 | 40:7 | phrase [2] | 109:9 | 150:18 | |
| opposed [6] | 26:5 | 56:11 | 89:7 | | 41:16 42:25 | 41:19 43:4 | 42:1 43:7 | 42:5 43:11 | phrased [2] | 23:25 | 152:21 | |
| Ī IĪ 2:8 116:1 | 140:19 | | | | 44:24 | 46:5 | 46:9 | 47:5 | phys [1] 56:15 | | | |
| oral [2] 124:13 | 124:14 | | | | 48:9 | 48:12 | 48:13 | 50:1 | physical [2] | 34:11 | 112:18 | |
| orally [1] | 123:20 | | | 50:2 | 52:2 | 52:11 | 53:16 | 57:4 | physician [17] | 12:5 | 48:5 | 56:16 |
| ordinary [1] | 20:14 | | | | 57:18 | 58:23 | 59:20 | 63:1 | 65:12 65:14 | 85:25 | 86:22 | 87:11 |
| organization [1] | 115:2 | | | 66:5 79:12 | 66:6 | 67:5 | 68:16 93:4 | 68:23 | 93:14 96:19 | 103:13 | 110:3 | 110:19 |
| original [9] | 5:22 | 6:3 | 6:19 | 93:16 | 85:20 97:7 | 86:15 117:5 | 95:4 122:16 | 93:12 129:4 | 112:18 117:12 | 142:13 | 157:2 | |
| 49:4 69:21 | 74:6 | 85:10 | 96:3 | | 131:18 | 133:3 | 133:6 | 133:8 | physician's [1] | 8:21 | | |
| 101:18 | | | | 134:25 | 135:6 | 135:8 | 139:20 | 144:3 | physicians [11] | 4:21 | 26:15 | 37:5 |
| otherwise [1] | 162:14 | | | • | 152:14 | 157:21 | | | 110:4 110:6 | 110:22 | 111:20 | 112:11 |
| otolaryngology | [1] | 39:12 | | patient's | | 34:1 | 34:7 | 35:15 | 115:4 126:7 | 140:4 | 21.17 | 00.14 |
| Otto [2] 28:1 | 53:12 | | | | 39:5 | 40:21 | 93:9 | 146:20 | physicist [30] 32:15 32:18 | 16:16 33:1 | 31:16 40:5 | 32:14 41:22 |
| outcome [5] | 88:11 | 88:19 | 88:21 | 152:17 | | | | | 42:8 55:17 | 55:18 | 40:3 56:10 | 58:6 |
| 147:14 147:21 | | | | patients | | 11:19 | 11:20 | 13:4 | 60:10 61:12 | 61:16 | 104:20 | 124:10 |
| outline [2] | 63:6 | 109:18 | | | 19:3 37:16 | 19:23 37:17 | 20:2 38:19 | 20:9 41:9 | 129:13 132:11 | 132:20 | 132:24 | 133:9 |
| outlined [2] | 57:23 | 85:23 | | | 56:23 | 58:15 | 58:19 | 41:9 87:20 | 133:15 137:3 | 137:6 | 137:24 | 138:2 |
| outpatient [7] | 118:13 | 118:13 | 135:9 | | 111:19 | 115:12 | 115:16 | 115:20 | 138:9 156:13 | | 10.05 | |
| 135:12 135:18 | 139:21 | 144:4 | | 118:16 | 118:21 | 120:1 | 120:16 | 120:18 | physicists [18] | 25:25 | 42:23 | 54:19 |
| outside [1] | 20:9 | | | | 121:16 | 121:17 | 122:19 | 122:20 | 54:23 54:24 114:14 114:19 | 56:12 126:19 | 57:1 135:24 | 61:1 137:9 |
| overall [4] | 41:18 | 89:14 | 89:16 | 122:24 136:24 | 125.11 | 131:21 | 134:17 | 136:10 | 137:16 137:20 | 120:19 | 133.24 | 160:7 |
| 111:3 | | | | patients | | 20.75 | 156.10 | | physics [6] | 30:20 | 30:21 | 45:6 |
| overdose [1] | 93:2 | | | | | 38:25 | 156:19 | | 103:8 103:18 | 103:19 | | |
| oversee [1] | 53:20 | | | Pause [1] | | 44:5 | | | pick [3] 125:21 | 141:24 | 145:25 | |
| owe [1] 86:15 | | | | pay [2] | | 126:1 | | | picked [4] | 59:4 | 64:25 | 101:23 |
| own [2] 70:13 | 114:20 | | | paying | | 125:24 | 10.5 | | 142:3 | | | |
| P _[1] 2:22 | | | | pediatri | | 18:11 | 18:14 | 18:15 | piece [2] 64:1 | 157:15 | | |
| page [23] 23:2 | 33:25 | 50:8 | 52:21 | | 18:20 | 21:18 | 21:20 | 22:3 | pink [1] 111:8 | | | |
| 57:24 78:16 | 79:11 | 79:11 | 80:1 | 22:3 37:8 | 30:17 37:16 | 35:4 37:21 | 36:19 37:22 | 37:6 37:23 | pivotal [1] | 73:8 | | |
| 102:3 102:20 | 103:7 | 135:1 | 141:4 | | 37:10 | 37:21 | 38:1 | 38:9 | place [4] 71:25 | 75:8 75:24 | 87:20 | 158:2 |
| 142:5 142:6 | 142:8 | 144:15 | 153:6 | 39:9 | 39:12 | 39:12 | 39:13 | 58:19 | ~ | | | |
| 153:19 154:3 | 154:5 | 154:14 | | 58:20 | 87:3 | 113:5 | 113:7 | 113:20 | placed [3] | 133:3 | 133:6 | 133:8 |
| paid [2] 12:18 | 55:24 | | | 115:7 | 115:16 | 115:20 | 116:20 | 117:5 | places [1] | 140:2 | | |
| | | | | 1 | | | | | | | | |

| | | | | | ulti-P | | | | ^ | | ' - rang |
|----------------------------------|------------------|------------------|----------------|----------------------------------|-----------------|----------------------|-----------------|--------------------------------------|------------------|-----------------|------------------|
| plaintiff [4] 3:8 | 1:7 | 1:17 | 2:2 | 79:16 79:16 81:7 81:14 | 79:22 81:24 | 80:2 81:25 | 81:5 82:7 | protocol [4] 85:19 | 34:16 | 36:4 | 44:14 |
| Plaintiff's [6] 6:14 70:1 | 3:5 141:2 | 5:16 | 6:10 | 82:23 82:25 122:4 123:4 | 83:4 123:9 | 96:3 126:22 | 97:15 127:2 | protocols [7] 112:2 136:6 | 8:14 136:11 | 8:20 136:23 | 31:12 |
| plaintiffs [2] | 4:5 | 5:24 | | 127:2 128:1 131:12 131:13 | 128:4 132:3 | 130:24 132:4 | 131:4 137:7 | provide [7] | 7:21 | 7:22 | 16:2 |
| plan [11] 13:6 | 13:10 | 40:23 | 48:13 | 142:10 142:11 | 142:11 | 132:4 | 142:24 | 35:8 52:22 | 126:13 | 147:3 | |
| 67:6 123:5 141:7 141:8 | 125:6 | 125:10 | 126:13 | 143:8 143:12 | 143:23 | 144:10 | 144:18 | provided [8] 51:14 73:11 | 10:6 86:6 | 23:11 93:20 | 36:18 131:2 |
| planning [1] | 110:12 | | | 145:14 145:19 157:24 | 145:22 | 157:7 | 157:14 | provider [1] | 49:8 | 0.20 | water 24 Co 2 |
| plans [2] 122:25 | 126:11 | | | prescriptions [2] | 121:18 | 158:12 | | providing [3] | 31:5 | 42:16 | 152:16 |
| plate [1] 125:3 | | | | presence [2] | 12:2 | 40:22 | | province [1] | 137:11 | | |
| played [3] | 88:18 | 88:19 | 88:21 | present [16] | 2:24 | 5:7 | 12:1 | Provost [1] | 11:4 | | |
| player [1] | 111:13 | | | 19:4 25:11 73:15 96:9 | 25:19 97:18 | 37:5 97:22 | 38:25 114:23 | Public [3] | 1:19 | 162:5 | 162:20 |
| PLEAS [1] | 1:4 | | | 115:1 132:21 | 149:20 | <i>)</i> , <i>24</i> | 117.20 | pull [1] 69:3 | | | |
| plus [1] 133:7 point [31] | 14.00 | 16.1 | 22:12 | presentation [2] | | 39:19 | | purportedly [1] | 149:25 | 50.10 | £4.0 |
| 25:10 26:8 | 14:23 26:20 | 16:1 34:19 | 40:4 | presentations [1 | * | 133:25 | | purpose [5] 86:14 110:2 | 37:14 | 50:10 | 54:2 |
| 48:8 51:7 | 51:19 | 54:11 | 60:5 | presented [2] | 37:1 | 95:9 | | purposefully (1) | 85:2 | | |
| 65:10 66:3 87:10 90:18 | 73:11 91:11 | 86:18 91:22 | 86:23 95:20 | president [2] | 125:15 | 125:16 | | purposes [4] | 5:16 | 14:10 | 110:2 |
| 101:3 107:7 | 107:18 | 110:3 | 93:20 128:9 | presumably [1] | 100:9 | | | 150:22 | | | |
| 136:1 153:9 | 154:16 | | | presume [1] pretty [6] | 116:14 90:11 | 95:16 | 106:20 | put [17] 53:25 91:13 92:17 | 68:1 93:12 | 69:20 123:12 | 69:22 131:10 |
| policy [6] | 54:9 | 61:11 | 81:21 | 125:1 151:17 | 151:24 | 95:10 | 100:20 | 131:11 139:10 | 93:12 140:8 | 123:12 | 141:12 |
| 103:21 157:21 Polito [1] | 158:2 2:11 | | | previous [1] | 57:24 | | | 144:19 156:5 | 158:7 | | |
| poor [2] 146:22 | 2:11 152:14 | | | previously [4] | 3:3 | 109:25 | 122:20 | q.d [3] 40:25 | 67:6 | 68:1 | |
| portion [3] | 73:5 | 108:6 | 150:14 | 158:21 | | | | QA [2] 60:22 | 61:11 | | |
| portions [2] | 22:6 | 24:21 | 150111 | primarily [1] | 127:3 | 25.22 | | qualified [1] | 162:6 | 71 05 | 05.05 |
| ports [1] 48:14 | | | | primary [2] principal [1] | 35:2 110:24 | 35:23 | | quality [3] questioned [2] | 47:23 58:13 | 71:25 138:10 | 85:25 |
| position [8] | 8:18 | 13:20 | 29:24 | principally [6] | 34:6 | 34:9 | 111:12 | questioning [5] | 72:24 | 108:3 | 138:4 |
| 72:18 113:13 | 113:15 | 113:19 | 118:2 | 118:13 119:25 | 147:15 | 54.9 | 111.12 | 150:22 157:6 | 72,24 | 100.5 | 150.4 |
| possession [1] | 9:11 | 146.00 | | private [1] | 113:16 | | | questions [16] | 14:15 | 15:3 | 84:14 |
| possible [2] possibly [10] | 121:24 21:11 | 146:23 51:24 | 60:3 | privilege [3] | 150:10 | 150:15 | 150:20 | 109:3 124:11 137:3 140:12 | 126:21 145:7 | 135:20 146:6 | 136:1 148:7 |
| 60:4 65:18 | 76:23 | 121:24 | 123:13 | privileged [1] | 72:1 | | | 148:24 158:11 | 160:25 | 140.0 | 140.7 |
| 124:4 124:12 | | | | privileges [1] | 105:5 | | | quibbling [1] | 143:10 | | |
| post-doctoral [1 | | 30:8 | | probability [1] probable [1] | 147:20 98:20 | | | Quick [1] | 2:22 | | |
| Post-It [2] | 123:11 | 123:24 | 00.14 | probable [1] | 156:5 | | | quickly [2] | 17:25 | 63:23 | |
| potential [5] 155:8 156:8 | 34:22 | 37:18 | 90:14 | problem [1] | 47:11 | | | quite [1] 140:15 | | | |
| potentially [1] | 76:21 | | | problems [1] | 132:13 | | | quote [3] 46:3 | 46:17 | 98:21 | |
| practice [17] | 13:6 | 13:9 | 19:19 | procedure [7] | 1:18 | 42:17 | 43:17 | quoted [1] R.N [1] 135:9 | 146:14 | | |
| 115:17 116:19 | 124:21 | 125:6 | 125:10 | 44:14 92:15 | 154:17 | 158:18 | | radiation [93] | 6:17 | 6:25 | 18:15 |
| 125:20 126:6 129:3 131:17 | 126:10 146:19 | 126:11 156:19 | 126:13 | procedures [1] | 11:25 | | | 18:21 18:23 | 19:1 | 21:24 | 28:13 |
| practiced [1] | 110:15 | | | process [13] 48:7 77:4 | 21:14 105:6 | 33:2 107:8 | 41:18 107:18 | 28:15 28:25 | 29:23 | 30:15 | 31:1 |
| practices [1] | 11:13 | | | 108:6 108:12 | 119:9 | 130:1 | 132:1 | 31:4 31:20 32:20 35:5 | 32:5 35:12 | 32:16 36:1 | 32:20 37:8 |
| practicing [1] | 109:6 | | | produced [1] | 15:22 | | | 38:20 40:24 | 41:21 | 42:10 | 43:2 |
| preclude [1] | 14:25 | | | product [1] | 16:21 | | | 45:24 46:4 53:3 53:5 | 46:18 54:13 | 52:13 56:11 | 52:19 58:9 |
| predicated [1] | 106:2 | | | professional [6] 155:23 162:4 | 1:19 162:21 | 20:10 | 114:20 | 61:3 61:14 | 63:9 | 63:22 | 64:3 |
| predictable [1] | 120:15 | | | professor [1] | 13:23 | | | 65:1 65:6 | 65:20 | 66:2 101:2 | 67:23 102:6 |
| predicted [1] preparation [1] | 151:17 21:23 | | | profile [2] | 58:15 | 58:23 | | 83:15 87:16 102:13 104:7 | 101:1 106:19 | 101:2 | 102:6 |
| prepare [1] | 132:7 | | | prognosis [5] | 21:10 | 146:7 | 146:12 | 109:24 110:13 | 111:10 | 111:15 | 112:6 |
| prepared [4] | 8:3 | 8:7 | 116:7 | 152:15 152:17 | | | | 112:12 113:24 124:23 132:23 | 114:13 133:4 | 117:11 133:8 | 118:14 135:7 |
| Î 12Î:16 | | | | program [3] | 30:12 | 109:19 | 113:10 | 136:6 136:12 | 136:16 | 137:11 | 139:14 |
| prescribed [5] | 83:15 | 103:9 | 104:16 | programmed [1] | | 45.04 | 114.12 | 142:18 144:3 | 146:2 | 146:4 | 146:19 |
| 119:10 138:6 prescribing [2] | 58:9 | 61:14 | | programs [3] progress [2] | 30:14 52:10 | 45:24 119:19 | 114:13 | 147:10 147:12 158:13 158:21 | 147:19 158:22 | 151:6 159:10 | 154:20 160:16 |
| prescription [69] | | 27:8 | 48:6 | prolonged [1] | 91:2 | 117.17 | | radiologists [1] | 1111:1 | | |
| 55:7 56:21 | 57:22 | 57:23 | 59:14 | prolonging [1] | 147:14 | | | radiology [3] | 37:22 | 109:1 | 124:22 |
| 60:5 60:7 | 60:11 | 61:17 | 62:14 | proper [3] | 68:18 | 99:17 | 141:24 | Rainbow [1] | 128:11 | | |
| 62:15 63:2 65:5 69:13 | 63:5 70:7 | 64:11 79:13 | 64:22 79:14 | protected [3] | 72:4 | 72:5 | 150:10 | range [1] 58:14 | | | |
| 07.10 | | | | | | | | | | | |

| | | | | | N | Iulti-Pa | age | | | R | arely - | rewrot |
|---|---|--|--|--|---|---|---------------------------------|-----------------|--|--|--|------------------------|
| Rarely [] | | 130:6 | | | 91:23 92:1 | 92:4 | 92:7 | 93:4 | reports [1] | 37:20 | | |
| Ratches | OII [1] | 106:11 | | | 93:24 94:3 | 97:1 | 104:25 | 128:3 | represent [12] | 3:14 | 3:16 | 3:18 |
| rate [6] | 64:11 | 116:13 | 116:19 | 116:22 | 128:10 139:24 | 149:23 | 150:5 | | 3:20 3:23 | 3:24 | 4:5 | 5:23 |
| 117:3 | 117:6 | | | | RECROSS [2] | 149:11 | 160:1 | | 86:1 108:24 | 108:25 | 135:23 | |
| rates [4] | 47:4 | 47:18 | 48:7 | 116:9 | recruited [2] | 105:17 | 106:5 | | representative | 1] | 30:15 | |
| rather [2 | ม | 139:10 | 146:12 | | recruiting [1] | 110:2 | | | represented [5] | 13:12 | 49:20 | 90:18 |
| RB&C | | 45:10 | | | recurrence [3] | 89:13 | 95:3 | 129:4 | 154:16 155:7 | | | |
| read [21] | | 15:10 | 23:8 | 24:12 | red [1] 98:8 | | | | representing [2] | 4:18 | 4:21 | |
| | 25:7 | 40:18 | 61:7 | 61:9 | redepose [1] | 74:12 | | | request [2] | 6:1 | 101:10 | |
| | 70:15 | 70:16 | 81:19 | 81:20 | reduced [1] | 162:10 | | | requested [3] | 101:8 | 101:14 | 110:19 |
| 83:10 | 88:14 | 88:16 | 141:1 | 155:18 | reentered [1] | 144:22 | | | requests [2] | 14:19 | 14:22 | |
| 155:20 | 161:5 | | | | | | <i></i> | 110 14 | require [1] | 12:2 | 11.22 | |
| reads [1] | 40:15 | | | | refer [5] 18:25 154:14 | 19:23 | 56:20 | 115:14 | required [2] | 109:9 | 138:25 | |
| realistic | ally [1] | 91:14 | | | reference [7] | 22:11 | 49:5 | 40.17 | | | | |
| really [4] | | 109:6 | 151:16 | 152:15 | 49:18 69:19 | 22:11 141:3 | 49:5 143:23 | 49:17 | requires [2] | 120:10 | 131:23 | |
| 153:10 | | | | | 1 | | 145.25 | | reread [1] | 83:9 | | |
| reason 19 | 91 | 20:15 | 34:13 | 34:25 | referenced [1] | 49:19 | | | rescanning [1] | 35:24 | | |
| | 94:17 | 131:7 | 138:6 | 139:12 | referencing [1] | 49:16 | | | research [3] | 30:14 | 30:22 | 30:25 |
| 143:22 | | | | | referral [1] | 33:21 | | | researchers [1] | 30:24 | | |
| reasons | [2] | 14:24 | 147:15 | | referred [6] | 19:3 | 59:16 | 97:6 | Reserve [4] | 2:13 | 3:20 | 30:10 |
| recalcul | | 62:15 | | | 115:13 122:21 | 139:6 | | | 135:24 | | | |
| recalls (1 | | 150:23 | | | referring [1] | 31:22 | | | resident [1] | 12:6 | | |
| receipt p | - | 8:4 | | | refers [1] | 35:4 | | | residents [2] | 37:24 | 94:25 | |
| receive [] | | 8. 4 14:6 | 15:17 | 32:24 | reflect [4] | 81:13 | 93:1 | 93:3 | residual [2] | 35:1 | 35:22 | |
| | 39:21 | 41:10 | 67:25 | 32:24 81:6 | 99:21 | | | | resimulation [1] | | 551202 | |
| | 82:9 | 138:4 | 138:17 | 138:24 | reflected [2] | 93:12 | 129:8 | | resistance [1] | 131:16 | | |
| 159:10 | 0212 | | | 100121 | reflects [1] | 79:14 | | | Resnick [1] | | | |
| received | ไตก | 8:7 | 8:11 | 8:16 | refresh [1] | 33:8 | | | | 106:12 | | 100.04 |
| | 9:20 | 24:10 | 24:22 | 25:6 | refurbished m | 110:11 | | | respect [3] | 47:21 | 118:9 | 120:24 |
| | 26:21 | 38:17 | 64:18 | 67:7 | regard [5] | 14:18 | 136:12 | 127.7 | L V | | | |
| | 68:14 | 68:18 | 80:6 | 80:8 | 146:7 146:15 | 17.10 | 100.12 | 1.11.2 | respiratory [2] | 109:1 | 132:22 | |
| | 80:11 | 80:25 | 81:7 | 81:8 | regarding [1] | 133:25 | | | respond [1] | 124:2 | | |
| | 82:13 158:14 | 88:7 159:18 | 95:3 | 129:5 | Registered [3] | 1:19 | 162:4 | 162:21 | response [4] | 73:4 | 88:8 | 145:6 |
| receives | | 41:19 | | | regular [1] | 100:20 | 104.4 | 104.41 | 146:6 | | | |
| | | | 11.0 | 12.11 | regularly [3] | | 10.0 | 17 01 | responses [2] | 109:2 | 148:7 | |
| receiving 23:13 | g [11] 43:4 | 10:11 43:8 | 11:9 57:5 | 16:11 89:7 | | 18:25 | 19:3 | 45:21 | responsibilities | [12] | 9:3 | 12:6 |
| | 89:22 | 43.8 | 21.2 | 09.7 | regulations [2] | 8:15 | 8:20 | | 28:10 29:17 | 30:11 | 42:24 | 43:3 |
| recently | | 101:15 | | | reimburse [2] | 12:12 | 13:3 | | 43:7 49:7 | 59:20 | 118:10 | 119:5 |
| • | | | 05.25 | 1/2.77 | relapse [2] | 154:24 | 158:9 | | responsibility 15 | | 28.17 | 61:16 |
| recess [3] | | 49:1 | 95:25 | 148:22 | related [1] | 27:7 | | | 109:23 115:2 | 118:12 | | |
| recogniz | | 65:7 | 104:21 | 146:3 | relative [21] | 7:2 | 7:12 | 7:18 | responsible [7] | 60:22 | 61:20 | 93:24 |
| recogniz | | 111:16 | | | 9:7 9:15 | 10:17 | 11:11 | 12:8 | 111:3 111:12 | 119:15 | 125:5 | |
| recollect | | | 11:5 | 11:8 | 15:22 26:25 | 43:21 | 46:4 | 46:9 | rest [1] 109:11 | | | |
| | 33:8 105:1 | 37:3 150:4 | 38:11 | 87:21 | 47:4 47:17 84:14 156:4 | 52:10 162:13 | 52:14 | 66:22 | restaged [1] | 146:11 | | |
| | | | | | relevant [3] | | 15.1 | 124.70 | restaging [6] | 36:9 | 40:23 | 90:9 |
| recomm | | | 155.04 | | | 14:18 | 15:1 | 134:20 | 91:13 91:15 | 104:23 | | |
| recomm | | | 155:24 | 0.11 | relocated [1] | 112:17 | 154.00 | | restate [2] | 15:4 | 75:1 | |
| record [5 | | 3:13 | 6:18 | 8:11 | remain [2] | 101:10 | 154:22 | | result [5] 9:11 | 9:16 | 11:17 | 87:24 |
| | 15:21 17:7 | 16:4 33:10 | 16:12 61:9 | 16:20 66:16 | remember [4] | 24.3 | 24:6 | 76:17 | 89:23 | | | |
| | 66:24 | 73:5 | 73:7 | 75:22 | 84:3 | | | a | retained [1] | 10:7 | | |
| | 76:5 | 76:20 | 77:24 | 77:25 | Reminger [6] | 1:22 | 1:22 | 2:19 | retired [1] | 112:14 | | |
| 75:24 | 83:2 | 83:10 | 85:14 | 85:15 | 2:19 101:11 | 101:11 | 1.5.4.4.0 | | retirement [1] | 110:5 | | |
| 81:20 | | | 92:14 | 92:16 | remission [3] | 89:4 | 154:19 | 158:19 | retreatment (1) | 157:22 | | |
| 81:20 85:17 | 88:16 | 92:12 | | | removed [3] | 7:15 | 13:25 | 66:2 | return [2] | 124:3 | 154:24 | |
| 81:20 85:17 92:23 | 88:16 95:23 | 99:20 | 108:17 | 108:19 | | | | | | | | |
| 81:20 85:17 92:23 121:12 | 88:16 95:23 128:20 | 99:20 130:16 | 108:17 133:7 | 108:19 133:12 | render [1] | 21:15 | | | | 8:14 | | 25:4 |
| 81:20 85:17 92:23 121:12 135:23 | 88:16 95:23 128:20 139:21 | 99:20 130:16 139:22 | 108:17 133:7 139:25 | 108:19 133:12 144:4 | | 21:15 7:19 | 48:8 | 102:12 | review [17] | 8:14 37:19 | 23:7 | 25:4 61:21 |
| 81:20 85:17 92:23 121:12 135:23 148:21 | 88:16 95:23 128:20 139:21 149:10 | 99:20 130:16 | 108:17 133:7 | 108:19 133:12 | render [1] | | 48:8 42:25 | 102:12 | review [17] 33:25 34:3 62:4 62:24 | 37:19 68:5 | 23:7 48:16 68:8 | 25:4 61:21 68:17 |
| 81:20 85:17 92:23 121:12 135:23 148:21 150:24 | 88:16 95:23 128:20 139:21 149:10 155:20 | 99:20 130:16 139:22 149:20 | 108:17 133:7 139:25 | 108:19 133:12 144:4 | render [1] rendered [3] rendering [2] | 7:19 42:11 | | 102:12 | review [17] 33:25 34:3 | 37:19 | 23:7 48:16 | 61:21 |
| 81:20 85:17 92:23 121:12 135:23 148:21 150:24 recorded | 88:16 95:23 128:20 139:21 149:10 155:20 d [1] | 99:20 130:16 139:22 149:20 50:8 | 108:17 133:7 139:25 | 108:19 133:12 144:4 | render [1] rendered [3] rendering [2] renowned [1] | 7:19 42:11 45:17 | | 102:12 | review [17] 33:25 34:3 62:4 62:24 72:1 91:23 reviewed [9] | 37:19 68:5 94:3 21:22 | 23:7 48:16 68:8 111:9 21:24 | 61:21 68:17 22:3 |
| 81:20 85:17 92:23 121:12 135:23 148:21 150:24 recorded recordin | 88:16 95:23 128:20 139:21 149:10 155:20 d [1] Ig [1] | 99:20 130:16 139:22 149:20 50:8 17:3 | 108:17 133:7 139:25 150:2 | 108:19 133:12 144:4 150:24 | render [1] rendered [3] rendering [2] renowned [1] reorganize [1] | 7:19 42:11 45:17 157:23 | 42:25 | 102:12 | review [17] 33:25 34:3 62:4 62:24 72:1 91:23 reviewed [9] 85:25 87:8 | 37:19 68:5 94:3 | 23:7 48:16 68:8 111:9 | 61:21 68:17 |
| 81:20 85:17 92:23 121:12 135:23 148:21 150:24 recorded recordin | 88:16 95:23 128:20 139:21 149:10 155:20 d [1] lg [1] [42] | 99:20 130:16 139:22 149:20 50:8 17:3 7:2 | 108:17 133:7 139:25 150:2 7:11 | 108:19 133:12 144:4 150:24 7:15 | render [1] rendered [3] rendering [2] renowned [1] reorganize [1] repeat [2] | 7:19 42:11 45:17 157:23 15:4 | 42:25 90:9 | 102:12 | review [17] 33:25 34:3 62:4 62:24 72:1 91:23 reviewed [9] 85:25 87:8 158:13 | 37:19 68:5 94:3 21:22 97:18 | 23:7 48:16 68:8 111:9 21:24 97:22 | 61:21 68:17 22:3 |
| 81:20 85:17 92:23 121:12 135:23 148:21 150:24 recorded recordin records [9:4 | 88:16 95:23 128:20 139:21 149:10 155:20 d [1] lg [1] [42] 9:19 | 99:20 130:16 139:22 149:20 50:8 17:3 7:2 9:25 | 108:17 133:7 139:25 150:2 7:11 10:5 | 108:19 133:12 144:4 150:24 7:15 10:6 | render [1] rendered [3] rendering [2] renowned [1] reorganize [1] repeat [2] repetitive [2] | 7:19 42:11 45:17 157:23 15:4 126:25 | 42:25 90:9 137:5 | 102:12 | review [17] 33:25 34:3 62:4 62:24 72:1 91:23 reviewed [9] 85:25 87:8 158:13 reviewing [2] | 37:19 68:5 94:3 21:22 | 23:7 48:16 68:8 111:9 21:24 | 61:21 68:17 22:3 |
| 81:20 85:17 92:23 121:12 135:23 148:21 150:24 recorded recordin records [9:4 10:14 | 88:16 95:23 128:20 139:21 149:10 155:20 d [1] [42] 9:19 10:16 | 99:20 130:16 139:22 149:20 50:8 17:3 7:2 9:25 11:6 | 108:17 133:7 139:25 150:2 7:11 10:5 11:8 | 108:19 133:12 144:4 150:24 7:15 10:6 11:13 | render [1] rendered [3] rendering [2] renowned [1] reorganize [1] repeat [2] repetitive [2] report [2] | 7:19 42:11 45:17 157:23 15:4 126:25 85:22 | 42:25 90:9 137:5 119:7 | | review [17] 33:25 34:3 62:4 62:24 72:1 91:23 reviewed [9] 85:25 87:8 158:13 | 37:19 68:5 94:3 21:22 97:18 | 23:7 48:16 68:8 111:9 21:24 97:22 | 61:21 68:17 22:3 |
| 81:20 85:17 92:23 121:12 135:23 148:21 150:24 recorded recordin records [9:4 10:14 21:22 | 88:16 95:23 128:20 139:21 149:10 155:20 d [1] lg [1] [42] 9:19 | 99:20 130:16 139:22 149:20 50:8 17:3 7:2 9:25 | 108:17 133:7 139:25 150:2 7:11 10:5 | 108:19 133:12 144:4 150:24 7:15 10:6 | render [1] rendered [3] rendering [2] renowned [1] reorganize [1] repeat [2] repetitive [2] | 7:19 42:11 45:17 157:23 15:4 126:25 | 42:25 90:9 137:5 | 102:12 95:15 | review [17] 33:25 34:3 62:4 62:24 72:1 91:23 reviewed [9] 85:25 87:8 158:13 reviewing [2] | 37:19 68:5 94:3 21:22 97:18 46:12 | 23:7 48:16 68:8 111:9 21:24 97:22 | 61:21 68:17 22:3 |

| | | | | | | | Iulti-P | age™ | | | rig | ght - so | metimes |
|------------------|-----------------|------------------|--------------------|--------------------|------------------------|-----------------|-----------------|------------------|--------------------|---------------------------------------|-----------------|----------------|---------|
| right 113 | | 4:22 | 5:7 | 5:10 | 83:19 | 83:20 | 87:13 | 102:6 | 102:24 | 101:18 | | | |
| 5:14 11:3 | 6:4 13:16 | 6:21 15:13 | 7:1 16:17 | 7:5 17:9 | 103:4 | 103:12 | 104:18 | 116:13 | 120:5 | shakes [1] | 146:1 | | |
| 17:16 | 17:17 | 13:15 | 10:17 | 20:4 | 130:13 | 134:15 | 135:14 | 141:18 | 143:2 | Shall [1] 33:3 | | | |
| 20:7 | 20:18 | 22:2 | 22:7 | 24:8 | scan [11] 36:14 | 80:19 | 36:11 81:12 | 36:12 82:20 | 36:13 90:9 | shareholder [1] | 125:14 | | |
| 24:20 | 24:24 | 25:8 | 28:8 | 28:16 | 105:1 | 105:2 | 01.12 | 82.20 | 90.9 | sheet [24] | 38:16 | 55:3 | 96:3 |
| 29:19 | 30:5 | 31:10 | 31:21 | 32:3 | scannin | | 110:13 | | | 97:6 97:9 | 97:12 | 97:14 | 97:17 |
| 32:12 | 32:22 | 35:11 | 35:17 | 35:19 | schedul | | 52:5 | 78:4 | 120:10 | 97:19 97:22 | 97:23 | 98:4 | 103:10 |
| 36:5 40:4 | 36:19 42:9 | 39:7 42:20 | 39:11 42:20 | 39:23 44:3 | | 135:8 | 140:3 | 70.4 | 120.10 | 111:8 130:7 132:4 143:24 | 130:14 | 131:5 157:7 | 131:13 |
| 44:23 | 45:3 | 45:5 | 45:20 | 48:22 | schedul | | 35:24 | 41:8 | 138:17 | 152.4 145.24 | 145:19 | 157.7 | 157:24 |
| 50:1 | 50:17 | 51:1 | 53:10 | 53:13 | 138:20 | | | | | sheets [2] | 45:7 | 130:5 | |
| 55:9 | 55:14 | 56:1 | 56:19 | 59:1 | schedul | ing [2] | 139:17 | 140:6 | | shield [1] | 133:5 | 150.5 | |
| 60:25 65:20 | 61:19 69:17 | 62:6 70:9 | 62:16 | 62:23 72:11 | school [| | 9:8 | 9:24 | 11:12 | Shina [16] | 2:9 | 3:23 | 25:9 |
| 76:2 | 76:6 | 70:9 | 70:24 79:21 | 79:25 | 12:19 | 13:21 | 125:8 | | | 26:4 77:18 | 77:23 | 77:24 | 78:1 |
| 80:23 | 82:4 | 82:4 | 82:8 | 83:22 | Scott [3] | 10:23 | 27:11 | 53:12 | | 112:13 113:3 | 113:8 | 113:25 | 114:1 |
| 83:25 | 84:12 | 84:16 | 89:20 | 93:1 | se [1] | 42:18 | | | | 114:2 116:2 | 149:13 | | |
| 95:21 | 97:11 | 98:4 | 99:24 | 101:9 | seal [1] | 162:17 | | | | short [4] 49:1 | 67:5 | 95:25 | 148:22 |
| 103:6 106:1 | 103:14 110:5 | 103:24 113:11 | $105:15 \\ 114:10$ | $105:21 \\ 114:12$ | search | [4] | 106:6 | 106:10 | 107:1 | shorter [1] | 120.4 | | |
| 120:11 | 121:6 | 122:17 | 122:23 | 127:16 | 108:13 | | | | | shortly [1] | 112:14 | | |
| 130:2 | 130:12 | 130:16 | 131:1 | 131:3 | Seattle | | 112:17 | 112:20 | 117:1 | show [9] 40:12 | 63:4 | 66:17 | 67:19 |
| 131:10 | 132:5 | 132:19 | 135:6 | 135:15 | second | | 6:6 | 54:25 | 70:20 | 69:12 83:3 | 83:14 | 84:2 | 111:7 |
| 136:21 | 139:8 | 141:17 149:18 | 142:2 | 142:4 | 80:12 | 85:14 | 119:13 | 140:6 | 157:22 | Shurin [4] | 27:2 | 27:3 | 113:5 |
| 142:19 152:23 | 143:5 153:25 | 149:18 154:4 | 149:24 155:2 | 151:4 158:1 | seconda | | 152:3 | | | 113:18 Shumin la ray | 110.1 | 110.10 | |
| 152:25 | 158:20 | 159:1 | 159:16 | 120,1 | secreta | - | 78:5 | 140:23 | | Shurin's [2] | 113:1 | 113:18 | |
| right-ha | and [2] | 70:5 | 103:12 | | See [47] | 17:3 | 17:3 | 17:15 | 38:8 | side [2] 41:6 | 52:21 | 00.5 | 100.01 |
| risk [1] | | | | | 38:12 48:12 | 38:16 69:5 | 48:5 74:6 | 48:9 79:5 | 48:10 80:14 | sign [7] 45:6 129:20 129:22 | 53:20 161:5 | 92:5 | 103:21 |
| risks [1] | | | | | 85:10 | 86:17 | 97:25 | 98:4 | 98:14 | signature [7] | 50:18 | 62:21 | 103:15 |
| Robert | | 106:11 | | | 98:18 | 103:25 | 118:25 | 119:11 | 119:25 | 127:6 127:7 | 127:18 | 143:4 | 103.15 |
| 1 | 19:17 | 32:14 | 56:7 | 88:19 | 120:15 | 120:16 | 120:17 | 120:18 | 122:19 | signed [11] | 41:8 | 53:16 | 67:8 |
| 88:21 | | | | | 122:25 | 127:6 132:14 | 129:4 133:14 | 130:13 134:25 | 130:15 135:3 | 68:4 68:6 | 85:24 | 103:17 | 103:19 |
| Ron [2] | 4:3 | 14:12 | | | 131.12 | 132.14 | 133.14 | 134.23 | 133.3 | 103:23 135:7 | 154:24 | | |
| Ronald | [1] | 2:3 | | | 145:14 | | 157:10 | | 1 (011) | significant [1] | 73:5 | | |
| room [4] | 52:3 | 100:1 | 143:20 | 144:23 | seeing [4 | () | 34:13 | 50:1 | 66:15 | significantly [1] | 63:18 | | - |
| rounds | [1] | 112:5 | | | 130:13 | | | | | signing [1] | 53:25 | | |
| routine | [2] | 6:23 | 62:1 | | seeming | | 125:25 | | | similar [2] | 103:10 | 107:17 | |
| rule [1] | 147:6 | | | | semanti | | 47:1 | | | simply [3] | 25:24 | 140:8 | 156:20 |
| rules [5] | 1:17 | 3:9 | 8:14 | 8:20 | semi [1] | | | | | simulated [1] | 48:14 | | |
| 74:13 | | | | | send [1] | 100:22 | | | | simulation [3] | 57:17 | 80:12 | 140:7 |
| rumbles | 5 (1) | 23:24 | | | sends [1] | 62:2 | | | | simulations [1] | 12:1 | | |
| rumblin | igs [1] | 23:19 | | | sense [1] | 112:2 | | | | simultaneously | [1] | 42:16 | |
| rumors | [2] | 23:19 | 23:24 | | sent [5] | 9:25 | 12:2 | 77:13 | 101:16 | site [1] 35:2 | | | |
| run [2] | 52:6 | 60:23 | | | 114:24 | | | | | sites [7] 35:1 | 35:22 | 35:23 | 40:22 |
| running | [1] | 57:16 | | | separat | | 48:15 | 131:5 | 157:15 | 110:23 111:17 | 111:23 | | - |
| runs [1] | | | | | separat | v | 120:25 | | | situation [5] | 65:18 | 88:17 | 141:13 |
| SAB [1] | 55:16 | | | | Septem | | 27:4 | | | 145:5 157:2 | 100 ~ | 102.01 | |
| safely [1] | | 61:19 | | | sequent | | 42:3 | | | situations [2] | 123:7 | 123:21 | |
| salutary | | 147:8 | | | sequent | | | | | six [1] 57:1 | 00.0 | | |
| Sam [9] | 2:13 | 3:21 | 27:13 | 55:19 | series 12 | | 111:19 | | | skill [3] 21:6 | 98:9 | 152:2 | |
| 55:20 | 133:15 | 133:20 | 135:25 | 148:1 | served | 4] | 4:23 | 5:2 | 5:8 | skull [2] 36:14 | 95:9 | | |
| Samuels | | 114:4 | | | 24:3 | | | | | sloppy [1] | 157:19 | | |
| Santa (1) | | | | | service | | 37:25 | 118:6 | | small [3] 30:7 | 89:14 | 147:2 | |
| sarcoma | | 21:21 | 134:10 | 134:16 | services | | 93:20 | 00 0 · | 20.25 | smaller [1] | 134:1 | | |
| sarcoma | | 30:17 | | | set [14] 44:1 | 1:24 49:21 | 7:3 52:23 | 23:21 74:17 | 29:25 81:15 | snowball's [1] | 153:11 | | |
| sat [1] | 25:3 | | | | 120:6 | 49:21 | 52:25 125:6 | 162:10 | 162:16 | so-called [1] | 111:8 | | |
| satisfied | | 35:13 | | | sets [2] | 83:3 | 83:15 | | | social [1] 34:9 | 114.63 | | |
| save [2] | 9:18 | 10:1 | | | setting | | 20:10 | 142:17 | 152:21 | societies [1] | 114:21 | | |
| saw [19] | | 22:4 | 22:7 | 24:18 | settings | - | 147:11 | a. 1999 1 k f | a. w. ane e ane 2. | solely [1] 111:12 | | | |
| 35:18 | 35:25 | 38:13 | 50:2 | 51:19 | setup [4] | | 57:19 | 132:25 | 133:2 | someone [8] | 24:25 | 32:8 | 71:14 |
| 92:10 143:14 | 98:11 150·14 | 100:1 152:24 | 127:18 153:1 | 139:4 159:4 | setup [4] | | 48:2 | 1,4.4. | 4.00 | 75:18 76:25 | 106:16 | 109:10 | 120:22 |
| Says [24] | | 53:13 | 55:4 | 55:10 | seven [3] | | 40.2 81:11 | 82:17 | | sometime [3] | 23:13 | 36:24 | 118:4 |
| 55:13 | 62:19 | 71:6 | 71:6 | 80:24 | several | | 30:16 | 30:23 | 101:16 | sometimes [6] 132:24 140:2 | 37:21 140:22 | 119:3 | 120:3 |
| | | | | · - • | scrual | [**] | 50.10 | 50.23 | 101.10 | 1.54.47 140.2 | 1.40.44 | | |

| 113:4 126:4 149:3 | 61:8 113:25 128:22 161:1 43:12 | 8:24 11:2 61:10 115:15 132:22 161:4 | 29:15 63:6 116:11 | 44:8 109:1 | sticker [1] sticky [1] | lulti-P 6:8 62:3 | | | 148:15 149:5 Switzer [1] | <u> </u> | | |
|---|--|--|-------------------------|-----------------|---------------------------|-------------------------------|---------|--------|--------------------------------|--------------------|-----------------|----------------|
| 54:17 113:4 126:4 149:3 sort [4] Southwe space [1] speak [2] 2 | 61:8 113:25 128:22 161:1 43:12 | 61:10 115:15 132:22 | 63:6 | | stickym | 62.2 | | | Switzer | 0.11 | | |
| 113:4 126:4 149:3 sort [4] sound [1] Southwe space [1] speak [2] 2 | 113:25 128:22 161:1 43:12 | 115:15 132:22 | | 100-1 | | 02.5 | | | Switzer [1] | 2:11 | | |
| 126:4 149:3 sort [4] sound [1] Southwe space [1] speak [2] 2 | 128:22 161:1 43:12 | 132:22 | 116:11 | | still [10] 10:25 | 14:25 | 51:11 | 94:8 | SWORN [2] | 3:10 | 162:8 | |
| 149:3 sort [4] 4 sound [1] Southwe space [1] speak [2] 2 | 161:1 43:12 | | 133:18 | 116:15 134:6 | 112:15 112:22 | 113:2 | 113:10 | 118:5 | system [26] | 15:21 | 16:4 | 16:5 |
| sort [4] 4 sound [1] Southwe space [1] speak [2] 2 | 43:12 | 101.4 | 133:18 | 154:0 | 140:15 | | | | 16:9 16:18 | 16:25 | 17:7 | 29:2 |
| sound [1] Southwe space [1] speak [2] 2 | | 109:22 | 125:3 | 125:7 | stood [1] 98:8 | | | | 29:7 43:10 | 43:11 | 43:21 | 44:25 |
| Southwe space [1] speak [2] 2 | St [2] | 64:7 | 123,5 | 12317 | Straighten [1] | 44:6 | | | 45:10 46:9 | 46:13 | 46:14 | 46:19 |
| space [1] speak [2] 2 | SL [2] | | 111 04 | | strange [1] | 125:1 | | | 46:24 47:4 110:17 111:14 | 47:8 112:4 | 47:16 | 109:21 |
| speak [2] 2 | | 29:11 | 111:24 | | strategies [1] | 114:8 | | | systemic [1] | | | |
| | | | | | strategy [1] | 14:24 | | | • | 104:5 | 16.4 | |
| special [1] | | 25:9 | | | Street [1] | 2:23 | | | systems [2] | 34:3 | 46:4 | |
| | | 133:5 | | | strength [1] | 127:21 | | | T _[1] 127:12 | | | |
| specialis | | 94:6 | 112:18 | | strike [2] 102:17 | 103:10 | | | table [1] 47:10 | | | |
| specialist | ts [2] | 37:6 | 39:2 | | stuck [2] 123:11 | 123:25 | | | tag [1] 87:13 | | | |
| specializ | ation [2 |] | 45:18 | 45:22 | students [2] | 30:7 | 30:8 | | takes [1] 63:12 | | | |
| specialize | e [1] | 110:20 | | | studies [2] | | | | taking [2] | 113:13 | 155:4 | |
| specialty | | 46:3 | | | | 37:4 | 37:20 | | tap [1] 39:1 | | | |
| specific p | | 14:23 | 17:6 | 36:12 | study [1] 134:23 | | | | Tape [1] 95:24 | | | |
| | 39:17 | 44:24 | 46:14 | 48:3 | stuff [1] 102:18 | | | | TBI [86] 16:11 | 26:5 | 26:9 | 26:22 |
| 92:15 | 111:17 | 121:24 | 122:1 | 133:19 | subject [1] | 159:25 | | | 36:8 36:18 | 39:21 | 40:8 | 40:24 |
| 139:2 | | | | | submitted [1] | 105:13 | | | 41:7 41:7 | 41:10 | 41:12 | 41:19 |
| specifical | | 5:22 | 9:18 | 10:15 | subsequent [4] | 8:3 | 15:16 | 35:25 | 42:18 42:25 | 43:4 | 43:8 | 43:11 |
| | 120:24 | 144:7 | | | 70:9 | | | | 43:20 45:10 47:18 48:17 | 46:5 | 46:9 49:8 | 47:5 50:2 |
| specifics | | 12:16 | 12:22 | 33:3 | subsequently [5] | 29:5 | 36:9 | 36:15 | 47:18 48:17 51:18 52:2 | 48:17 52:14 | 49:8 53:1 | 50:2 53:20 |
| speculati | on [1] | 91:7 | | | 125:3 135:17 | | | | 56:24 57:5 | 57:9 | 58:16 | 58:22 |
| spend [1] | | 28:22 | | | Substantially (1) | | 64:24 | | 61:24 62:12 | 63:5 | 65:24 | 66:5 |
| Spoiler [1 | .1 | 55:4 | | | substantiated [1 |] | 15:12 | | 66:12 67:6 | 67:7 | 67:22 | 67:25 |
| spoken [2 | | 124:16 | 124:19 | | substantive [1] | 12:8 | | | 68:17 68:17 | 68:22 | 69:6 | 69:13 |
| spot [2] | | 48:25 | | | substantively [1] | 1 | 11:21 | | 70:8 76:9 | 83:4 | 83:16 | 88:1 |
| spousal [] | | 150:10 | | | subtherapeutic | | 58:9 | 61:4 | 88:6 88:18 89:22 90:14 | 88:20 90:19 | 89:1 90:25 | 89:8 93:25 |
| Springm | | | | | 63:10 65:8 | 77:19 | 78:3 | 78:7 | 95:4 95:7 | 90:19 97:6 | 90:25 97:9 | 93:23 97:15 |
| | | 10:23 | | | 90:24 98:9 | 137:25 | | | 98:7 102:9 | 102:15 | 103:22 | 104:2 |
| squiggly | | 127:19 | | | successes [1] | 151:10 | | | 134:9 134:16 | 143:25 | 153:4 | 155:5 |
| | 1:1 | 162:2 | | | succumb [1] | 147:21 | | | 155:12 159:10 | | | |
| | 1:22 | 2:19 | 113:16 | 117:1 | such [6] 21:21 | 61:2 | 85:20 | 114:11 | teach [1] 30:8 | | | |
| staff [4] 🤉 | | 114:9 | 114:25 | 157:23 | 130:8 139:22 | | | | teaching [2] | 30:6 | 135:7 | |
| stage [3] 3 | 34:16 | 130:1 | 158:8 | | sued [2] 24:15 | 94:10 | | | team [10] 41:25 | 42:4 | 42:6 | 42:7 |
| staggered | 1 (1) b | 52:9 | | | suggest [2] | 119:17 | 147:13 | | 42:11 42:18 | 42:19 | 111:16 | 111:20 |
| staging n | J | 141:12 | | | suit [3] 27:20 | 86:23 | 145:22 | | 139:14 | | | |
| stamp [1] | | 127:1 | | | Suite [1] 2:23 | 00.20 | 1.10.22 | | teams [1] | 110:21 | | |
| standard | | 31:6 | 44:13 | 53:23 | summarized [1] | 95.24 | | | technical [2] | 48:3 | 61:20 | |
| | 81:21 | 89:12 | 89:17 | 107:16 | | | 156-0 | | technically [4] | 30:21 | 60:24 | 87:16 |
| 110:16 | | 158:17 | | | summary [2] | 17:16 | 156:9 | | 131:4 | | | |
| standpoi | | 147:18 | | | superimposed [| | 127:12 | | technique [2] | 41:6 | 122:13 | |
| start [5] | | 19:7 | 19:15 | 19:20 | supervises [1] | 32:15 | | | technologist [5] | | 41:21 | 52:19 |
| 110:7 | | | | - | supervising [1] | 30:3 | | | 53:3 65:1 | | | |
| started p | 5] | 16:12 | 19:9 | 19:9 | supervision [1] | 30:19 | | | technologists [4] | 43:3 | 54:13 | 63:22 |
| 19:10 | 19:16 | 19:18 | 28:3 | 28:4 | supervisor [3] | 118:5 | 118:7 | 120:14 | 65:6 | | | |
| | | 117:23 | 118:4 | 131:4 | supervisory [3] | 118:1 | 118:20 | 118:21 | techs [3] 42:10 | 52:13 | 53:5 | |
| 135:13 | | | | | support [2] | 30:13 | 115:3 | | teleconference | [1] | 112:4 | |
| starting (| | 24:11 | 50:13 | 135:9 | surgeons [2] | 39:9 | 110:25 | | Ten [1] 19:25 | | | |
| starts [2] 4 | | 67:25 | | | surgery [3] | 39:14 | 106:15 | 106:16 | tend [1] 122:19 | | | |
| state [6] | | 1:20 | 20:25 | 162:2 | surprise [2] | 26:3 | 152:5 | 100.10 | term [1] 136:16 | | | |
| | 162:21 | | | | | | 1.14.1 | | | 3.15 | | |
| statemen | t [1] | 38:24 | | | surprised [1] | 25:17 | | | Terminal [1] | 2:15 | 57.04 | 00.31 |
| statistics | | 146:14 | | | surrounding [1] | | | | terms [12] 100:7 109:21 | 48:2 | 57:24 111:17 | 90:11 117:6 |
| stature [1] | | 109:10 | | | survival [5] | 89:4 | 91:2 | 91:9 | 100:7 109:21 119:5 119:14 | $110:11 \\ 141:12$ | 147:21 | 117.0 |
| status [3] | | 56:18 | 151:17 | 156:3 | 146:21 152:18 | | | | testified [8] | | 4:14 | 46:16 |
| Stellato p | 11 | 106:14 | | | survive [1] | 152:3 | | | 72:12 132:17 | 4:11 145:21 | 4:14 156:13 | 46:16 160:6 |
| stenotype | | 162:11 | | | Susan [5] | 2:25 | 19:10 | 24:13 | testify [6] | 75:4 | 77:7 | 77:18 |
| | | | 2.10 | | 25:6 115:14 | | | | 78:13 150:14 | 75:4 162:8 | 11.1 | //.10 |
| Stephen (| | 2:14 | 3:19 | | suspended [1] | 20:20 | | | testifying [1] | 150:3 | | |
| steps [1] | | 100 5 | | | suspension [1] | 156:9 | | | testimony [13] | 5:12 | 12:7 | 26:19 |
| Steve [4] 2 | 22:23 | 102:24 | 135:23 | 161:1 | Sweeney [5] | 2:10 | 3:22 | 3:22 | 61:15 62:7 | 5:12 71:5 | 12:7 89:21 | 26:19 98:13 |

| | 11 97:3 :23 135:16 | |
|--|-----------------------|--|
| $ \begin{array}{ c c c c c c c c c c c c c c c c c c c$ | :23 135:16 | |
| $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ | | |
| $\begin{array}{l l l l l l l l l l l l l l l l l l l $ | 1 115:1 | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | 1 113.1 | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | | |
| $ \begin{array}{ c c c c c c c c c c c c c c c c c c c$ | | |
| $ \begin{array}{l c c c c c c c c c c c c c c c c c c c$ | | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | :24 | |
| $\begin{array}{l c c c c c c c c c c c c c c c c c c c$ | | |
| UFP $[1]$ 10:12UFP $[2]$ 125:19126:1913:12:12:13UFP $[2]$ 125:19126:1914:1314:1314:13114:13114:13UFP $[2]$ 125:19126:19114:13114:13transplant $[2]$ 59:18137:20137:20137:20137:20137:20131:1230:12UFP $[2]$ 125:19126:19131:12131:12137:20137:20137:20137:20137:20131:12131:12131:12131:12126:15126:15126:15131:12131:12131:12131:12131:1214:1439:2131:12131:1214:1439:2121:11122:11122:11122:1114:1439:2131:12131:1214:1439:2131:1214:1439:214:14 <th colsp<="" th=""><td></td></th> | <td></td> | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | :5 | |
| therapists [6]53:953:11109:11137:120137:120137:121ultimate [4]88:19147:21therapy (r)30:2240:23147:21transcription (II162:13thereafter (I)74:22transcription (II147:21uncommon (r)122:11122therefore (II72:1transcription (II141:1266:587:1831:1450:131116:24therefore (II72:1transcription (II147:21uncommon (r)122:11122therefore (II72:1Transplant (r)66:587:1831:1451:17 | | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | 21 89:5 | |
| Interapy [17]Solid 24Solid 24127:2127:20128:4130:23130:24transcription [1] 162:13143:23146:21146:22146:24136:12transplant [2]68:2139:17unacceptable [1]116:24thereafter [1]74:22146:24146:22146:24travel [1]114:18uncommon [3]122:11122travel [1]114:18unacceptable [1]162:4travel [1]114:18unacceptable [1]162:4travel [1]114:18unacceptable [1]162:4travel [1]114:18unacceptable [1]162:4travel [1]114:18unacceptable [1]122:11travel [1]114:18travel [1]114:12 | | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | | |
| 143:23146:21146:22146:24travel [1]114:18Intervel [1] $114:18$ thereafter [1]74:22travel [1]114:18under [37] $1:17$ $3:9$ therefore [1]72:1treat [4] $39:5$ $42:4$ $82:21$ $87:20$ $41:4$ $51:12$ $30:8$ $30:$ Thereupon [13] $3:2$ $3:5$ $6:10$ $97:7$ $110:8$ $122:20$ $136:10$ $139:20$ $31:14$ $50:13$ $56:7$ $58:$ $7:7$ $70:1$ $74:8$ $85:12$ $85:16$ $97:7$ $110:8$ $122:20$ $136:10$ $139:20$ $60:9$ $61:2$ $61:16$ $65:7$ $78:$ though [10] $68:14$ $75:4$ $77:4$ $77:4$ $14:8$ $17:16$ $19:1$ $19:24$ $29:10$ $101:13$ $106:11$ $116:11$ $129:18$ 131 three [11] $4:25$ $5:1$ $19:9$ $35:5$ $35:8$ $35:9$ $35:13$ $35:15$ $10derdose [1]$ $93:2$ threefold [1] $110:13$ $120:3$ $48:14$ $88:14$ $88:16$ $83:16$ $83:16$ $83:16$ $83:16$ $130:19$ $136:57$ $40:25$ $50:13$ $60:19$ $110:13$ $120:3$ $36:2$ $41:25$ $42:16$ $48:$ | | |
| Itration of the second | | |
| therefore [1]72:171.1 <td>4:12</td> | 4:12 | |
| Thereupon [13]3:23:56:107:770:174:885:1285:16108:18143:20144:22148:20149:9158:21158:21100:961:261:1665:0third [1]110:812:2013:10thought [10]68:1475:477:4thee [11]68:1475:477:4three [11]4:255:119:935:535:535:631:634:1634:25three [11]4:255:119:935:535:535:548:948:1148:1248:948:1148:1246:366:2367:780:1110:2:110:2:110:2:110:2:1through [11]10:610:2:110:2:110:2:110:2:1110:1310:2:110:2:110:2:1110:1310:2:1110:1310 | | |
| T:r $1:3:1$ T:r $1:4:22$ T:r $1:4:22$ T:r | | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | 7 86:16 | |
| third [1] 119:1339:240:753:24110:8110:9110:11110:11129:18131thought [10] $68:14$ 75:477:4treatment [76] $6:18$ 7:18 $8:21$ 155:11157:13122:4145:24145:2414:817:1619:119:2429:1029:1229:1431:634:1634:22underdose [1]93:240:2550:1360:19110:13120:336:241:2542:246:548:840:2550:1360:19110:13120:336:241:2542:246:548:840:2550:1360:19110:13120:336:241:2542:246:548:8133:3138:18139:1735:535:835:935:1335:15understand [19]42:1542:1threefold [1]110:666:2367:780:1986:687:1083:697:8109:5109133:25136:18142:16154:12131:21133:25129:5129:8131:18135:6135:18137133:25136:18142:16154:12131:21133:25136:9141:7141:8131:18136:14137133:25136:18142:16154:12131:21133:25136:9141:7141:8130:20151:16152:13133:25136:18142:16154:12131:21133:25136:9 </th <td></td> | | |
| thought [10] $68:14$ $75:4$ $77:4$ treatment [76] $6:18$ $7:18$ $8:21$ underdose [1] $93:2$ $86:3$ $100:7$ $115:11$ $122:4$ $145:24$ $14:8$ $17:16$ $19:1$ $19:24$ $29:10$ underdose [1] $93:2$ $155:11$ $157:13$ $29:12$ $29:14$ $31:6$ $34:16$ $34:22$ underdose [1] $93:7$ $40:25$ $50:13$ $60:19$ $110:13$ $120:3$ $36:2$ $41:25$ $42:2$ $46:5$ $48:8$ undergoing [2] $47:5$ $47:1$ $40:25$ $50:13$ $60:19$ $110:13$ $120:3$ $36:2$ $41:25$ $42:2$ $46:5$ $48:8$ understand [19] $42:15$ $42:1$ $133:3$ $138:18$ $139:17$ $48:9$ $48:11$ $48:13$ $48:15$ $51:20$ $68:8$ $72:14$ $75:2$ $81:1$ threefold [1] $110:6$ $66:23$ $67:7$ $80:19$ $86:6$ $87:10$ $83:6$ $97:8$ $109:5$ 109 $33:9$ $34:3$ $51:20$ $107:8$ $108:25$ $103:20$ $10:12$ $119:13$ $102:13$ $103:18$ $130:19$ $136:5$ $136:18$ 137 $33:25$ $136:18$ $142:16$ $154:12$ $131:21$ $133:25$ $129:5$ $129:8$ $131:18$ undertical [3] $84:22$ $155:13$ $133:25$ $136:18$ $142:16$ $154:12$ $143:16$ $143:25$ $144:2$ $145:10$ $147:14$ $130:20$ $151:16$ $152:13$ < | | |
| 86:3 $100:7$ $115:11$ $122:4$ $143:24$ $143:24$ $14:8$ $17:16$ $19:1$ $19:24$ $29:10$ $29:10$ $155:11$ $157:13$ $29:12$ $29:14$ $31:6$ $34:16$ $34:22$ $34:16$ $34:22$ $three [11]$ $4:25$ $5:1$ $19:9$ $35:5$ $35:8$ $35:9$ $35:13$ $35:15$ $35:13$ $35:15$ $40:25$ $50:13$ $60:19$ $110:13$ $120:3$ $36:2$ $41:25$ $42:2$ $46:5$ $48:8$ $undergoing [2]$ $47:5$ $47:1$ $133:3$ $138:18$ $139:17$ $36:2$ $41:25$ $42:2$ $46:5$ $48:8$ $understand [19]$ $42:15$ $42:15$ $threefold [1]$ $110:6$ $66:23$ $67:7$ $80:19$ $86:6$ $87:10$ $83:6$ $97:8$ $109:5$ 109 $through [17]$ $29:24$ $32:1$ $33:1$ $39:14$ $89:16$ $93:15$ $102:13$ $103:18$ $130:19$ $136:5$ $136:18$ 137 $33:9$ $34:3$ $51:20$ $107:8$ $108:25$ $103:20$ $110:12$ $119:13$ $119:14$ $120:16$ $130:19$ $136:5$ $136:18$ 137 $133:25$ $136:18$ $142:16$ $154:12$ $131:21$ $133:25$ $129:5$ $129:8$ $131:18$ $130:20$ $151:16$ $152:13$ $133:25$ $136:18$ $127:21$ $143:16$ $143:25$ $144:2$ $145:10$ $147:14$ $130:20$ $151:16$ $152:13$ 14110 $147:6$ | .12 | |
| three [11] 4:25 5:1 19:9 35:5 35:8 35:9 35:13 35:15 undergoing [2] 47:5 47:1 40:25 50:13 60:19 110:13 120:3 36:2 41:25 42:2 46:5 48:8 undergoing [2] 47:5 47:1 133:3 138:18 139:17 35:1 35:1 35:23 64:20 66:8 68:8 72:14 75:2 81:1 threefold [1] 110:6 57:14 61:19 63:23 64:20 66:8 87:10 83:6 97:8 109:5 109 109:20 119:2 125:10 126:13 130:21 103:20 110:12 119:13 119:14 120:16 130:19 136:5 136:18 137 133:25 136:18 142:16 154:12 131:21 133:25 129:5 129:8 131:18 159:6 199:5 199:5 130:20 159:6 130:20 159:6 130:20 159:6 159:6 159:6 159:6 159:20 151:16 152:13 130:20 151:16 152:13 < | | |
| 40:25 50:13 60:19 110:13 120:3 36:2 41:25 42:2 46:5 48:8 understand [19] 42:15 42:1 133:3 138:18 139:17 48:9 48:11 48:13 48:15 51:20 68:8 72:14 75:2 81:1 threefold [1] 110:6 57:14 61:19 63:23 64:20 66:8 87:10 83:6 97:8 109:5 109 through [17] 29:24 32:1 33:1 39:14 89:16 93:15 102:13 103:18 130:19 136:5 136:18 137 33:9 34:3 51:20 107:8 108:25 103:20 110:12 119:13 119:14 120:16 130:19 136:5 136:18 137 133:25 136:18 142:16 154:12 131:21 133:25 129:5 129:8 131:18 144:2 155:10 144:2 155:10 144:2 145:10 147:14 130:20 151:16 152:13 130:20 151:16 152:13 130:20 151:16 152:13 130:20 | 18 | |
| 133:3 138:18 139:17 48:9 48:11 48:13 48:15 51:20 68:8 72:14 75:2 81:1 threefold [1] 110:6 57:14 61:19 63:23 64:20 66:8 83:6 97:8 109:5 109 109:20 119:2 125:10 126:13 130:21 130:21 103:20 110:12 119:13 119:14 120:16 130:19 136:5 136:18 137 133:25 136:18 142:16 154:12 131:21 133:25 129:5 129:8 131:18 130:20 159:6 106:20 151:16 152:13 90:5 130:20 159:6 100:12 151:16 152:15 129:8 131:18 130:20 159:6 100:20 151:16 152:13 103:20 151:16 152:13 130:20 151:16 152:13 130:20 151:16 152:13 100:20 151:16 152:13 130:20 151:16 152:13 130:20 151:16 152:13 130:20 151:16 152:13 130:20 151:16 152:13 130:20 151:16 | | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | | |
| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | | |
| 33:9 34:3 51:20 107:8 108:25 103:20 110:12 119:13 119:14 120:16 107:8 107:8 108:25 103:20 110:12 119:13 119:14 120:16 107:8 108:25 103:20 110:12 119:13 119:14 120:16 108:25 103:20 122:25 123:5 129:5 129:8 131:18 100:16 100 | :16 143:10 | |
| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | :13 155:23 | |
| throughout [2] 123:18 127:21 143:16 143:25 144:2 145:10 147:14 130:20 151:16 152:13 thumb [1] 147:6 152:16 152:20 153:4 153:11 154:23 unintentionally [5] 71:1 | | |
| thumb $_{[1]}$ 147:6 152:16 152:20 153:4 153:11 154:23 unintentionally $_{[5]}$ 71:1 |) 127.17 | |
| | 15 75:19 | |
| Thursday [3] 38:18 38:18 120:4 155:14 155:24 156:20 157:22 158:14 99:18 99:19 99:22 | | |
| Thursdays (1) 120-18 120-21 158.25 158.14 Umits [3] 116:15 116:17 116 | :23 | |
| thwarted (u. 80.8 (internet internet in | 2:13 | |
| Inwarted [1] 89:8 81:11 82:17 129:1 135:8 135:16 3:18 3:20 8:18 9:8 Tim [3] 3:22 148:24 149:3 154:21 135:8 135:16 3:18 3:20 8:18 9:8 | 10:13 21 14:16 | |
| times [8] 4:23 39:8 40:25 84:18 Treu [1] 2:7 11:11 12:9 12:18 13:2 19:12 19:13 19:14 29:1 | | |
| 87:18 104:1 120:22 122:2 triggers in 142:15 29:6 29:22 30:9 30:1 | 10 44:20 | |
| Timothy [6] 1:13 1:16 2:10 true [6] 35:15 98:10 115:3 117:14 45:2 55:24 87:12 87:1 | | |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | | |
| truth [3] 49:7 54:4 134:9 truth [3] 162:8 162:9 162:9 112:1 112:19 112:25 114 | | |
| today [24] 4:9 5:21 5:25 try [8] 20:11 22:9 83:12 88:23 119:1 124:22 125:20 126 | :5 126:7 | |
| $ \begin{array}{c ccccccccccccccccccccccccccccccccccc$ | :7 139:10 | |
| 111.21 136.17 136.25 137.1 149.21 [Lying]] 00.18 | | |
| 150:3 150:22 158:6 158:6 159:8 Tuesday (1) 120:1 Oniversity S (1) 29:13 | 0 05.17 | |
| 160:6 Tuesdays [1] 120:17 unless [3] 69:10 71:1 160:6 120:17 120:17 120:17 120:17 140:10< | | |
| today's [1] 99:1 tumor [21] 30:16 30:17 36:20 unquote [3] 46:3 46:1 together [2] 37:19 120:25 37:1 37:5 37:11 37:14 38:3 untruthful [1] 77:20 | 90:21 | |
| 28.0 28.02 20.00 (0.11) | :4 122:4 | |
| 57:24 86:1 86:4 110:23 111:19 122:7 122:20 122:24 | .m i2221.44 | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | 25 39:4 | |
| $turn_{[9]} 22:15 24:25 48:18 78:16 41:1 44:8 59:4 65:1$ | 83:13 | |
| Tom [1] 106:14 102:3 102:20 149:1 149:2 149:6 88:9 93:17 101:23 102 100:00 < | | |
| tomorrow [1] 135:9 turned [2] 99:9 99:9 117:7 119:3 120:6 125 too [2] 36:21 118:8 furning [1] 142:8 125:21 126:23 134:8 140 | | |
| 142,2 142,17 145,25 160 | | |
| $\mathbf{twice}[\mathbf{s}] \ 5:23 \ 5:23 \ 131:15 \ \mathbf{twice}[\mathbf{s}] \ 5:1 \ 30:2 \ 00:10 \ 134:21 \ \mathbf{undate}(\mathbf{u}) \ 131:24$ | | |
| top [6] 69:14 71:5 74:18 102:5 147:11 appende [1] 131.24 | | |

| | | | | Μ | ulti-Pa | age | | | | update | ed - [sie |
|--------------------------------------|-------------------------|--------------|--------------|----------------------------|------------------|--------------------------|--------------------------|------------------------------|-----------------|-----------------|-----------|
| updated [1] | 81:6 | | | Washington [1] | | | | 140:21 140:21 | 140:22 | 142:13 | |
| upper [1] | 127: | 6 | <i>x</i> | Wednesday [2] | 1:14 | 120:1 | | writing [11] | 70:12 | 70:17 | 70:25 |
| urology [1] | 106: | 13 | | Wednesdays [1] | 120:17 | | | 78:20 100:8 | 104:21 | 130:4 | 130:10 |
| usage [1] 51: | 2 | | | week [7] 29:25 | 82:14 | 101:21 | 120:15 | 130:12 144:20 | 162:11 | | |
| used [5] 17: | | 112:9 | 125:5 | 120:15 131:22 | 134:21 | | | written [17] | 8:24 | 43:17 | 44:1 |
| 132:1 | | | | weekly [1] | 30:18 | | | 44:14 64:11 | 65:12 | 65:14 | 69:9 |
| using [3] 42: | 19 134: | 24 141:24 | | weeks [4] | 101:16 | 101:19 | 131:21 | 70:10 79:20 133:24 145:15 | 83:18 157:14 | 122:5 157:14 | 127:9 |
| usual m 129 | | | | 134:22 | | | | | 16:6 | 60:5 | 78:14 |
| usually [16] | 21:1 | 2 31:22 | 48:15 | Weiden [1] | 13:19 | | | wrong [7] 93:9 93:11 | 93:12 | 100:8 | /0,14 |
| 51:25 92: | | | | Wessels [7] | 2:13 | 3:21 | 25:16 | wrote [28] | 22:8 | 57:22 | 59:14 |
| 118:17 122 | :13 122: | 18 131:10 | | 27:24 135:25 | 148:1 | 148:9 | | 60:5 63:2 | 67:2 | 68:7 | 70:22 |
| 140:21 140 | :24 144: | 4 | | West [1] 2:23 | | | | 71:3 75:19 | 76:23 | 79:16 | 82:23 |
| utilized [3] | 16:1 | 8 93:25 | 97:14 | Western [4] | 2:13 | 3:20 | 30:10 | 82:25 84:2 | 93:8 | 93:11 | 93:13 |
| UW [1] 11: | 4 | | | 135:24 | | | 00110 | 94:18 128:4 | 130:16 | 139:4 | 142:25 |
| VA [1] 29: | 23 | | | Westlake [1] | 29:13 | | | 143:7 143:14 | 144:2 | 144:8 | 144:10 |
| vacationed | | 14 | | Weston [1] | 2:15 | | | X [1] 158:9 | | | |
| vague [1] | 43:1 | | | whatsoever [1] | 155:6 | | | X-rays [1] | 55:3 | | |
| vagueness [| | | | WHEREOF [1] | 162:16 | | | XRT [2] 40:23 | 68:3 | | |
| Valdivieso | | | 7.0 | Whiley [1] | | | | year [12] 14:4 | 14:5 | 24:7 | 86:19 |
| 7:13 7:1 | | 6:18 31:2 | 7:3 33:19 | | 11:4 | 100.0 | 101 10 | 114:25 115:16 | 115:24 | 116:1 | 121:13 |
| 57:4 58: | | | | whole [5] 158:7 162:8 | 100:16 | 103:8 | 131:13 | 121:15 141:24 | 142:1 | | |
| | :24 147: | | 159:9 | | 0.17 | 0.03 | 2.25 | yearly [2] | 19:24 | 41:12 | |
| 160:8 160 | | | | Wiersma [35] 3:16 3:25 | 2:17 4:2 | 2:21 18:4 | 2:25 18:8 | years [9] 9:10 | 10:2 | 19:9 | 53:24 |
| Valdivieso' | s [1] 92:2 | | | 18:11 18:25 | 4:2 19:3 | 18:4 | 18:8 | 113:14 121:10 | 136:20 | 136:22 | 151:6 |
| Varian [2] | 16:2 | 1 16:23 | | 19:23 21:5 | 21:9 | 27:19 | 33:21 | yellow [1] | 62:3 | | |
| various [8] | 30:3 | 30:13 | 43:7 | 38:3 40:1 | 49:10 | 87:6 | 96:20 | young [1] | 146:8 | | |
| 45:6 50: | | | | 96:24 100:9 | 149:2 | 149:20 | 149:25 | yourself [8] | 7:12 | 9:9 | 11:12 |
| vast [1] 118 | | | | 150:4 150:9 | 150:19 | 150:23 | 153:19 | 12:20 35:14 | 60:19 | 73:17 | 96:9 |
| verbally [1] | 108: | 11 | | 154:9 154:13 | | | | yourselves [1] | 39:3 | | |
| Verify [6] | 15:2 | | 16:13 | wife [2] 21:13 | 24:13 | | | zero [1] 91:14 | | | |
| 16:20 16: | | 1 10.4 | 10.15 | Willoughby [1] | 29:5 | | | [sic] [3] 27:22 | 55:11 | 156:14 | |
| versus [3] | 63:1 | 3 88:7 | 89:24 | Willson [1] | 106:9 | | | Lovel (o) 27.22 | 55.11 | 150,14 | |
| VIDEOGR | | | | Wisconsin [14] | 9:8 | 11:12 | 12:10 | | | | |
| 85:15 95: | | | 44:10 | 12:18 13:21 | 14:5 | 14:16 | 16:19 | | | | |
| | | 1.7 | | 19:12 19:13 | 44:21 | 107:20 | 108:8 | | | | |
| | | | | 110:18 | | | | | | | |
| view [2] 110 | | | | wisdom [1] | 39:1 | | | | | | |
| Vincent's n | - | 16 | | wished [2] | 58:13 | 59:12 | | | | | |
| violative [1] | 85:5 | | | withdraw [1] | 63:7 | | | | | | |
| visit [1] 119 | | | | withdrawn [3] | 14:19 | 14:22 | 14:23 | | | | |
| visited m | 120: | 25 | | within [3] | 23:19 | 95:17 | 113:19 | | | | |
| vitae [1] - 5:1' | 7 | | | without [4] | 1:21 | 68:3 | 80:7 | | | | |
| vivo [2] 57: | 12 57:13 | 3 | | 133:22 | | | | | | | |
| void [1] 93: | | | | witness [26] | 4:13 | 4:16 | 4:24 | | | | |
| volume [2] | 81:3 | 81:11 | | 5:3 5:9 | 14:14 | 19:13 | 23:8 | | | | |
| voluntarily | | | | 40:17 44:8 | 48:19 | 67:16 | 72:13 | | | | |
| vote [1] 14: | | - 10,10 | | 72:16 73:12 | 74:12 | 79:1 | 81:18 | 1 | | | |
| votes [1] 14: | | | | 96:4 101:22 146:1 150:1 | 104:13 162:16 | 128:20 | 128:22 | | | | |
| | | | | | | | | | | | |
| VS [1] 1:8 | | 10 | | woman [1] | 112:16 | | | | | | |
| $W_{[2]} = 2:13$ | | | 110 0 | wondering [1] | 130:1 | 05.5 | | | | | |
| Wait [4] 40: | | | 149:2 | word [3] 17:21 | 47:21 | 85:1 | | | | | |
| waiver [2] | 14:2: | | | words [5] | 32:20 | 77:14 | 122:17 | | | | |
| walk [2] 33: | | 4 | | 140:8 143:10 | 10.0 | | | | | | |
| Walt [1] 94: | 8 | | | worked [8] | 18:8 | 56:18 | 56:23 | | | | |
| Walters [30] | 2:14 | | 3:19 | 57:3 116:25 | 117:23 | 121:9 | 136:8 | | | | |
| 22:17 22: | | | 59:7 | works [4] | 120:2 | 120:9 | 121:5 | | | | |
| | | | 102:21 | 139:19 | a. a. | | | | | | |
| 59:25 60: | | | 107:13 | world [1] | 21:21 | | | | | | |
| 103:1 103 | | | 149:1 | worse [1] | 141:13 | | | 1 | | | |
| 103:1 103 108:2 135 | | | | | | | | | | | |
| 103:1 103 108:2 135 151:14 151 | :22 152: | | | Wright [1] | 104:19 | | | | | | |
| 103:1103108:2135151:14151160:25161 | :22 152: :2 | 8 153:20 | | Wright [1] write [22] | 48:6 | 80:12 | 92:17 | | | | |
| 103:1 103 108:2 135 151:14 151 | :22 152: :2 10:1: | 8 153:20 | | Wright [1] | | 80:12 94:14 131:17 | 92:17 97:19 131:19 | | | | |